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3.- Annex #3: Eur J Pharmacol. 2006;544:104-10.  




AIDS  Acquired Immunodeficiency Syndrome
ApoE_/_  Apolipoprotein E deficient mice
BCA  Bulb Carotid Artery
CAD  Coronary artery disease
CCA  Common Carotid Artery
CCR-2  CC Chemokine receptor 2
CCR-5  CC Chemokine receptor 5
CV  Cardiovascular
CVD  Cardiovascular diseases
CX3CR-1 Fractalkine receptor 
CxCR4  CXC Motif, receptor 4
Env  Viral envelope glycoprotein
FH  Familiar Hypercholesterolemia
HAART  Highly Active Antiretroviral Therapy
HIV  Human Immunodeficiency Virus
ICA  Internal Carotid Artery
LTNP  HIV-infected patients considered long term non-progressors
MCP-1  Monocyte Chemoattractant Protein-1
MI  Myocardial Infarction
MIP-1α  Macrophage inflammatory factor-1 α
MIP-1β  Macrophage inflammatory factor-1 β
NNRTI  Non Nucleoside Reverse Transcriptase Inhibitors
NRTI  Nucleoside Reverse Transcriptase Inhibitors
PBMC  Peripheral Blood Mononuclear Cells
PI  Protease Inhibitors
R5   Macrophage (M)-tropic or non-syncytium inducing HIV
RANTES Regulated on activation, normal T cell expressed and secreted
SDF-1  Stromal Derived Factor-1
SNP  Single Nucleotide Polymorphism
Tat  Trans-activator protein
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The introduction of the Highly Active Antiretroviral Therapy (HAART) in 
HIV-infection has been associated with a marked decrease in morbidity 
and mortality from AIDS-related diseases1. However, the increase in the 
life expectancy and the side effects of HAART2,3 are leading  clinicians to 
challenges in the treatment of HIV-infected patients. Atherosclerosis is a 
systemic and progressive disease4 that explains most of cardio-vascular 
events, and then the identification of either atherosclerosis risk factors or 
atherosclerosis itself is of great relevance. In recent years, the management 
of lipid abnormalities in HIV clinics5, are a great focus of concern and the 
overall CV risk is increasing steadily in this population6. The reduction of 
the CV risk implementing conventional strategies (life style changes, lipid-
lowering drug prescriptions) have been adapted, but we should take into 
account the influence of genetic variations on these processes and how, 
once identified, we could modify them, in order to minimize the incidence 
of CV events in this young population. This thesis deals with the early 
identification of atherosclerosis and these non-conventional markers 








































8 9     
UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
The incidence of CVD in HIV-infected patients has been addressed in several 
prospective and retrospective studies. In the Data Collection on Adverse 
Events of Anti-HIV Drugs (DAD) study7, of 23,468 participants, 126 (0.5 
percent) had a first MI, an incidence of 3.5 per 1000 person-years. Although 
there is no comparing data with non-infected population coming from 
prospective studies, one of the strongest conclusions of DAD was that the 
incidence of MI increased directly with longer exposure to antiretroviral 
therapy (relative risk, 1.26 [95 percent confidence interval, 1.12 to 1.41] per 
additional year of exposure; P<0.001) (Figure 1). 
Figure 1. Incidence of myocardial infarction in HIV-infected patients 
according to time of exposure to antiretroviral therapy. (N Engl J Med. 
2003;349:1993-2003.)
According to the DAD study, classical-known cardiovascular risk factors, 
such as, male sex, hypercholesterolemia, older age, smoking and prior 
history of cardiovascular disease, were also associated to a higher risk of 
developing MI. In a recent publication, investigators of the DAD study up-
to-dated these results, collecting data of 23,437 HIV-infected patients, with 
an absolute number of MI of 345, resulting in an incidence of 3.65/1000 
person-years. Further they found a significant increased relative rate of MI 
in those patients who had been treated with a PI-based HAART scheme 
[1.16 (1.10-1.23)] when compared to those with NNRTI [1.05 (0.98-1.13)]8. 
However, these results have not been confirmed by other studies. Bozzette 
et al. analyzed retrospectively the rate of CVD since the generalization of 
HAART and  evidenced that the rate of admission or death due to CVD did 
not increase with increasing exposure to HAART (Figure 2)9. 
2.- Cardiovascular diseases in 
HIV- infected patients
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An overview of the studies addressing cardiovascular incidence in HIV-
infected patients are summarized in Table 1. Although these data indicate 
the great benefits of the HAART in terms of increased survival, they also 
suggest that the rate of CVD is higher in HIV-infected patients taking PI and 
the risk increases as the duration of treatment lengthens10.
Adapted from Stein JH. J Acquir Immune Defic Syndr 2005;38:115-123.
“the rate of CVD is 
higher in HIV-infected 
patients taking PI and the 
risk increases as the 
duration of treatment 
lengthens Table 1. Studies of CVD rates in HIV–infected patients.
Figure 2. Years of exposure to different types of antiretroviral therapies 
(Panel A) and the number of deaths and cardiovascular events in Panel 
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It is of interest to remark that when compared the clinical appearance 
of coronary events between HIV-infected patients and non-infected 
population, those HIV-infected were predominantly younger males, with 
significantly lower HDL-cholesterol concentrations and with a higher rate 
of restenosis after coronary angioplasty or stenting (Table 2)17,18,19,20,21. 
Similarly, a pathologic study revealed, that the appearance of atherosclerotic 
lesions of coronary arteries of HIV-infected patients compared with non-
infected population, were highly inflamed and resembled those observed 
in patients with a chronic cardiac transplant22. These results indicate 
that the inflammatory response of HIV-infected patients is particularly 
over expressed in the pathogenesis of atherosclerosis, and therefore, its 
inflammatory pathways are relevant in determining a different clinical 
presentation. 
* Restenosis rates compared with non-infected population. Adapted from 
Circulation 2005:112:3947-395723.
“atherosclerotic lesions 
of coronary arteries of 
HIV-infected patients com-
pared with non-infected 
population, were highly 
inflamed and resembled 
those observed in patients 
with a chronic cardiac 
transplant
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3.- Surrogate markers for 
atherosclerosis 
The need of reliable data on cardiovascular studies lead to the design of 
large scale trials in which the end-points are cardiovascular events24. This 
strategy has several benefits but they need several years of follow-up, 
and it means that they are time and financially-consuming. Taking into 
account that HIV affects especially younger population, the need for a 
surrogate marker for atherosclerosis is of great value. The measurement of 
arterial intima-media thickness (IMT) (Figure 3) was first reported in 198625. 
Since then, this non-invasive method has been validated with pathologic 
studies26, and it has been correlated with both CVD risk factors and the 
prevalence of CVD27,28,29. The measurement of the IMT as an end-point ,in 
intervention studies, met the set of criteria to be considered a surrogate 
marker for atherosclerosis30: it is efficient; the linkage between the values 
of carotid IMT and cardiovascular events has been repeatedly assured; it 
is congruent and the therapeutic intervention impact independently in 
the course of IMT and in the rate of CVD. Further, IMT constitutes a direct 
method to detect atherosclerosis, and then a way to assess disease and 
not only risk factors for the disease. The measurement of the IMT has been 
proposed as an initial test, similar to the determination of the coronary 
calcium score, to stratify the risk of individuals to suffer from a CV event31.
Footnote: the interphase lumen-intima is depicted by arrows and the interphase 
media-adventitia is depicted by arrow-heads. The distance between them 
constitutes the intima-media thickness (IMT).
IMT is an strong indicator of atherosclerosis in its early phases, because 
it is a reliable way to assess the artery wall, and not the consequences of 
atherosclerosis in the lumen 32.  The ability of IMT to predict future CV events 
“IMT constitutes a direct 
method to detect 
atherosclerosis, and then a 
way to assess disease and 










































Figure 3. Overview of carotid 
intima-media thickness. 
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“the higher the carotid 
IMT the higher the 
likelihood of having a CV 
event in the future
has been assessed in large observational studies. The increase of 0.3mm in 
the IMT of the common carotid artery was associated with a 78% higher 
risk of suffering from a coronary ischemic event and a 196% increased 
risk of having an stroke33.  Similarly, prospective studies have shown that 
the higher the carotid IMT the higher the likelihood of suffering from MI or 
stroke34. O’Leary et al35 in a population-based study of 5858 subjects found 
that the relative risk of having an MI/stroke of those participants in the fifth 
quintile of carotid IMT was 3.15 [(95% CI:2.19-4.52), Figure 4]. Further, the 
values in the carotid IMT are highly correlated with the extent of coronary 
lesions diagnosed by angiography 36. All prospective studies reviewed are 
in accordance with the same conclusion, i.e.: the higher the carotid IMT the 
higher the likelihood of having a CV event in the future37. In a metanalyses 
of the main intervention studies in the course of IMT, for an absolute carotid 
IMT difference of 0.1 mm, the future risk of MI increases by 10% to 15%, 
and the stroke risk increases by 13% to 18%. Another interesting remark 
of this study, is that vascular events are rare in young individuals, which 
makes IMT particularly attractive as an end point in epidemiological and 
treatment studies in young populations (such as HIV-infected patients). 
This fact explains the non-linearity relationship between carotid IMT 
and cardiovascular risk: young individuals with increased IMT are at 
considerably lower absolute risk but higher relative risk of vascular events.
Figure 4. Incidence of myocardial infarction according to quintiles 
of carotid IMT.




s in atherosclerosis and HIV-infection
UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
One of the critical points in comparing studies based on carotid IMT are 
the different protocols applied, and this may lead to a misinterpretation 
of results. Conditions of blood flow in the CCA make the presence of a 
focal IMT protrusion (atherosclerotic plaque) unlikely, and conversely the 
likelihood of a diffuse enlargement is higher than in the ICA 38. The impact 
of assessing different anatomic regions in predicting CV events have been 
previously studied, and the values of the ICA are a better surrogate marker 
of atherosclerosis than those in the CCA. However, each image laboratory 
should check for the repeatability of the exams, since the variability in ICA 
tended to be higher than in the CCA 39.
Several manuscripts addressed the role of IMT in femoral arteries, with 
comparable results with those obtained in the carotid exams; higher values 
of femoral IMT were observed in older participants and with higher number 
of classical cardiovascular risk factors 40.  Further, the results of carotid and 
femoral IMT combined are highly related to coronary atherosclerosis 41. 
Besides the use of IMT in cross-sectional designs, this technique has also 
been analyzed in follow-up studies, in order to know whether the rate of 
IMT increase/decrease yield stronger conclusions in terms of atherosclerosis 
risk than cross-sectional studies. de Groot E. et al 42, studied patients with 
familiar hypercholesterolemia and matched controls at different periods of 
their lives. They concluded that the rate of IMT progression was significantly 
higher in the group of FH-affected patients, i.e.: the carotid IMT observed at 
40 years of age in the FH patients was the same which was at 80 years for 
the unaffected population (Figure 5).
3.1.-Which is the best carotid IMT 
segment as surrogate marker?
Figure 5. Progression of IMT in 
different populations; Familiar 
Hypercholesterolemic patients 
(red dots) compared with un-
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Most of the IMT progression studies have been performed in patients 
who had already had a CV event, and then, they are limited to secondary 
prevention. Hodis et al.43 demonstrated that independently of the group 
of therapy (placebo or colestipol/niacin) a rate of IMT progression of 
>0.03mm/year was significantly related with a higher likelihood of having 
a CV event (Figure 6). These results were further confirmed in other 
studies 44,45, indicating that not only  cross-sectional studies of IMT are 
highly informative in assessing the CV risk, but also longitudinal studies 
addressing the rate of IMT increase/decrease.
Figure 6. Incidence of myocardial infarction/death  according to the 
progression rate of carotid IMT.
 Ann Intern Med 1998;128:262-26
“a rate of IMT 
progression of >0.03mm/
year was significantly 
related with a higher 
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4.- Intima-media thickness 
studies in HIV- infected patients
The availability of the ultrasound examination and the higher 
rates of dyslipidemia and other classical CV risk factors have 
pointed researchers to study atherosclerosis non-invasively in 
HIV-infected patients. Table 3 summarizes studies of carotid 
IMT in HIV-infected patients. According to these, they reach 
a definitive conclusion:  the IMT of HIV-infected patients is 
significantly higher than non-infected population, and further, 
the carotid IMT progression of HIV-infected patients is also 
significantly faster than non-infected individuals 46. However, 
the influence of antiretroviral therapy on the increase of carotid 
IMT is still a matter of debate. Preliminary results showed that, 
the control in classical cardiovascular risk factors, and the 
rationale use of PI as the mainstay of HAART is associated to a 
significant control in the progression rate of IMT 47.
“the IMT of HIV-infected 
patients is significantly 
higher than non-infected 
population
Table 3. IMT studies in HIV-infected patients.









































UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 




5.- Causes for higher 
atherosclerosis rates  in 
HIV- infected patients
 
Several variables exert a detrimental influence in the risk of HIV-infected 
patients to suffer from atherosclerosis. First, the life expectancy of HIV-
infected patients has increased 60 and then, they are also under the 
detrimental influence of the most powerful and non-modifiable risk 
factor for the development of atherosclerosis, age. Further, most of HIV-
infected patients are or used to be heavy smokers, a factor that might 
induce the premature development of atherosclerosis. Dyslipidemia, as 
in non-infected population, is highly correlated with atherosclerosis in 
HIV-infected patients 61. It is interesting to highlight however, that HIV has 
direct influences in several metabolic parameters. Newly diagnosed HIV-
infected patients generally presented with lower HDL cholesterol and 
higher triglyceride concentrations 62,63. Further, HIV-infected patients under 
antiretroviral therapy experienced lower HDL cholesterol concentrations 
with hypertriglyceridemia compared with non-infected patients 64,65, 
and these changes yields to a more pro-atherogenic lipid profile. The 
characterization of different lipoproteins in HIV-infected patients, showed 
that HDL subpopulation profiles resembled those of coronary heart 
disease affected patients. Moreover, the HDL subpopulation profile 
changed unfavorably after a PI-based HAART, characterized by increased 
concentrations of the small, lipid-poor pre-beta-1 HDL and decreased 
concentration of the large, cholesterol-rich alpha-1 HDL 66. According 
to these data, the lipid profile of HIV- infected subjects is deteriorated 
after receiving a PI-based treatment, which may cause increased risk of 
suffering from atherosclerosis. Although controversial, several works have 
assessed the efficacy of switching these therapies to a PI-sparing regimen, 
based on the use of efavirenz or nevirapine, and these results showed a 
favorable effect in decreasing total and LDL cholesterol, and increasing 




profiles resembled those 
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technical difficulties in measuring HDL concentration (i.e. HIV-infected 
patients with hyperglobulinemia, which is relatively common due to 
chronic hepatic disorders, presented falsely low HDL levels) 68. Further, no 
study has addressed the effect of these therapies on changes in carotid 
IMT, and as such we have data on classical cardiovascular risk factors, and 
not in the impact on atherosclerosis.
The prevalence of metabolic syndrome is significantly higher in HIV-
infected patients than in age-and-sex matched uninfected population69. 
Several causes have been hypothesized 70 but, as opposed to the 
“traditional” metabolic syndrome, patients receiving HAART may develop 
a lipotoxicity due to mitochondrial dysfunction resulting in the excess 
release of free fatty acids 71 , which in turn might be associated to the 
development of insulin resistance 72, one of the first key mechanisms in 
metabolic syndrome. The increase in free fatty acid concentration results in 
increased production of VLDL and small, dense LDL as well as low plasma 
levels of HDL. All these deleterious consequences have lead researchers to 
test the efficacy of acipimox, a nicotinic acid derivate that mainly blocks 
lipolysys. Acipimox resulted in significant sustained reductions in lipolysis, 
improved glucose homeostasis, and significant but modest reductions in 
triglycerides in HIV-infected individuals with abnormal fat distribution and 
hypertriglyceridemia 73 (Figure 7).  
However, all these metabolic alterations may be the source of  an 
overproduction of adipokines and  inflammatory cytokines, that in turn, 
may increase the likelihood of suffering from CVD 74, due to an exceedingly 
inflammatory response located in the artery wall. The relationship between 
cytokines and metabolic variables will be further developed in chapter 6. 
Figure 7. Pathophysiology of 
dyslipidemia and lipodystrophy 
in HIV-infected patients and the 
derived inflammatory response. 
Adapted from Biochimie 
2005;87:65-71 75.
“patients receiving 
HAART may develop a 
lipotoxicity due to 
mitochondrial 
dysfunction resulting in 
the excess release of free 
fatty acids
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5.2.- Lipodystrophy and 
atherosclerosis   
Lipodystrophy has been characterized as a syndrome of fat redistribution. 
Several variables have been involved in its origin, some HAART drugs, the 
HIV itself and immune variables 76, that in conjunct lead those patients 
to have persistent metabolic disturbances 77. These effects have not only 
physical and emotional consequences (Figure 8) but also are commonly 
associated with a greater cardiovascular risk profile. 
Figure 8. Clinical appearance of HIV-infected patients with 
lipodystrophy.
Footnote: note the loss of subcutaneous fat in both cheeks and the abnormal 
accumulation in the dorso-cervical pad; these changes exemplify two different 
phenotypes in lipodystrophy.
In fact, lipodystrophy resembles the definition of the metabolic syndrome: 
abdominal obesity, hypertriglyceridemia and low concentrations of HDL 
cholesterol, high blood pressure and insulin resistance 78,79. However, there 
is much controversy in its definition, and in fact, some authors consider the 
lipodystrophy in just those patients who develop lipohypertrophy, and not 
those with features of lipoatrophy 80,81.  Eventually, HIV-infected patients 
with lipodystrophy may be under the influence of several inflammatory, 
immunologic and metabolic alterations that may boost the development 
of early atherosclerosis. Although prospective observational studies in the 
incidence of CVD have not been conducted, Mercié P. et al 47 found that the 
presence of lipodystrophy was significantly associated with higher carotid 
IMT.
“lipodystrophy 
resembles the definition of 
the metabolic syndrome: 
abdominal obesity, 
hypertriglyceridemia and 
low concentrations of HDL 
cholesterol, high blood 





s in atherosclerosis and HIV-infection
UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
5.3.- Role of CD4+ 
T-cells in atherosclerosis
Atherosclerosis is an inflammatory disease82 and several inflammatory-
related variables have been not only identified in the atheromatous 
plaque83, but also implicated in the risk of suffering from cardiovascular 
events84. HIV infection is associated with accelerated T-cell proliferation, 
heightened T-cell activation, and high levels of inflammatory markers85,86. 
This immune activation has been independently associated with the 
number of CD4+ T-cells at the moment of HIV infection diagnoses87, 
which, in turn, was a predictor of atherosclerosis progression (being 
diagnosed of HIV infection with less than 200 CD4+T cells/mm3, was nearly 
significantly (p=0.08) correlated with a higher IMT progression)46. These 
data indicate that both immunodeficiency and immune reconstitution 
may be atherogenic. T lymphocytes, of which CD4 cells constitute the 
major population, play a key role in atherogenesis88,89. Among the cellular 
components of the atherosclerotic plaque, endothelial cells, monocytes 
and smooth muscle cells are the main players. However, T lymphocytes 
are also present and promote atherosclerosis through elaboration of pro-
inflammatory cytokines, including tumor necrosis factor and interleukins90. 
The progression of atherosclerosis is also modulated by the immune 
system in which the role of CD4 cells is of great relevance 91. The presence of 
oxidized LDL are considered the main antigenic stimuli in the atheromatous 
plaque among others such as heat shock proteins, beta-2-glycoprotein I 
and microbial antigens. It is well known the influence of Cytomegalovirus 
(CMV) and Chlamydia in atherosclerosis 92 , but this is specially relevant in 
HIV-infected patients, because they are under the influence of a higher T-
cell activation and in whom the thicker carotid IMT has been related to 
the presence of CMV-specific T-cell responses 54 .These data support the 
results of Tabib et al. 22 in which an extensive, inflammatory activity are 
observed in atheromatous plaques of HIV-infected people. Accordingly, 
Barbaro G et al 93, reported the presence of HIV particles in endothelial 
cells, supported by an intense infiltration of T lymphocytes, in HIV-infected 
people who suffered from a myocardial infarction (Figure 9). Interestingly, 
studies in vitro revealed that the HIV replication rate is far more increased 
in the presence of endothelial cells in the medium of culture 94.
All these data may indicate that the HIV infection itself and the direct 
influence on CD4+T cells are able to promote an intense immune-
inflammatory reaction in the artery wall, which might lead HIV-infected 
patients to be highly susceptible to known CV risk factors, and then they 
are prone to develop a highly inflammatory atheromatous plaques. 
“T lymphocytes, of 
which CD4 cells constitute 
the major population, play 
a key role in atherogenesis
“HIV infection itself 
and the direct influence on 
CD4+T cells are able to 
promote an intense 
immune-inflammatory 
reaction in the artery wall
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Supporting these observations, recent data on the efficacy of interrupting 
HAART schemes, showed that the programmed interruption of  HAART is 
associated with a higher risk of having a major cardiovascular event 95, and 
therefore, this may enhance the hypothesis that atherosclerosis in HIV-
infected patients might be influenced by the immunologic and virologic 
status. These mechanisms should explain the arteritis in large-medium 
arteries observed in some HIV-infected patients 96. 
In summary, HIV-infected patients presented a CV risk profile that should 
be encouragingly managed because of the clustering of risk factors which 
are boosted by the HIV infection itself and by the activation of the immune 
system, that might enhance the development of CVD in the future (Figure 
10).
Figure 9. In Situ Hybridization 
of an HIV-1 RNA Probe in 
a Transverse Section of a 
Branch of the Left Anterior 
Descending Coronary Artery, of 
an HIV-infected patient with a 
myocardial infarction. Intense 
staining indicates the presence 
of HIV-1 sequences within the 
intima and the media (arrows). 
There is a dense infiltration of 
lymphocytes within the media 
and necrosis of the intima, 
which is covered with swollen 
endothelial cells.
Figure 10. Summary of the known 
CV risk factors and those related 
with the HIV infection, that may 
accelerate the development of 
atherosclerosis in HIV-infected 
patients.
“ HIV-infected patients 
presented a CV risk profile 
that should be 
encouragingly managed 
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of risk factors which are 
boosted by the HIV 
infection itself and by the 
activation of the immune 
system, that might 
enhance the development 




s in atherosclerosis and HIV-infection
UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
6.- Pathogenesis of atheroscle-
rosis: the role of chemokines
6.1.- Introduction
In the atheromatous plaque several types of inflammatory cells have 
been identified 97. These cells reached the arterial wall proceeding from 
the arterial lumen and in these processes several molecules are implicated 
(Figure 11).
Chemokines are cytokines whose main function is to direct the migration 
of circulating leukocytes to sites of inflammation 98. Whether a leukocyte 
responds to a particular chemokine is determined by its complement of 
receptors. Chemokine binding activates a signal transduction cascade 
that activates phosphatidylinositol-3 kinase, increases levels of inositol 
triphosphate and intracellular calcium, activates Rho and mitogen-
activated protein kinases, and eventually leads to actin re-arrangement, 
shape change, and cell movement 99,100. 
There are four main families of chemokines, classified according to structure 
and function. The largest family is the CC chemokines, named because the 
first two of the four cysteine residues are adjacent to each other 101. The 
Figure 11. Overview of the 
inflammatory cell types in the 
arterial wall and processes 
mediated by chemokines. 
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most studied chemokine in the CC family is monocyte chemoattractant 
protein-1 (MCP-1) and its natural receptor is CCR-2. However, other CC 
chemokines (MIP-1α, MIP-1β, RANTES) also attract mononuclear cells to 
sites of chronic inflammation 102. A second family of chemokines consists 
of CXC chemokines, with a single aminoacid interposed between the 
two cysteines. Among them, interleukin-8 (CXCL8) has been strongly 
related to the attraction of polymorphonuclear leukocytes to sites of 
acute inflammation103. The third family is characterized by having three 
aminoacids between cysteines, and so they are named CX3C family. 
The unique chemokine in this group is fractalquine (CX3CL1), and it is 
of particular interest because it may act either as a direct adhesin or as 
a soluble chemoattractant with the participation of TNF-α converting 
enzyme 104.  
Insults to endothelial or smooth muscle cells, such as hypercholesterolemia 
or flow shear stress, stimulate the production of leukocyte chemoattractants 
that are both displayed on the luminal surface of endothelial cells and also 
secreted into the sub-endothelium 105. When these factors activate their 
receptors on rolling leukocytes, this induces firm integrin-dependent 
adhesion to the endothelium, followed by diapedesis into the sub-
endothelium 106. 
6.2.- MCP-1/CCR-2 and 
atherosclerosis
 6.2.1. Introduction
In the artery wall, monocytes differentiate into macrophages and take 
up cholesterol to become  foam cells, a major component of the fatty 
streak 107. The target cell specificity of MCP-1 for monocytes makes 
this chemokine a key candidate for the signal that brings circulating 
monocytes into the vessel wall 108, 109 . This may be the reason why MCP-
1 is strongly expressed in macrophage-rich regions of human and rabbit 
atherosclerotic lesions110 . Further, the induction of flow shear stress (in an 
animal model of hypertension) or the presence of oxidized LDL cholesterol 
have been associated with higher MCP-1 expression 111 , and interestingly, 
the sole interaction between monocytes and endothelial cells resulted 
in the increased expression of MCP-1112. The expression of MCP-1 is also 
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ability to promote inflammation in the vascular endothelium, by inducing 
the genes coding for vascular cellular adhesion molecule-1 and MCP-1113. 
TNF-α also modulates the expression of MCP-1, mediated by reactive oxygen 
species114 and through a NF-kappa B-dependent distal enhancer115.  The role 
of enhancers in MCP-1 expression is specially relevant, since the presence 
of activators, which bind the enhancers of the MCP-1 gene, accelerate the 
rate of gene transcription, indicating that the promoter region is highly 
influenced by these distal regions. One of these activators is CCAAT/
enhancer-binding protein (C/EBP), that stimulate transcription of MCP-1, 
interact with HIV particles 116 and intervene in adipocyte differentiation 117. 
In summary, all these evidences indicate that MCP-1 may be the mediator 
of known cardiovascular risk factors  (hypercholesterolemia, hypertension) 
in the inflammation of the artery wall, a process in which a complex 
chemokine interaction takes place.
The recruitment of monocytes/macrophages and migration to sites of 
inflammation may be performed by a number of different signaling 
molecules, but MCP-1 is probably the most important. Curiously, increased 
MCP-1 is detected in atherosclerotic lesions but not in normal arteries118. 
Mice rendered genetically deficient for MCP-1 have significant defects 
in the recruitment of monocytes to sites of inflammation119, and, when 
crossed with well-known models of atherosclerosis (LDL receptor or ApoE-/- 
), showed a decreased lesion formation 120 (Figure 12). 
The effect of CCR-2 deficiency has been also tested in a model of femoral 
arterial injury 121 in which it was observed that a significant reduction in 
intimal hyperplasia occurs after arterial injury in CCR-2 -/- mice compared 
with CCR-2 +/+ littermates. Conversely, the over-expression of MCP-1 
accelerates atherosclerosis in ApoE-deficient mice by increasing the number 
of macrophages in the artery lesion and oxidized lipid accumulation as 
reported in irradiated Apo E -/- mice 122. All these data suggest that MCP-1 
and/or CCR-2 play a pivotal role in critical and early stages of atherosclerosis 
development. 
“MCP-1 may be the 
mediator of known 
cardiovascular risk factors  
(hypercholesterolemia, 
hypertension) in the 
inflammation of the artery 
wall
Figure 12. Aorta photomicro-
graphs from mice deficient in LDL 
receptor (LDLr) (Panel A) and in 
double knockout (LDLr and MCP-
1, Panel B) animals, showing a 
significant reduction in the area 
of atheromatous plaque in those 
animals deficient in MCP-1.
“MCP-1 and/or CCR-2 
play a pivotal role in critical 
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Recent research has investigated MCP-1 as a potential therapeutic target in 
animal models of atherosclerosis. It has been described that an N-terminal 
deletion mutant of MCP-1 (7ND) gene, which lacks N-terminal amino acids 
2 to 8, produce a modified MCP-1 molecule that blocks the MCP-1/CCR-2 
pathway and completely inhibits MCP-1-mediated monocyte chemotaxis in 
vitro 123. Similarly, in ApoE-/-  mice, it inhibited the formation of atherosclerosis 
lesions without significant effects on serum lipid concentrations, and it 
also limited the progression of preexisting lesions 124. Moreover, the lesion 
composition showed fewer macrophages, less lipids, more smooth muscle 
cells and more collagen 125. Furthermore, the use of 7ND gene therapy is 
associated with a significant reduction in the intima hyperplasia of the 
vein graft 126, and rats and monkeys transfected with the mutant gene were 
more resistant to restenosis after balloon injury 127. 
In summary, these studies showed that MCP-1 is a promising therapeutic 
target to reduce not only the development of atherosclerosis but also 
the restenosis of coronary artery by-pass grafting or stent implantation 
in atheromatous plaques. The lack of MCP-1 is followed by impaired 
monocyte recruitment to the inflamed or injured artery wall, and then 
the development or instability of atheromatous plaques is less likely. 
Although these investigators found no adverse effects associated with 7ND 
transfection (studies lasted for 2 to 8 weeks), it is unlikely that a continuous 
blockade of MCP-1 function would have no major consequences. However, 
if limited to short periods of time, i.e. to prevent restenosis after coronary 
manipulation, this gene therapy may prove to be useful, and consequently, 
the search for products which may transiently inhibit the MCP-1 response 
to inflammation seems to be an strong strategy 128. 
 6.2.2. MCP-1-based strategies in   
 the management of atherosclerosis
“MCP-1 is a promising 
therapeutic target to 
reduce not only the 
development of 
atherosclerosis but also 
the restenosis of coronary 
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MCP-1 and its receptor CCR-2 have not only a direct effect in determining 
the impact of the inflammatory response in the atherosclerotic lesion, 
but they are also under the influence of metabolic variables and vice 
versa. The expression of CCR-2 is up-regulated in cell cultures enriched 
with LDL cholesterol, and these results have been confirmed in vivo. The 
CCR-2 expression was increased about 2-fold in monocytes isolated from 
hypercholesterolemic patients, compared to monocytes from normal 
controls, and there was a significant correlation between CCR-2 expression 
and plasma LDL concentration 129.  Similarly, Tous M et al. 130 described a 
significant increase in MCP-1 expression in aorta and in the liver that was 
mediated, at least in part, by the hypercholesterolemia experienced by 
ApoE-/-  mice.  It implies a higher likelihood for MCP-1/CCR-2 to interact and 
therefore a higher monocyte recruitment could be expected.
MCP-1 is sensitive to insulin resistance states, as shown in obese mice. The 
hyperinsulinemia that accompanies obesity leads to an over-expression 
of MCP-1, which in turn modifies the function of adipocytes 131. This may 
be important in the assessment of complications in type II diabetes and 
metabolic syndrome affected patients. 
Recent evidence showed that CCR-2 exerts a significant influence in both 
the development and maintenance of obesity. When mice were fed a high-
fat diet,  CCR-2  modulated feeding behavior, the development of obesity, 
and the development of obesity-associated adipose tissue inflammation 
and insulin resistance 132. 
Obesity has been closely related with the over-expression of chemokines 
and the plasma concentration of MCP-1 is higher in obese subjects than in 
controls 133, an association that is significantly attenuated by a reduction 
in body weight 134. These data indicate that there is a close link between 
the inflammatory response and some metabolic variables, a link that is bi-
directional, and that it could become an interesting focus of research in 
years to come.  It is of note that these findings suggest that the influence of 
MCP-1/CCR-2 is beyond the monocyte chemotaxis regulation and they are 
implicated in the pathophysiology of complex metabolic disturbances.
 6.2.3. MCP-1 is an insulin-responsive  
  gene; implications in metabolic   
  alterations.
“there is a close link 
between the inflammatory 
response and some 
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The variables implicated in the plasma concentration of MCP-1 were first 
reported in a cohort of Japanese participants 135. Age was significantly 
associated with higher plasma concentrations of MCP-1, even when 
participants with any atherosclerosis-related events were excluded.  
Several polymorphisms in the MCP-1 gene also have effects on MCP-1 
expression and, consequently, on its plasma concentration. The substitution 
of adenine for guanine at the position –2518 of the promoter region is 
the most studied, and influences the plasma concentration of MCP-1136. 
Those individuals who bear the mutated allele may be more responsive to 
any inflammatory stimuli, and then, more monocytes can be recruited to 
sites of inflammation. This boosted inflammatory response was probably 
a selective factor when infections were the main cause of death among 
population.  This concept may well be exemplified with the deletion 
of 32 base pairs in the CCR-5 gene, a mutation that protects against the 
consequences of Yersinia pestis infection 137. Nowadays, however, it may be 
a predisposing factor to a detrimental inflammatory response in the artery 
wall and in particular may become a strong atherosclerosis promoter.  
The oxidation of lipids, specially the presence of ox-LDL cholesterol in the 
artery wall, is a highly efficient trigger in the inflammatory cascade, which 
leads to the development of atherosclerosis 138. The presence of these 
oxidized particles increases the expression of MCP-1 139, and again, these 
data confirm that MCP-1 may be the driver of the inflammatory cascade 
originated by oxidized particles in the artery wall. 
There are several drugs that may modulate both the expression and 
concentration of MCP-1. Statins, by inhibiting HMG-CoA reductase, are 
potent inhibitors of MCP-1 expression in several cell culture lines 140. 
Studies in humans have confirmed a beneficial influence of lipid-lowering 
therapy, with statins and/or fibrates,  in the reduction of plasma MCP-1 
concentration, an effect that is not solely a consequence of the significant 
reduction in LDL cholesterol concentration but is a direct effect on the gene 
expression of MCP-1141, 142. This reduction was further incremented when 
patients with hypercholesterolemia and hypertension were treated with a 
combination of statins and an angiotensin II receptor antagonist 143. 
 6.2.4. Determinants of plasma  
  MCP-1 concentration
“individuals who bear 
the mutated allele may be 
more responsive to any 
inflammatory stimuli, and 
more monocytes can be 
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MCP-1 has been assessed in several studies addressing its influence in 
atherosclerosis and results are summarized in Table 4. Serum concentrations 
of MCP-1 are higher in salt-sensitive high blood pressure patients 144, and 
have also been related to a worse metabolic control in diabetic patients 
145, suggesting that persistently higher concentrations of plasma glucose 
are associated with an up-regulation of MCP-1 and CCR-2. In another 
study, the serum concentration of MCP-1 did not show an independent 
predictive value in the vascular risk assessment, although the presence of 
the mutated allele in the promoter region (-2518G) was associated with a 
higher risk of subclinical atherosclerosis 146. 
Several studies have addressed the relationship between MCP-1 and the 
occurrence and severity of cardiovascular diseases. Studies combining 
the measurement of IMT or the coronary calcium score and the systemic 
inflammatory activity revealed that the higher the plasma MCP-1 
concentration, the higher the carotid IMT or the CAC score 147, 148 (Table 4). 
Results from a large prospective study showed a significant association 
between plasma MCP-1 concentration and clinical outcomes in patients 
with acute coronary syndrome 149. The association was also strong with 
cardiovascular risk factors such as age, smoking, family history of coronary 
artery disease, hypertension, diabetes, hypercholesterolemia and higher 
concentration of C-reactive protein. MCP-1 has also been studied in 
patients after receiving coronary angioplasty, and the findings indicate 
that the higher the plasma concentrations of MCP-1, the higher the 
likelihood of having a restenosis, which highlights the potential of using 
plasma MCP-1 as a biomarker to assess the prognosis of the acute coronary 
syndromes150. Although, most of these studies showed a clear relationship 
between plasma MCP-1 concentration and the presence of the disease, it is 
not clearly stated whether MCP-1 represents an independent risk factor for 
its development . More recently, Van Mieghem CA. et al 151 have published 
their results concerning the use of non-standard laboratory and image-
related variables for the prediction of coronary events. The concentrations 
of C-reactive protein, interleukin-6 and MCP-1 were not associated with 
changes in novel invasive imaging modalities, such as palpography or 
virtual histology of the coronary arteries, adding further controversies to 
the feasibility of using MCP-1 as a biomarker for CV diseases.
6.2.5. MCP-1 and atherosclerosis  
 in humans.
“significant association 
between plasma MCP-1   
concentration and clinical 
outcomes in patients with 
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Biomarkers are generally considered to be plasma measurements of 
molecules, proteins, or enzymes that provide independent diagnostic or 
prognostic value by reflecting an underlying disease, state or condition. 
Several issues should be accomplished by the biomarker to emerge in the 
clinical settings 152:
        1. It should be able to account for a significant proportion of the disease 
being evaluated.
        2. It should be accurate and reliable. 
        3. It should provide good sensitivity, specificity, and predictive value.
        4. It should be available for widespread application. 
Moreover, the clinical application ultimately requires that the biomarker 
substantively must add new information to traditional risk factors, such as 
those used in the Framingham risk score. Among relatively new biomarkers, 
these attributes have been partly accomplished by C-reactive protein 153. 
Only three studies provide data to assess plasma MCP-1 as a biomarker 
for atherosclerosis. McDermott et al 136 measured the serum concentration 
of MCP-1 in the Framingham cohort. There was a significant correlation 
with age, cigarette smoking, triglycerides, body mass index, and waist-to-
hip ratio. However, these covariates explained only 6% of the variability 
in serum MCP-1, which in turn were not associated with the prevalence 
of myocardial infarction in multivariate models. Similarly, Iwai N. et al 154 
reported that MCP-1 concentration is highly correlated with carotid IMT, 
but this association lacked significance in the multivariate model. In this 
study, however, there was no data on the plasma MCP-1 concentration 
for patients with MI. Finally, Mosedale DE et al.155 assessed the role of 
plasma MCP-1 concentration in predicting atherosclerotic burden and the 
correlation with the Framingham risk score. They did not find any significant 
relationship.
All these results suggest no value for circulating MCP-1as a biomarker 
for atherosclerosis. It may be argued, however, that because MCP-1 acts 
in the inflamed sites, including the artery wall, the measurement of its 
circulating concentrations is not reliable. Technical limitations (due to the 
inherent circulating nature of MCP-1) should not overshadow the relevant 
implications of this chemokine in atherosclerosis.  The role of MCP-1 in 
atherosclerosis is beyond discussion, and chemokine research specially 
focused in MCP-1/CCR-2 supports the role of this chemokine axis in 
the pathophysiology of atherosclerosis.
6.2.6. MCP-1 as a potential 
biomarker for atherosclerosis 
and concluding remarks.
“The role of MCP-1 in 
atherosclerosis is beyond 
discussion, and chemokine 
research specially focused 
in MCP-1/CCR-2 supports 
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Table 4. Summary of human studies assessing the relationship between 
circulating MCP-1 and atherosclerosis.
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DM indicates diabetes mellitus. IMT: intima-media thickness; CAC: coronary 
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1α, MIP-1β/CCR-5 and 
atherosclerosis
RANTES, MIP-1α, MIP-1β belong to CC group of chemokines, and their 
natural receptor is CCR-5, a trans-membrane protein164. They are also 
involved in the recruitment of monocytes to the inflamed arterial wall, 
although the implication of these chemokines in atherosclerosis is more 
controversial165,166. CCR-5 is present on human aortic smooth muscle cells, 
and its ligands mobilize intracellular calcium and induce the expression of 
tissue factor 167. Thrombosis mediated by tissue factor is widely regarded as 
a key factor in the pathogenesis of acute coronary syndromes 168. Thus, CCR-
5 may transduce signaling pathways known to have clinical manifestations 
and to be associated with smooth muscle cell activation. Met-RANTES, a 
chemokine receptor antagonist that blocks CCR-1 and CCR-5, significantly 
reduced lesion progression in atherosclerotic mice169. Met-RANTES also 
inhibits intimal hyperplasia after arterial injury to ApoE -/- 170,supporting 
a role for these chemokines in mediating the response to arterial injury 
(Figure 13).
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Figure 13. Effect of Met-RANTES (block of CCR-5) in the aorta of mice 
prone to atherosclerosis. (Circ Res. 2004;94:253-261).
Footnote: a significant reduction in plaque area was observed in those mice 
treated with Met-RANTES paralleled with a reduction in lipid deposition (black 
bars in figure G). C and F slides withdraw those treated with Met-RANTES.
These research have led to the design and study of anti CCR-5 molecules that 
have been tested in mouse-model of atherosclerosis. TAK-779 is an anti-CCR5 
agent that effectively decreased the development of atherosclerosis in mice, 
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6.4.- SDF-1 and 
atherosclerosis
SDF-1 is a CXC chemokine that mainly chemoattracts lymphocytes and 
monocytes 172. It has been associated with the aggregation and activation 
of platelets 173, it is highly expressed in atherosclerotic plaques 174, and it 
has been associated with the mobilization of progenitor cells in diabetic 
patients treated with insulin 175 . Interestingly, platelets express and release 
SDF-1 into the microcirculation upon activation, and platelet-derived SDF-
1 is functionally involved in the recruitment of endothelial progenitor 
cells  to arterial thrombi 176. SDF-1 also induces tissue factor synthesis in 
smooth muscle cells, mediating a procoagulant state in the arterial wall 177. 
Furthermore, neutralizing antibodies to SDF-1 inhibited intimal hyperplasia 
after carotid arterial injury in the ApoE _/_ mice 178. These data attribute a 
detrimental effect of SDF-1 in the development of atherosclerosis and in 
the destabilization of atheromatous plaques. However, data on animal 
models targeting SDF-1 in the development of atherosclerosis is lacking 
and studies in humans are scarce. 
Interestingly, SDF-1 is also related with metabolic and immune variables. 
The SDF-1 gene is located on chromosome 10q11.1 near type 1 diabetes 
susceptibility locus IDDM10, that may suggest a contribution by SDF-1 to 
the induction of diabetes.  A selected polymorphism in the SDF-1 gene is 
associated with the age-at-onset of diabetes mellitus, and this association 
is probably related with the activation of monocytes and naïve T cells 
mediated by SDF-1, that determine the degree of the insulitis before 
development of overt diabetes 179. Indeed, Matin and coworkers 180 have 
reported that administration of anti-SDF-1 antibody to female diabetic 
mice resulted in the suppression of insulitis and diabetes onset.
Footnote: arrowheads indicate lymphocyte infiltration. Note the lymphocyte 
spread in the untreated diabetic mice( in slide C) when compared to anti-SDF-
1 treated mice (B) and non-diabetic controls (A).
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Figure 14. Photomicrographs 
of pancreatic islets in : A) non-
diabetic mouse, B) anti-SDF-1 
treated  diabetic mice and 
C) untreated diabetic mice 
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6.5.- CX3CR-1 and 
atherosclerosis
Fractalkine and its natural receptor, CX3CR-1, have a critical role in the 
chemotaxis of circulating monocytes to the subendothelial space 181. 
Fractalkine contain multiple domains and is structurally distinct from other 
chemokines. The extracellular domain connects to an extended mucin-like 
stalk, followed by a transmembrane domain and an intracellular domain of 
37 amino acids 182, and therefore, it functions not only as a chemo-attractant 
but also as an adhesion molecule 183,  thereby obviating the need for both 
the association with proteoglycans and other adhesion molecules 184. The 
CX3CR-1 gene is located in the chromosome 3q22 and fractalkine is in 16q. 
The expression of fractalkine can be markedly induced by inflammatory 
cytokines, such as tumor necrosis factor (TNF-α), interleukin (IL)-1, and 
interferon γ (IFN) 185. 
CX3CR1-expressing cells bind rapidly and with high affinity to immobilized 
fractalkine or fractalkine-expressing cells in both static and  physiological 
flow conditions (Figure 15).
This particularity supports the active research concerning CX3CR-1/
fractalkine and atherosclerosis 186. Fractalkine expression is upregulated in 
atherosclerotic lesions and crossing CX3CR1-/- into the ApoE-/- mice, results 
in decreased atherosclerotic lesion formation with reduced macrophage 
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Figure 15. Schematic overview of monocyte chemotaxis, comparing 
chemokines (Panel A) and fractalkine (Panel B) (Arterioscler Thromb 
Vasc Biol. 2004;24:34-40). Interestingly, fractalkine is selectin and 
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7.- Have these chemokines been 
involved in HIV pathogenesis?
The entry of HIV into the cell is highly influenced by molecular interactions, 
in which chemokines and chemokine-receptors have a relevant role 189. HIV 
possess a single type 1 integral membrane glycoprotein, the viral envelope 
(Env), which is responsible for both receptor binding and mediating the 
membrane fusion between the virus particle and the host cell membranes. 
Env is initially synthesized as a monomeric glycoprotein precursor (gp160) 
which is processed into the gp120 surface subunit and gp41 transmembrane 
subunit domains 190. The entry process is a two-step event where an initial 
association of Env with CD4+ cell surface elicits conformational changes 
in gp120 that expose the chemokine receptor binding site. Subsequent 
interaction of the gp120-CD4 complex with the relevant chemokine 
receptor molecule results in further conformational changes in the gp41 
subunit which in turn facilitates the fusion event between the viral and 
host cell membranes 191 (Figure 16).
 Figure 16. Schematic overview of the process of HIV-entry into the cell 
(Biochimica et Biophysica Acta 2003; 1614: 36– 50 192). 
“The entry of HIV into 
the cell is highly influenced 
by molecular interactions, 
in which chemokines and 
chemokine-receptors have 
a relevant role
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Different chemokine receptors (CCR-2, CCR-3, CCR-5, CXCR-4, STRL33) 
or orphan, chemokine receptor-like molecules (GPR1, GPR15, V28, APJ) 
may participate in HIV entry, but the initially described CXCR-4 and CCR-
5 molecules remain the principal co-receptors for X4 (T cell line-tropic 
or syncytium inducing) or R5 (macrophage (M)-tropic or non-syncytium 
inducing) isolates, respectively 193.
In early stages of HIV-infection, HIV generally uses M-tropic co-receptors 
(CCR-5), and progressively the virus may use both ways of cellular entry 
(CCR-5 and/or CXCR-4)194. Thus, all the natural ligands of these chemokine 
receptors may interact and compete with HIV in the entry into the cell 
(Figure 17). The inhibitory effect of the CCR-5 natural ligands, MIP-1α, 
MIP-1β and RANTES, on the infection by R5 HIV strains in vitro is well 
established. Likewise, SDF-1 suppresses the entry of X4 HIV strains. Both 
blocking and down-regulation of chemokine receptors are ways by which 
their physiologic ligands or modified analogs can reduce HIV entry 195. 
Besides, co-receptor dimerization is postulated  as a powerful mechanism 
in avoiding the interaction between HIV-Env proteins and host cell co-
receptors 196.
Figure 17. Interaction of chemokines, chemokine co-receptors and 
HIV virus.
“all the natural ligands 
of these chemokine 
receptors may interact and 
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entry into the cell 
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In conclusion, the entry of HIV into the cell and the migration of monocytes 
through endothelial cells in the first steps of atherosclerosis development, 
share molecular mechanisms, in which chemokines and their receptors 
are highly involved. HIV needs these chemokine-based nets to reach the 
interior of CD4+ cells, and consequently both systems (i.e. HIV virus and 
host chemokine system) display mechanisms to interact with each other. 
In fact, the virus itself is able to modify the expression of both chemokine 
and chemokine-receptors in cells 197. HIV infection may influence the 
intracellular signaling pathways 198 and potentially modify the cellular 
response to chemokines. For instance, HIV-1 transactivator (Tat) protein 
is produced by infected cells and released into the extracellular medium. 
Tat can mediate its effects either by penetrating cells and inducing gene 
transactivation, or binding to cell surface molecules such as integrins or 
chemokine receptors199. It was recently observed that incubation of PBMC 
with Tat increased surface expression of CCR-5 and CXCR-4 200. Analysis of the 
Tat protein sequence revealed conserved amino acids which corresponded 
to critical sequences seen in chemokines and remarkably, Tat was
a potent chemoattractant for monocytes. Tat or its ‘‘chemokine-like’’ 
region induced rapid and transient calcium influx in monocytes and 
macrophages199. These “pleiotropic” activities of Tat constitute a defense 
mechanism run by HIV itself, that ultimately favors HIV replication, but 
simultaneously imply a major likelihood for mononuclear cells to interact 
with inflamed sites, such as the artery wall. For these reasons, the influence 
of HIV on chemokines should be considered in the study of atherosclerosis, 
since it might represent a key mechanism for its development (Figure 18).
“Tat or its 
‘‘chemokine-like’’ region 
induced rapid and 
transient calcium influx in 
monocytes and 
macrophages
Figure 18. Overview of the 
influences of HIV on chemokines. 
Its potential implications in 
atherosclerosis are depicted, 
focusing on the effects of Tat.
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Figure 19. Schematic overview 
of the effects of selected SNPs in 
chemokines affecting the entry 
of HIV into the cell .
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“SNPs cause a relevant 
alteration in the function 
or the quantity of the gene 
product, and therefore, 
different clinical 
phenotypes should be 
expected
Single nucleotide polymorphisms (SNPs) in genes coding for these 
molecules have been identified. These SNPs cause a relevant alteration in the 
function or the quantity of the gene product, and therefore, different clinical 
phenotypes should be expected, both in HIV-infection and atherosclerosis 
201,202 (Figure 19 and Table 5). The influence of selected polymorphisms 
in MCP-1 and CCR-2 genes in the development of atherosclerosis have 
been previously analyzed (see Pathogenesis of atherosclerosis: the role of 
chemokines, Chapter 6).
a. The homozygous deletion of 32 base pairs in the CCR-5 gene, alters the structural 
conformation of CCR-5, that makes this receptor unable to interact with HIV 
proteins.
b. The loss of 32 base pairs in one of the alleles in the CCR-5 gene, alters the 
expression of CCR-5 and makes the interaction of HIV with CCR-5 unlikely.
c. The substitution of Valine for Isoleucine in the position 64 of the CCR-2 gene alters 
the function of CCR-2. This change may difficult the interaction between CCR-2 
and HIV.
d. The substitution of G to A in the untranslated region of the SDF-1 gene (801), 
named SDF1-3’A, is associated with changes in the expression of the gene product, 
that interacts with its receptor and block the entry of HIV into the cell.
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The substitution of Adenine for Guanine in the position 2518 of the 
promoter region of MCP-1 gene, confers a major MCP-1 expression in 
response to inflammatory stimulus 203. HIV-infected patients have higher 
plasma concentrations of MCP-1 than non-infected population 204, and 
probably this is related to the effect of Tat protein of HIV 205. Taking all these 
data into account, we could hypothesize that those HIV-infected patients 
who bear the mutated MCP-1 allele would be predisposed to an even 
higher MCP-1 expression than those individuals non-infected who bear 
the mutated allele.
Studies in HIV-infected patients and MCP-1 yield contradictory results. 
The presence of –2518G allele of the MCP-1 gene has been related to a 
lower risk of acquiring HIV infection. Conversely, it has been found that, 
in patients who are already infected and who carry the MCP-1mutated 
allele, the progression to AIDS is accelerated and the risk of suffering from 
HIV-associated dementia and Mycobacterium avium complex infection is 
higher than in patients with the common variant 206. Conversely, in a Spanish 
cohort study, the allele frequency of MCP-1-2518 G was significantly 
higher in HIV-infected patients than 36 exposed-uninfected individuals 
and 100 controls 207. Several reasons may explain the discrepancies, such 
as the different genetic background between populations or the different 
study design and eligibility criteria for the inclusion in the study. However, 
a wider approach should be addressed, probably studying haplotypes 
instead of SNPs. Modi WS et al.208 studied the long arm of chromosome 17 
along 33 kb, where MCP-1, MCP-3 and eotaxin are encoded. They find that 
three SNPs (-2136 T located in the MCP-1 promoter region, 767G in intron 
1 of MCP-1, and -1385A in the Eotaxin promoter) were nearly always found 
together on a 31 kb haplotype (H7). Frequencies of the three variants and 
the H7 haplotype were significantly elevated (odds ratio, 0.6; P = 0.005) in 
uninfected European- Americans repeatedly exposed to HIV through high-
risk sexual behavior or contaminated blood products, suggesting that 
genetic variation in the H7 region protects to acquire HIV-1 infection. 
Thus, MCP-1 expression had a two-edged role in HIV infection: it might 
afford partial protection from viral infection, but during infection, its pro-
inflammatory properties collectively may contribute to accelerates disease 
progression and increases risk of dementia and other AIDS-associated 
diseases 206.
“we could hypothesize 
that those HIV-infected 
patients who bear the 
mutated MCP-1 allele 
would be predisposed to 
an even higher MCP-1 
expression than those 
individuals non-infected 
who bear the mutated 
allele.
“genetic variation in the 
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The substituion of Valine for Isoleucine in the position 64 (in the first 
transmembrane domain) of the CCR-2 gene has been associated to changes 
in receptor functions 209. CCR-2 is a minor co-receptor for HIV infection, and 
it is CCR5’s closest gen, based on chromosomal proximity (Figure 20).
Figure 20. Genetic map of chemokine receptor gene cluster on human 
chromosome 3p21. CCR2-64I, CCR5 delta 32 and single nucleotide 
variants of the CCR5 promoter region are indicated by their nucleotide 
position ( Immunological Reviews 2000; 177: 99–111. 210).
Although studies in human populations have yielded  contradictory 
results, probably due to the low mutated allele frequency 211, this 
polymorphism has been associated to a delay in the onset of AIDS for 
homozygotes and heterozygotes, without effect on HIV transmission 
(Figure 21) 212.  Interestingly, HIV-infected patients with nadir CD4+T cells 
between 200 and 500 and who bear the CCR-2 mutated allele, achieved 
undetectable HIV viral loads significantly earlier than wild type individuals, 
although this beneficial response was not paralleled by a better rate of 
CD4+T cell recovery 213. The mechanisms underlying  these effects are 
“this polymorphism has 
been associated to a delay 
in the onset of AIDS for 
homozygotes and 
heterozygotes, without 




s in atherosclerosis and HIV-infection
UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
not fully understood. The presence of the CCR2-64I allele is in complete 
linkage disequilibrium with CCR-5∆32, thus, CCR5∆32 and CCR2-64I had 
independent and potent additive effects on delaying AIDS 214. Functional 
assays showed little difference in monocyte chemoattractant protein-1 
ligand signaling or in the quantity of CCR-2 expressed on peripheral blood 
mononuclear cells of different CCR-2 genotypes, but they did show indirect 
evidence for heterodimerization between CCR-2 and the quantity of CXCR-
4 and CCR-5 expressed 215, 216. Similarly, Rodriguez-Frade et al. reported the 
beneficial effects of CCR-2 activation using a monoclonal antibody, that 
acts as its natural substrate, MCP-1,in blocking the entry of HIV into the cell 
217. This observation is mediated by the heterodimerization of CCR-2 with 
CCR-5 and CXCR-4.
CCR-5∆32
The CCR-5∆32 is a mutant allele containing a 32 base pair deletion in 
the open reading frame of the CCR-5 gene that induces a frame shift, a 
premature stop codon, and loss of  HIV co-receptor activity 218, 219 (Figure 
22). These changes may alter the correct interaction between CCR-5 and its 
natural ligands, RANTES, MIPs 1-α and β, and then, the chemotaxis might be 
severely impaired 220. The frequency of this mutant allele is approximately 
1% in the homozygous state and 10 to 20% for the heterozygous state 
among Caucasians in North America or Europe, but is lower or absent in 
subjects of African, Asian, and Latin American heritage 221.
The influence of this mutated allele in HIV infection has been fully 
studied. Similarly, intense research in animal models prone to develop 
atherosclerosis, have resulted in relevant insights in atherosclerosis. 
Theoretically this polymorphism should be associated to a protective 
effect in the development of atherosclerosis, but studies did not yield 
uniform results. Szalai C et al 165, found a lower prevalence of homozygous 
individuals for CCR-5∆32 among those cases of coronary artery disease, but 
it has not been further confirmed 222,223 .
CCR-5 was one of the first HIV co-receptors identified for those M-tropic 
HIV strains. Thus, research have been focusing on the influence of mutated 
CCR-5 alleles in HIV infection and disease progression. The highlights of 
these studies are consistent with the following:
- those individuals homozygous for ∆32 allele in the CCR-5 gene 
has a natural resistance to HIV-infection although being several 
times exposed 224.
- Those HIV-infected patients who bear at least one mutated 
allele for the  ∆32 are more prone to delayed HIV-disease 
progression 225 (Figure 21).
“Theoretically this 
polymorphism should be 
associated to a protective 
effect in the development 
of atherosclerosis








































UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 




s in atherosclerosis and HIV-infection
Figure 21. Influence of CCR-5∆32 and CCR-2 64I polymorphisms in 
AIDS (From Science 1997;277:959–965).
Footnote: Kaplan Meier survival curves for AIDS-free or alive participants of 
MHCS cohort (panels A, C and E) and a composite of several cohorts including 
MHCS (panels B, D and F). ++ indicate CCR-5 wild type; +/64I heterozygote for 
CCR2-64I; +/∆32 heterozygote for CCR-5∆32. RH: hazard ratio.
Figure 22. Schematic representation of CCR-5 receptor.
Footnote: Panel a. No-mutated CCR-5 receptor. Panel b. CCR-5 receptor with 
32 base pairs deleted.
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The screening for polymorphisms of the CXCR4 gene have to date 
yielded only two nucleotide variants which have little epidemiologic 
consequences226 . When the coding region of the only known CXCR4 ligand, 
SDF, was interrogated, a common SNP variant at position 801 (counting 
from the AUG codon) in the 3’ un-translated region (3’UTR) for SDF-1β was 
discovered 227 (Figure 23 ).
Figure 23. Gen map of SDF-1 locus on human chromosome 10q11.1 
(Immunological Reviews 2000; 177: 99–111). 
Because SDF expression is limited to stromal cells and other tissues that 
are not easy to quantify 228, studies based on the circulating concentrations 
of SDF-1 present serious limitations; however, individuals who bear the 
SDF1-3’A presented a minor SDF-1 expression and lower circulating levels 
of SDF-1 229 . Further, circulating levels of SDF-1α have been found to be 
lower in an acute coronary heart disease study 230 although no relationship 
has yet been found between the allelic frequency of the SDF1-3’A and the 
presence of coronary artery disease 231. 
HIV-infected individuals homozygous for the SDF1-3’A/3’A variant show 
a remarkable level of protection against AIDS in pooled or separated 
cohorts. Among individuals with both SDF1-3’A/3’A and CCR-5 (or CCR-2) 
heterozygous mutant alleles, the protective effect is quite strong – several-
fold higher than that conferred by CCR-5 or CCR-2 heterozygosity alone 
232 (Figure 24), although results from meta-analyses did not support this 
conclusion 233 . Several hypothesis have arose concerning SDF-1 and HIV, 
“studies based on the 
circulating concentrations 
of SDF-1 present serious 
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individuals who bear the 
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and in fact, the epidemiologic interaction of CCR-5 or CCR-2 and SDF1-
3’A (a genetic phenomenon termed epistasis) suggests that a functional 
interaction might explain the enhanced protection. One hypothesis is that 
CCR-2 and CCR-5 variants slow AIDS by limiting the number of CCR-5 co-
receptors that mediate the replication and spread of primary, early stage 
R5 HIV, while the SDF1-3’A variant restricts the emergence of X4 tropic HIV 
strains and the ensuing AIDS-accelerating process. A possible mechanism 
would be overproduction of SDF-1 in local compartments, which binds to 
and blocks the CXCR-4 receptors required for X4 viruses to emerge and 
predominate.
Figure 24. Kaplan Meyer Curves of the effects of SDF1-3’A on HIV 
disease progression (Immunological Reviews 2000; 177: 99–111).
Footnote: it is of interest to remark the enhanced protection in those HIV-
infected patients who bear the mutated alleles in all (CCR-5 or CCR-2 and 
SDF-1) to keep AIDS-free. SDF-1 and these chemokine receptors are involved 
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These two polymorphisms in the CX3CR-1 gene are in complete linkage 
disequilibrium, and those individuals who bear the mutated allele 
(either 249I or 280 M) presented an impaired leukocyte migration related 
with a decrease in the CX3CR-1 expression 234. Therefore, the CX3CR-1/
fractalkine axis might be less effective in the chemotaxis of monocytes. 
These polymorphisms have been largely studied in atherosclerosis. A case 
control study of coronary artery disease (CAD) affected patients revealed 
that individuals with the 249I allele were less frequent in the CAD group 
compared with those without CAD (38% vs. 51%) 235, probably related with 
an impairment of the monocyte adhesive function 236. The evaluation of 
coronary vascular function in 339 subjects according to polymorphisms 
in CX3CR-1 gene resulted in that both the prevalence and severity of 
CAD were less relevant in the group that was heterozygous for the 249I 
allele compared with the group that was homozygous for V249 237. Studies 
using the measurement of carotid IMT revealed a beneficial influence in 
those participants who bear the 280M 238, although these results are not 
supported by other studies 239.
In HIV-infected patients the CX3CR-1 gene has also been a focus of intense 
research and controversial results. HIV-infected patients homozygous 
for CX3CR1-249I, progressed to AIDS more rapidly than those with other 
haplotypes. Functional CX3CR-1 analysis showed that fractalkine binding 
is reduced among patients homozygous for this particular haplotype 240. 
However, an study performed in the United States, based in homosexual 
men did not yield similar results, and the authors did not find any genetic 
association between the course of HIV infection and the polymorphisms in 
the CX3CR-1 gene 241. When these association studies were applied to HIV-
infected patients under antiretroviral therapies, the presence of CX3CR-1 
280M homozygosity was associated with higher peripheral CD4+ T cell 
counts than those bearing the wild type allele (p = 0.003) 242.
“individuals who bear 
the mutated allele 
presented an impaired 
leukocyte migration
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9.- Summary of chemokine 
related polymorphisms in HIV 
infection and atherosclerosis. 
(Table 5)
As previously stated, the initial steps of atherosclerosis and the entry of 
HIV into the cell share similar biological mechanisms. The expression and 
structural composition of these molecules are influenced by the individual 
genetic background, resulting in different disease manifestations. For 
this reason, we have studied molecules implicated in both processes, 
atherosclerosis and HIV infection. In table 5 we have summarized the main 
effects of the polymorphisms studied in both diseases.
CAD denotes coronary heart disease. LTNP: long term non-progressors.
The presence of the mutated MCP-1−2518G allele has been described to 
be protective as far as the HIV infection is concerned, but once infected, 
patients with the mutated allele would be more prone to HIV associated 
diseases, and also in the development of atherosclerosis. Conversely, 
those patients with the CCR2-64I are protected to HIV infection and to the 
development of atherosclerosis, although human studies are scarce. Those 
patients with the deletion of 32 base-pairs in the CCR-5 gene are protected 
to be infected by HIV, progress to AIDS significantly slower, and probably 
would also be protected in the development of atherosclerosis. The study 
of SDF1-3’A has yielded contradictory results in HIV disease progression 
and data concerning atherosclerosis are scarce. Finally, CX3CR-1 V249I/
T280M are robustly associated with a lesser expression of atherosclerosis, 
although its role in HIV is far more controversial.
Table 5. Influence of several 
SNPs in genes coding for 
chemokines and chemokine-
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HIV-infected patients live longer since the generalization of highly 
effective antiretroviral therapies. This relevant advance has yielded those 
patients to the presentation of concomitant diseases. Cardiovascular 
diseases represent the first cause of morbidity and mortality in non-
infected individuals in industrialized countries. However, there is not a 
uniform presentation concerning atherosclerosis in HIV-infected patients, 
and consequently, a genetic predisposition could be hypothesized. In the 
search of these genetic candidates we have explored chemokines and 
chemokine-receptors, because these systems are involved in both HIV 
infection and atherosclerosis, and theoretically, HIV infection present a 
relevant influence in these chemokine networks.
Therefore, the aim of this work is to study the role of selected chemokines, 
implicated in the entry of HIV into the cell, in the development of 
atherosclerosis. We have also studied whether this functional polymorphisms 
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Outline of the thesis
 1.- To explore the role of the following chemokine and chemokine-
receptor polymorphisms:  MCP-1−2518G, CCR-2 64I, SDF1-3’A and CX3CR-
1V249I/T280M,
in atherosclerosis (measured by intima-media thickness [IMT]) in HIV-
infected patients.
 2.- To study the influence of MCP-1−2518G in HIV disease 
progression, in patients under antiretroviral therapy.
 3.- To study the impact of the above-mentioned genetic variants, 
in the progression/regression of IMT in HIV-infected patients.
 4.- To introduce the assessment of IMT in the HIV clinic, in order 
to determine the presence of atherosclerosis, in addition to the study of 
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Original Manuscript #1 published in                       
Circulation 2004;110:2204-2209.
“Atherosclerosis in Patients 
Infected With HIV is Influenced 
by a Mutant Monocyte 
Chemoattractant Protein-1 
Allele”
In the first cross-sectional study, we studied 183 HIV-infected subjects (124 men, 59 women, 20 to 66 
years old). The aim of this study was to assess atherosclerosis and its related-variables and , therefore, 
we analyzed data according to a case-control design (presence or absence of atherosclerotic lesions). 
We performed carotid and femoral ultrasound exams to explore IMT values and the presence of 
atheromatous plaques. Clinical data and biologic samples (plasma, serum and DNA) were collated.
Participants with atherosclerosis were significantly older than the control group (P<0.001). Most of 
them were heavy smokers and with higher rates of hypertension and abnormal fasting glucose 
concentrations. Those HIV-infected patients with atherosclerosis had a  significantly higher 
concentration of plasma MCP-1 than those without atherosclerosis. 
The majority of patients (n=139; 76.0%) presented with atherosclerotic lesions in either carotid or 
femoral arteries. The frequencies of GG and GA genotypes in the MCP-1 gene polymorphism were 
significantly higher in subjects with atherosclerosis than in those without (47.5% versus 18.2%; 
P<0.001). When data was analyzed according to age, subjects with at least 1 mutated allele for MCP-1 
had higher rates of atherosclerotic lesions in each of the age quartiles, and further, age was significantly 
associated with atherosclerotic lesions (OR 1.32, 95% CI 1.17 to 1.50, P<0.001) as was the MCP-1–2518G 
allele (OR 5.72, 95% CI 1.74 to 18.80, P<0.004). 
The effect of the MCP-1–mutated allele was evaluated with respect to the clinical course of the 
atherosclerotic lesions with the stored images available for 40 subjects, and those who bear the 
mutated MCP-1 allele, presented a significantly higher increase in the area of atheromatous plaques. 
Our results attribute a critical role to MCP-1 in the development of atherosclerosis in HIV-infected patients. 
It is particularly interesting to highlight that both the mutated allele and the plasma concentration of 
MCP-1 were implicated in atherosclerosis. The HIV infection itself is able to over express MCP-1 gene 
(boosting the influence in those individuals who bear the mutated allele), and consequently, renders 
those individuals with both conditions to a higher risk of developing atherosclerosis. The main result is 
that the study of the inflammatory status is relevant in the assessment of atherosclerosis (studied non-
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Atherosclerosis in Patients Infected With HIV Is Influenced
by a Mutant Monocyte Chemoattractant Protein-1 Allele
Carlos Alonso-Villaverde, MD; Blai Coll, MD; Sandra Parra, MD; Manuel Montero, MD;
Nahum Calvo, MD; Mònica Tous, PhD; Jorge Joven, MD; Lluis Masana, MD
Background—Patients infected with HIV present with premature atherosclerosis, and the 2 diseases share common
pathogenic pathways. We investigated mutations in the monocyte chemoattractant protein-1 (MCP-1) and CCR-2 genes,
which are known to control aspects of these pathways, to ascertain whether they are involved in atherogenesis in these
patients.
Methods and Results—We performed carotid and femoral artery ultrasonography to detect subclinical atherosclerosis in
patients infected with HIV (n�183). MCP-1–2518G and CCR-2 64I polymorphisms were determined in the HIV group
and in a population-based control group (n�348). We also determined MCP-1 circulating levels in the HIV group. The
presence of MCP-1–2518G in the group of patients with subclinical atherosclerosis was significantly higher than in
patients without atherosclerotic lesions (47.5% versus 18.2%, respectively; P�0.001). Furthermore, the patients with
atherosclerotic lesions had higher MCP-1 plasma concentrations than did patients without lesions (74.15 [4.03] versus
57.81 [3.67] pg/mL, respectively; P�0.03). When adjusted for known cardiovascular risk factors, the MCP-1–2518G
allele was associated with subclinical atherosclerosis (OR 5.72, 95% CI 1.74 to 18.80, P�0.004). Compared with
measurements conducted �2.5 years earlier in a subset of 40 patients, intima-media thickness (IMT) in the carotid artery
progressed at a mean rate of 0.06 mm/y more rapidly in patients bearing the MCP-1–mutated allele (P�0.08).
Conclusions—HIV-infected patients with the MCP-1–2518G allele have a 5-fold increased risk for atherosclerosis, as
assessed by ultrasonography. (Circulation. 2004;110:2204-2209.)
Key Words: atherosclerosis � HIV � inflammation � genotype � prevention
Patients infected with HIV develop proatherogenic meta-bolic abnormalities. These abnormalities have been
linked to the effects of antiretroviral drugs and to the HIV
infection itself. The patients present with premature subclin-
ical atherosclerosis.1–4 It is conceivable that, as survival of
individuals with the infection increases,5 atherosclerotic vas-
cular disease could become an important complication. In-
flammation is of paramount importance in the development
of atherosclerosis,6,7 and HIV, together with other infectious
agents, may contribute inflammatory stimuli that could initi-
ate or exacerbate atherogenesis or both.8 In the development
of atherosclerosis, mononuclear phagocytes (monocytes and
macrophages) are primarily involved in the inflammatory
processes.9 The monocyte chemoattractant protein-1
(MCP-1) is a potent activator of these mononuclear phago-
cytes and, once its receptor (CCR-2) is stimulated, the
monocytes migrate into the subendothelial space, commence
phagocytosis of modified lipoproteins, and become lipid-
laden foam cells.10 Several studies implicate the MCP-1–
CCR-2 axis in the clinical course of HIV infection as well as
in atherosclerosis.11–25 The different levels of expression of
MCP-1 between the 2518G allele and the 2518A allele may
represent a mechanism that in adults provides partial protec-
tion from the infection.11 Furthermore, CCR-2 is a natural
co-receptor used by HIV to enter the CD4 lymphocytes.12
Although controversial, the G allele in this gene has been
shown to be related to a different rate of progression for
AIDS.13–15
In mice, being knockout for either the MCP-1 or CCR-2
genes has been associated with a reduction in atherogenesis,
and the atheromatous lesions that are present are far more
stable.16–18 The MCP-1–2518G allele is associated with
higher MCP-1 expression,19 and patients diagnosed as having
ischemic heart disease exhibit a higher prevalence of the
MCP-1–2518G/G genotype.20 In patients with acute coronary
syndrome, the higher the levels of MCP-1 the higher the
likelihood of myocardial infarction or death appears to be.21
Interestingly, the polymorphism in the CCR-2 gene (A190G
or V64I) has been shown to be associated with reduced
coronary artery calcification,22 whereas homozygosity for the
CCR-2 64I allele seems to have a protective effect with
regard to the development of coronary artery disease.20
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Some HIV proteins can induce the overexpression of
MCP-1, and the levels of this protein may be altered during
the course of HIV progression.23–25 This disease feature is
exacerbated in carriers of the MCP-1 mutant allele. As such,
the evidence to date suggests that HIV infection and athero-
sclerosis share pathways in their pathogenesis. It is a reason-
able hypothesis that mutations in genes that control aspects of
these pathways could affect the course of both diseases.
Hence, we assessed whether known associations between
MCP-1 and CCR- 2 mutant alleles and atherosclerosis in the




We performed a case-control study based on the presence or absence
of atherosclerosis in 183 subjects infected with HIV. We also
evaluated clinical, laboratory, and genotyping results in the cases and
controls to assess the risk factors for atherosclerosis in this particular
clinical setting. For genotype comparisons we used a general
population–based control group of unrelated subjects (n�348), the
details of which have been described elsewhere.26
Study Participants and Eligibility
From among the patients infected with HIV who attended our clinic
(n�305), 183 accepted the invitation to participate in the study and
provided fully informed consent. Among the exclusion criteria were
being �18 years old, having AIDS-related opportunistic diseases at
the commencement of the study, and declining the invitation to
participate. The Ethics Committee of the Hospital Universitari de
Sant Joan de Reus approved the study.
Outcome Measurements
Clinical and Laboratory Measurements
A detailed clinical record was taken of each subject and a thorough
physical examination was performed at interview. The traditional
cardiovascular risk factors assessed were smoking status, presence or
absence of hypertension, and body mass index (defined as the weight
in kilograms divided by the square of the height in meters). A sample
of fasting venous blood was taken for the measurement of glucose,
total cholesterol, HDL cholesterol, and triglycerides. The analyses
were conducted using standard laboratory methods. The LDL cho-
lesterol level was calculated using the Friedewald formula.
Ultrasonography Measurements
Ultrasonography to measure intima-media thickness (IMT) was
performed as previously described27 with a LOGIQ 700 MR system
(General Electric). When a plaque was identified at a predefined
point, the IMT was determined in adjacent segments. The presence
of atherosclerosis was defined as IMT �0.8 mm, the presence of a
plaque, or both27 in either carotid or femoral territories. We used this
selection criterion to define the subject as a case or as a control. The
concordance between the 2 sonographers responsible for the athero-
sclerosis evaluations indicated a high correlation coefficient of �
�0.8 for the independently conducted measurements.
Inflammatory Marker Measurements
Venous blood samples were collected into EDTA-containing tubes.
The concentration of C-reactive protein (CRP) was measured by a
particle-enhanced turbidimetric immunoassay (Quantex hs-CRP kit,
Biokit), which had a sensitivity of 0.10 mg/L. The plasma concen-
tration of MCP-1 was measured according to the manufacturer’s
recommendations with an enzyme-linked immunosorbent assay (Hu-
man MCP-1 ELISA Development Kit, PeproTech), which had a
measurement range of 8 to 3000 pg/mL.
Genotyping
DNA was extracted by a standard phenol-chloroform procedure. The
mutations MCP-1–2518G and CCR-2 64I were identified according
to previously published methods.20
Risk Factor Analysis
Multivariate logistic regression analyses were performed to adjust
for known cardiovascular risk factors. The data on carotid, femoral,
or carotid and femoral atherosclerosis were the dependent variables,
and the independent variables included age, sex, smoking habit,
blood pressure, lipid profile, plasma glucose, mean duration of each
antiretroviral treatment (ie, protease inhibitor, non-nucleoside inhib-
itors, and nucleoside analogues) and the DNA polymorphisms.
Atherosclerosis Progression
In a pilot study conducted �3 years previously, 40 patients were
examined and clinical and ultrasonography data were documented.
The stored images were retrieved and compared with the present
measurements to assess atherosclerosis status. Comparisons included
the mean IMT change (in millimeters) of predefined carotid arterial
segments and the change (in square millimeters) in the area of a
previously selected carotid plaque. These data were used to assess
changes in the dimensions of the arterial lesions during the specific
period.
Statistical Analyses
Data are presented as means with the standard error of the mean in
parentheses. Standard methods (Kolmogorov-Smirnov and Shapiro-
Wilk tests) were used to check for normality of the distributions.
Analysis of variance was used to compare differences in quantitative
variables, and the �2 test was used for categorical variables. Allele
frequencies were calculated by the gene-counting method. The
Hardy-Weinberg equilibrium and the differences in biallelic poly-
morphisms (genotype distributions and allele frequencies) between
groups were tested using the �2 test. Analysis of variance was used
to compare changes in mean IMT and the area of the plaque over
time. The significance of association between the MCP-1 allele and
the increase in the variables was assessed using a multiple linear
regression model in which adjustment was made for other conven-
tional cardiovascular risk factors. All probability values �0.05 were
considered to be statistically significant. All analyses were per-
formed with SPSS statistical software (version 11.0).
Results
We studied 183 HIV-infected subjects (124 men, 59 women,
20 to 66 years old). The subgroup of 40 HIV-infected subjects
(34 men, 6 women, 32 to 58 years old) used for assessing
atherosclerosis progress did not present any clinical differ-
ences when compared with the overall HIV study group.
When known cardiovascular risk factors were compared (age,
lipid profile, or patients with high blood pressure or abnormal
fasting glucose), we did not find any statistically significant
differences.
Subclinical Atherosclerosis and Control Groups
The measured variables, including conventional cardiovascu-
lar risk factors and segregated with regard to presence of
atherosclerosis, are presented in Table 1. Subjects were of the
same ethnic (white) background. The participants with ath-
erosclerosis were significantly older than the control group
(P�0.001). We evaluated conventional cardiovascular risk
factors between groups. Most subjects were heavy smokers.
Although we did not find differences in the mean body mass
index (BMI) when cases and controls were compared (23.10
[0.27] versus 23.00 [0.52], respectively; P�0.857), we found
higher rates of hypertension and abnormal fasting glucose
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concentrations in the subjects who had atherosclerosis. Only
7 of these subjects were receiving statin therapy (for �1
year), and fibrates had been used in 10 subjects during the
previous 6 months. None of the participants included in the
study presented with either cardiac or cerebral ischemic
events. We did not find any statistically significant differ-
ences with regard to HIV-related variables such as baseline
CD4 cell count, AIDS-related opportunistic disease, or the
time lapse after HIV diagnoses. Seven cases (5.0%) and 5
controls (11.4%) were naïve with regard to antiretroviral
therapy (P�0.163). Segregation by sex, age, or both did not
affect the distribution of genotypes; thus, all subjects were
analyzed as a single group. The allelic distribution of MCP-1
and CCR-2 genotypes followed the Hardy-Weinberg equilib-
rium (�2, P�0.30 and P�0.81, respectively) in patients in the
case group as well as in controls. No statistically significant
differences between the unrelated subject control group and
either of the case groups with regard to genotype distributions
or in allelic frequencies were found (Table 2). Also, no
differences were found in the distributions of both the
mutations.
Analysis of Subclinical Atherosclerotic Lesions
The majority of subjects infected with HIV (n�139; 76.0%)
presented with atherosclerotic lesions in one or another of the
territories assessed, a percentage that is equivalent to that
observed in other similar studies.1,2 Analysis of the distribu-
tion of genotypes according to the presence or absence of
subclinical atherosclerosis indicated that the frequencies of
GG and GA genotypes in the MCP-1 polymorphism were
significantly higher in subjects with atherosclerosis than in
those without (47.5% versus 18.2%; P�0.001). The results
showed that subjects with at least 1 mutated allele were more
likely to show evidence of atherosclerosis (89.2%). No
differences were observed in the distribution of CCR-2
polymorphism between subject populations (Table 2).
It is worth noting that our study population was relatively
young, with �75% of subjects �42 years old. An analysis of
TABLE 1. Characteristics of HIV-Infected Patients Segregated According to










Conventional cardiovascular risk factors,* %
Current smoker 82.6 88.6 0.32
Hypertension 15.6 2.4 0.01
Abnormal fasting glucose 14.4 � � � 0.01
Dyslipemia 27.0 16.7 0.16
Lipid profile, mmol/L
Total cholesterol 5.06 (0.12) 4.77 (0.16) 0.22
LDL cholesterol 2.85 (0.09) 2.63 (0.12) 0.22
HDL cholesterol 1.16 (0.04) 1.28 (0.06) 0.15
Triglycerides 2.44 (0.18) 1.82 (0.28) 0.09
Risk factor for HIV infection 0.67
Intravenous drug use, % 59.0 52.3
Male homosexual contact, % 9.7 13.6
Heterosexual contact, % 31.3 34.1
Months since HIV diagnosis 89.25 (4.34) 78.48 (7.83) 0.22




Previous antiretroviral therapy, mo
Nucleoside analogs 100.87 (5.41) 85.25 (8.74) 0.15
Protease inhibitor 29.70 (2.39) 26.06 (3.78) 0.44
Non-nucleoside reverse transcriptase
inhibitors
8.35 (0.89) 8.70 (1.69) 0.85
AIDS-related disease, % 32.4 31.8 0.94
*Hypertension defined as �140, �90 mm Hg, or both. Abnormal fasting glucose defined as fasting
plasma glucose �6.1 mmol/L. Dyslipemia defined as LDL cholesterol �3.36 mmol/L.
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the data segregated with regard to age quartiles indicated that
subjects with at least 1 mutated allele for MCP-1 had higher
rates of atherosclerotic lesions in each of the quartiles (Figure 1).
This finding was especially relevant in subjects �34 years old.
We then analyzed the association between atherosclerosis
and inflammatory markers such as CRP and MCP-1. Al-
though no significant differences were found among MCP-1
plasma concentrations according to the MCP-1 polymor-
phism, a higher concentration was observed when subjects
with HIV and atherosclerosis were compared with those
without any arterial lesions (74.15 [4.03] versus 57.81 [3.67]
pg/mL, respectively; P�0.03). We did not find significant
differences in CRP concentrations between subjects with
atherosclerosis and those without (3.38 [0.31] versus 3.46
[0.54] mg/mL, respectively; P�0.905).
Multivariate logistic regression analysis with known car-
diovascular risk factors as independent variables revealed that
only age and the MCP-1–2518G polymorphism were signif-
icantly associated with the presence of subclinical atheroscle-
rosis (Figure 2). Treatments with protease inhibitor or non-
nucleoside–based regimens were not associated with the
presence of subclinical atherosclerosis (P�0.64 and P�0.56,
respectively). Age was significantly associated with athero-
sclerotic lesions (OR 1.32, 95% CI 1.17 to 1.50, P�0.001) as
was the MCP-1–2518G allele (OR 5.72, 95% CI 1.74 to
18.80, P�0.004).
The effect of the MCP-1–mutated allele was evaluated
with respect to the clinical course of the atherosclerotic
lesions with the stored images available for 40 subjects. The
time lapse between the 2 ultrasonographic measurements was
2.61 (0.07) years. When subjects were segregated into those
with the MCP-1–2518G (n�13) allele and those with the AA
genotype (n�27), the subjects with the mutated allele ap-
peared to have a poorer clinical outcome (Figure 3). The data
indicated an increase in carotid IMT of 0.06 mm/y in the
subject group with the mutated allele (MCP-1–2518G). In the
group of subjects with the AA genotype, this increase was
0.03 mm/y; however, the difference did not reach statistical
significance (P�0.08). When the areas of predefined carotid
lesions were analyzed it was apparent that subjects with at
least 1 mutated allele experienced a significantly higher
increase than did subjects with the wild-type allele (12.9 [4.3]
versus 32.3 [6.4] mm2, respectively; P�0.04).
Discussion
Some genetic variants of the chemokines are reputed to
influence individuals’ susceptibility to HIV infection, the
progression of the disease, and even the presence of so-called
HIV-associated manifestations.28 Considerable research has
focused on the role of chemokine polymorphic genes impli-
cated in the inflammatory response and, as a consequence, in
atherosclerosis.29
An important finding of our study is that a mutation in the
promoter region of the MCP-1 gene has an atherosclerosis-
promoting effect. Infiltration of tissues by monocyte-derived
Figure 2. ORs for subclinical atherosclerosis. Horizontal lines
represent 95% CI. »; indicates that OR is higher than represent-
ed. (See Methods for further information.) *P�0.001; †P�0.004.
TABLE 2. Distribution of Genotypes and Inflammatory Markers







MCP-1–A2518G genotype distribution, n (%)
GG � GA 66 (47.5) 8 (18.2)*
AA 73 (52.5) 36 (81.8)
CCR-2–A190G genotype distribution, n (%)
GG � GA 25 (18.0) 9 (20.5)†
AA 114 (82.0) 35 (79.5)
Inflammatory markers
CRP, mg/L 3.38 (0.31) 3.46 (0.54)




Figure 1. Percentage of subjects infected with HIV with subclin-
ical atherosclerosis according to MCP-1–2518G (�) and –2518A
(f) polymorphism and distributed by quartiles of age. Logistic
regression model was applied to assess association of carotid
and femoral atherosclerosis with presence of MCP-1–mutated
allele adjusted for age (P�0.001).
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macrophages is a prominent feature of atherosclerosis.
MCP-1 and possibly other chemoattractant proteins are
thought to be the molecular signals that direct such infiltra-
tion. We measured plasma MCP-1 concentrations and, de-
spite these individuals’ being subject to multiple infections
and inflammatory insults and receiving antiretroviral thera-
pies that can induce further changes in MCP-1 levels,23–25 we
found an association between higher values of MCP-1 and
atherosclerosis. This finding provides support for our hypoth-
esis that MCP-1 may play a crucial role in atherogenesis. In
previous studies,20,22 atherosclerosis was less extensive in
patients who had well-established cardiovascular disease and
who carried the mutation in the CCR-2 gene. We are unable
to confirm such results based on our multivariate analyses.
We wish to highlight that with regard to conventional
cardiovascular risk factors, subjects with atherosclerosis ex-
perienced higher rates of hypertension and abnormal fasting
glucose. In multivariate analyses, these variables lost their
statistical significance in relation to atherosclerosis.
Ultrasonography, being a noninvasive tool, is widely ac-
cepted in the evaluation of IMT, and IMT has been validated
as a surrogate marker for atherosclerotic vascular disease.30
For example, a yearly increase of carotid artery IMT of
0.03 mm is associated with an increase in coronary events in
patients with established atherosclerosis.31 Conversely, the
reduction of 0.03 mm/y achieved with high-dose statins
appears to have a significant impact on the prevention of
coronary artery disease.32 Although the present statistical
analyses are not a case-control study of “atherosclerosis”
versus “no-atherosclerosis” comparisons, the yearly increase
of carotid IMT in our subjects was clearly �0.03 mm and was
more evident in subjects with the MCP-1–2518G allele.
Although drug interactions, toxicity, intolerance, and de-
creased adherence to treatment are common in these subjects,
we believe our data suggest that the prescription of statins,
fibrates, or both in subjects with HIV could induce favorable
outcomes with regard to the development of atherosclerosis
in these subjects.
In summary, our results indicate that the MCP-1–CCR-2
gene axis is related to carotid and femoral atherosclerosis in
patients infected with HIV. These findings need to be
reflected in proposals for new therapies. For example, an
increase in the prescription of statins, platelet antiaggregants,
or both together with the use of antiretroviral regimes would
be appropriate. Conversely, the inducers of metabolic distur-
bances would need to be reduced to minimize the risk of
vascular events in these patients. Knowledge of the activation
mechanisms of chemokines in HIV and other inflammatory
disorders would provide insight into better management and
control of HIV-associated diseases, including atherosclerosis.
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“Influence of a monocyte 
chemoattractant protein 1 
mutated allele on the response 
to protease inhibitor-based 
antiretroviral therapy”
In the second study we addressed the role of MCP-1 and CCR-2 in the course of HIV infection. 
For this purpose, we selected those patients who had never been treated with Protease 
Inhibitors (N=164), and their CD4 cell counts and HIV viral load were monitored according 
to the results of MCP-1 analyses. We did not find significant differences between groups ( 
wild type or mutated alleles for MCP-1-2518G) in genotype distributions of the CCR-2, CCR-
5 and SDF-1 mutated alleles.  Patients who bear MCP-1-2518G experienced a significantly 
better CD4 response in months 6 and 21 after initiation of PI therapy. The baseline CD4 
cell count and the presence of the MCP-1–2518G mutated allele were significantly (P<0.01) 
related to a better CD4 cell response in a multivariate analyses. 
Patients bearing the MCP-1–2518G and CCR-2 64I mutated alleles, i.e. those with a blocked 
MCP-1–CCR-2 axis (n=22), had a higher likelihood of continuing to have an undetectable 
HIV-1 viral load than patients (n=142) carrying both wild-type alleles.
These results may be explained by several mechanisms ( competition, heterodimerization, 
etc) but they clearly states an strong relationship between key genetic variables and the 
course of HIV-infection. The over expression of  MCP-1 and /or structural changes in its 
natural receptor, CCR-2, leads HIV-infected patients to a better response to PI and present 
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ORIGINAL RESEARCH
Influence of a monocyte chemoattractant protein 1
mutated allele on the response to protease inhibitor-based
antiretroviral therapy
B Coll,1 C Alonso-Villaverde,1 S Parra,1 A Rabassa,1 L Martorell,2 J Joven2 and L Masana1
1Servei de Medicina Interna and 2Centre de Recerca Biomèdica, Hospital Universitari de Sant Joan, Reus, Spain
Background
Antiretroviral drug efficacy has been widely studied in relation to viral factors. Mutations in the HIV
co-receptors and their natural chemokines, however, may be critical in HIV infection and treatment
response. We compared the efficacy of protease inhibitor (PI) treatment among PI-naı̈ve patients
grouped according to whether they carried the chemokine CC motif receptor 2 (CCR-2) 64I and
monocyte chemoattractant protein 1 (MCP-1)–2518G alleles.
Methods and results
HIV-infected patients who were PI-naive were selected for the study (n5 164) but there was no
restriction on lymphocyte CD4 count or plasma HIV viral load. Follow-up was for the first 24
months of treatment. Clinical and laboratory data were obtained every 3 months. All the participants
were genotyped for the MCP-1–2518G, CCR-2 64I, CCR-5 D32 and stromal derived factor 1 (SDF1)
30A mutated alleles. The results indicated that patients carrying the mutated allele of MCP-1 had a
higher mean CD4 cell count throughout the follow-up period than those with the common allele
(P5 0.01). Also, patients with the MCP-1 and CCR-2 mutated alleles were more likely to continue to
have an undetectable viral load following treatment (P5 0.05).
Conclusion
A better response to PI treatment appears to be conferred by mutations in the hostMCP-1 and CCR-2
genes, and may be related to the cellular axis-of-entry used by the retrovirus.
Keywords: chemokines, genetics, HIV course, monocyte chemoattractant protein 1
Received: 15 July 2005, accepted 13 January 2006
Introduction
Biological differences among HIV isolates and resistance to
highly active antiretroviral therapy (HAART) have been
explored extensively, but the individual variation in
treatment response observed indicates the importance of
host genetic determinants, such as the cell chemokine
receptor 5 (CCR-5) D32 and stromal derived factor 1 (SDF1)
30A alleles [1–6].
In the early stages of the infection, the virus adopts a
macrophage tropism (M-tropism) using CCR-2 and CCR-5
as CD4 co-receptors [7,8]. Patients who carry a valine-for-
isoleucine substitution at position 64 of the CCR-2 gene
(CCR-2 64I) have a higher likelihood of being long-term
survivors [9–11], with this probably being related to
heterodimerization of the mutated CCR-2 with the HIV
co-receptor CCR-5 or chemokine, CXC motif receptor 4
(CXCR4) [12]. The natural chemokine of CCR-2 is monocyte
chemoattractant protein 1 (MCP-1), which plays a pivotal
role in the involvement of monocytes/macrophages in
tissue inflammation. However, it also influences the
response of cytotoxic T lymphocytes [13], and has effects
on both innate and adaptive immunity through the control
of T helper cell polarization [14]. The substitution of
adenine for guanine at position � 2518 in the promoter
region has been associated with MCP-1 over-expression
[15] and may have several consequences, for example
promotion of the heterodimerization of CCR-2 with HIV
co-receptors [16], competitive inhibition of CCR-2, activa-
tion of T-cell immunity or lymphokine production [17].
This mutation has been investigated as a genetic marker
influencing the risk of HIV transmission and the likelihood
of developing HIV-associated dementia [18,19], but
here we explored the hypothesis that this mutation in the
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MCP-1 promoter region improves the response to anti-
retroviral treatment in HIV-infected patients undergoing
protease inhibitor (PI)-based antiretroviral therapy (ART).
Methods
Among those attending our clinic, 232 HIV-infected
patients (164 male and 68 female, aged between 20 and
66 years) agreed to participate in the study. We identified,
from our computerized database, those patients (n5 164)
who were naı̈ve to the proposed protease inhibitor (PI)-
based HAART regimen. Patients eligible in terms of ART for
PI treatment in this study included those who had failed
previous ART schemes and naı̈ve patients with CD4 cell
counts o350 cells/mL. We did not exclude any patient on
the basis of CD4 cell count or viral load. Also, patients who
had been treated previously with nucleoside reverse
transcriptase inhibitors (NRTIs) were not excluded. Clinical
and laboratory data that are routinely obtained every 3
months were collated and analysed during the first 24
months of PI treatment. The Ethics Committee of the
Hospital Universitari de Sant Joan approved the study.
Fully informed consent to the genetic testing was obtained
from all the participants.
Serum HIV-1 RNA viral load was measured with the
Amplicor Analyser (Roche Diagnostics, Branchburg, NJ,
USA). The lower limit for reliable quantification was con-
sidered to be 200 HIV-1 RNA copies/mL, and lower values
were regarded as undetectable. CD4, CD8 and lymphocyte
cell counts were determined by standard FACscan flow
cytometry (Becton-Dickinson, Madrid, Spain).
Venous blood samples were collected into tubes contain-
ing ethylenediaminetetraacetic acid (EDTA), and DNA was
obtained from leucocytes using the Puregene Kit (Gentra
Systems, Minneapolis, MN, USA). The mutations MCP-1–
2518G, CCR-2 64I, CCR-5 D32 and SDF1 30A were identi-
fied according to previously published methods [20].
Genotypes were scored independently by two observers
who were blind with respect to the clinical data.
Data are presented as the mean and the standard error of
the mean (SEM). We used the standard Kolmogorov–
Smirnov test to check for normality of distribution.
Differences in quantitative variables were assessed using
analysis of variance (ANOVA), and the w2 test was used for
categorical variables. We tested for Hardy–Weinberg
equilibrium using the w2 test. We considered patients who
were heterozygous and homozygous for the mutated allele
as a single group so as to compare these patients with those
carrying the common allele. Nadir CD4 cell count was the
value recorded at the time of diagnosis of HIV infection.
The endpoints analysed were CD4 cell count during the
first 24 months of PI therapy and the time for which the
patients continued to have undetectable HIV viral load.
A general linear regression model was used to test the
association between CD4 cell course with genotype. The
baseline CD4 cell count and the presence of CCR-5, CCR-2
and SDF1 mutated alleles were used as covariates in the
assessment of the CD4 cell count response. We also perfor-
med a single regression analysis in the difference of CD4 T
cells from baseline in each time point. The Kaplan–Meier
method was used to evaluate the influence of genotypes on
the time for which HIV-1 viral load remained undetectable.
The log-rank test was used to calculate the overall P-value.
All analyses were performed with the SPSS 11.0 statistical
package (SPSS Inc., Chicago, IL, USA).
Results
Characteristics of the HIV-infected patients and
genotype distributions
Participants were of the same ethnic background (Cauca-
sian). A comparison of variables, including immunological
status at initiation of the PI-based ART regimen, between
two groups of patients differing in the MCP-1 polymorph-
ism is presented in Table 1. There were no statistically
significant differences between the two groups in any of
the characteristics examined. CD4 cell count and viral load
did not differ significantly between the groups. Almost half
of the population studied had been on NRTI-based ART
before commencing the PI regimen. We did not find
significant differences between the groups in the genotypic
distributions of the CCR-2, CCR-5 and SDF1 mutated
alleles. The allelic distribution of the genotypes studied was
consistent with Hardy–Weinberg equilibrium.
Analysis of CD4 cell count
Patients with at least one mutated MCP-1–2518G allele did
not have different CD4 cell counts from other patients
either at baseline or at the commencement of PI
therapy. Similarly, we observed no significant difference
in CD4 cell count between groups of patients differing in
the CCR-2 polymorphism. However, patients with the
mutated allele in the promoter region of MCP-1 experi-
enced a significantly better CD4 response in months 6 and
21 after initiation of PI therapy (single regression model,
Po0.05; Fig. 1). Further, in the multivariate model in
which the results of the CCR-5, CCR-2 and SDF1
polymorphisms were included, the baseline CD4 cell count
and the presence of the MCP-1–2518G mutated allele were
significantly (Po0.01) related to a better CD4 cell response
(Fig. 1).
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Analysis of HIV-1 viral load
In a comparison of HIV-1 viral load at the commencement
of PI therapy among groups of patients differing with
respect to the MCP-1 and CCR-2 polymorphisms, no
statistically significant differences were found. We further
analysed the influence of the MCP-1 mutated allele on the
length of time that patients continued to have undetectable
HIV viral load. Although those with the MCP-1–2518G
allele presented a better antiretroviral response, the finding
did not reach statistical significance (log rank 0.97;
P5 0.32). However, the Kaplan–Meier model showed that
patients bearing theMCP-1–2518G and CCR-2 64I mutated
alleles, i.e. those with a blocked MCP-1–CCR-2 axis
(n5 22), had a higher likelihood of continuing to have
an undetectable HIV-1 viral load than patients (n5 142)
carrying both wild-type alleles (log rank 3.65; P5 0.05).
Discussion
We assessed the treatment responses of HIV-infected
patients initiating PI-based ART in relation to mutated
alleles of genes implicated in the entry of HIV into the cell.
Our results indicated that an allelic variant of MCP-1
associated with over-expression of MCP-1 was related to a
better CD4 cell count response in patients undergoing ART.
The influence of chemokines and chemokine receptors in
HIV infection and disease progression has been widely
studied, and several mechanisms have been implicated. It is
likely that the better response found in the present study in
patients with the mutatedMCP-1 allele can be attributed to
substrate competition between the MCP-1 molecule and
HIV particles for the CCR-2 receptor, a phenomenon termed
‘steric hindrance’ [21]. However, the presence of the
mutated allele MCP-1–2518G may be associated with
down-regulation of HIV co-receptors, which can assist the
patient’s natural mechanism for blocking HIV entry into
the cell [6,22].
Table 1 Characteristics of HIV-infected subjects (n5 164) at the start
of protease inhibitor (PI)-based treatment grouped according to pre-







P-value(n5 89) (n5 75)
Age (years) 38.77 (0.58) 39.24 (0.92) 0.65
Gender (male) [n (%)] 59 (66.2) 51 (68) 0.78
Time since HIV diagnosis (years) 6.37 (0.33) 5.65 (0.33) 0.13
Risk factor for HIV infection (%) 0.94
Intravenous drug use 54.3 45.7
Heterosexual contact 51.1 48.9
Male homosexual contact 52.9 47.1
Nadir CD4 cell count (cells/mL) 303 (32) 362 (38) 0.23
Nadir HIV viral load (log10 copies/mL)* 4.98 (0.10) 4.68 (0.14) 0.10
CD4 cell count (cells/mL) 252 (26) 311 (32) 0.15
HIV viral load (log10 copies/mL) 4.40 (0.15) 4.17 (0.17) 0.32
Hepatitis C virus coinfection (%) 54.5 45.5 0.93





PI-boosted therapyw 6.9 12.3







Prior NRTI-based therapy (%) 47.4 41.5 0.59
AIDS-related opportunistic disease (%) 32.2 32.9 0.92
CCR-2 64 I (%) 13.8 21.9 0.17
CCR-5 D32 (%) 12.6 9.6 0.54
SDF1–3 0A (%) 48.8 44.3 0.57
Values are the mean and the standard error of the mean (SEM), unless
otherwise stated. Time since HIV diagnosis relates to years of seropreva-
lence (unknown seroconversion date). The genetic results indicate the
percentage of patients carrying the mutated alleles CCR-2 64I, CCR-5 D32
and SDF1–30A.
*These data were available for 85 patients.
wPI-boosted regimens were as follows: indinavir1 ritonavir, saquinavir1
ritonavir, nelfinavir1 ritonavir, amprenavir1 ritonavir and lopinavir1 rito-
navir.
CCR, cell chemokine receptor; NRTI, nucleoside reverse transcriptase










0 3 6 9 12 15 18 21 24
89 88 78 68 63 63 64 56 52















Time on PI (months)
*
**
Fig. 1 CD4 cell count (mean and two-tailed standard error of the
mean) over the follow-up period for patients on a protease inhibitor
(PI)-based highly active antiretroviral therapy regimen grouped
according to the monocyte chemoattractant protein 1 (MCP-1)
polymorphism. The CD4 cell count differed persistently and
significantly (P5 0.01) in the mixed model analyses of data for all
visits, with covariates including cell chemokine receptor 5 (CCR-5),
CCR-2 and stromal derived factor 1 (SDF1) polymorphisms and
baseline CD4 cell count. *Po0.01; **Po0.05 in the single regression
model for comparison with the baseline CD4 cell count. Squares (and
the solid line) represent individuals (n5 89) with the MCP-1 wild-
type allele. Triangles (and the dotted line) indicate individuals
(n5 75) with theMCP-1–2518G allele. Numbers of patients at each
time-point are shown below the horizontal axis.
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However, as stated by other authors [8], CCR-2 has
been recognized as a minor CD4 co-receptor, so the
influence of CCR-2 might be exerted indirectly through
changes in the activation of the immune system. In fact, it
is known that the product of the mutated CCR-2 64I allele
heterodimerizes in the lipid raft of the cell membrane with
the ‘major’ HIV co-receptors, CCR-5 and CXCR-4, and this
effect may be responsible for blocking HIV entry [12].
Interestingly, MCP-1 has the ability to promote CCR-2
heterodimerization with the other receptors, and so
over-expression of MCP-1 as a result of a genetic variant
in its promoter region may produce a better immunolo-
gical response in HIV-infected patients who carry the
mutated allele. Similarly, Rodriguez-Frade et al. [23]
reported the beneficial effects of CCR-2 activation
using a monoclonal antibody that acts as its natural
substrate, MCP-1, in blocking the entry of HIV into the
cell. This effect is mediated by the heterodimerization of
CCR-2 with CCR-5 and CXCR4. These data provide new
insights into the therapeutic opportunities of HIV-infected
patients [23].
Further, MCP-1 plays a pivotal role in the activation of
cytotoxic T cells [13], in the production of lymphokines
and in turn in lymphocyte proliferation [17]. These effects
may contribute to the benefits found to be conferred by the
mutated allele in our patients.
The presence of the G allele at position � 2518 of the
MCP-1 gene has been related to a lower risk of acquiring
HIV-1 infection. Conversely, it has been found that, in
patients who are already infected and who carry theMCP-1
mutated allele, the progression to AIDS is accelerated and
the risk of suffering from HIV-associated dementia and
Mycobacterium avium complex infection is higher than in
patients with the common variant [19]. However, the
course of CD4 cell count in patients on ART has not been
reported. Further, the presence of the mutated MCP-1 allele
has been shown not to be associated with cytomegalovirus
infection, Pneumocystis carinii pneumonia or Kaposi’s
sarcoma [19], raising more questions regarding the role
of MCP-1 in HIV infection.
Our study has several limitations, mainly related to the
small sample size. Further, nadir CD4 cell count and viral
load, time since diagnoses and the genotype distribution of
CCR-2, were slightly different between groups (mutated
and wild type alleles for the MCP-1 genotype), although the
differences were not statistically significant, and this could
call into question any conclusions drawn from the results.
However, these factors were included in the statistical
model as covariates in order to eliminate potential bias,
and their inclusion did not alter the findings of the study.
Another limitation of the study is that we performed a
genotypic assessment of the immunological course of HIV
infection in the patients, but we did not obtain phenotypic
data. It would be of great value to determine the plasma
concentration of MCP-1 and/or CCR-2 mRNA expression,
in order to assess the exact status of the MCP-1–CCR-2
axis.
We did not find a significant influence of the CCR-5 D32
allele on the CD4 cell response, and this was probably
related to the low allele frequency (0.05) and the small
sample size (n5 164). Similarly, we did not find any
significant influence of the SDF1–30A allele in our study
population, but the effects of this genetic variant are a
matter of debate [11]. However, we took into account these
genotypes as covariables in the analysis of the course of
CD4 cell count.
Evidence is emerging that immunological pressure on
HIV in human hosts is causing population-dependent
genetic changes in the virus itself. One of the main
concerns discussed in the current literature is the
possibility that chemokines might favour the emergence
of X4 strains of HIV-1 that use CXCR4 for cell entry [24]. It
should be noted that individuals on ART who are carrying
the MCP-1 mutated allele have a better outcome in terms
of CD4 response and, according to our data, the emergence
of a predominant X4 HIV-1 strain is unlikely.
The beneficial effects of the chemokine receptor gene
polymorphisms CCR-5 D32 and CCR-2 64I on the course of
HIV-1 infection in patients on ART have already been
described [25,26]. Moreover, in vitro studies have revealed
that mutated alleles for these chemokine receptors may
modify the interaction between inhibitory fusion agents
(T-20) and their activity sites, and hence different
therapeutic activity might be expected [27]. Our results
indicated that patients carrying a combination of alleles
blocking the M-tropism pathway of HIV entry into the cell
(i.e. theMCP-1 and CCR-2mutations) had a better response
to a PI-based regimen, as measured by the time for which
viral load remained undetectable.
In summary, genetic variations affecting host cells need
to be taken into account in the management of patients
infected with HIV. Mutated alleles of genes affecting the
M-tropism of HIV could influence the patient’s response to
HAART and the clinical evolution of the disease. These
findings could be useful in establishing more appropriate
and individualized antiretroviral strategies.
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In the third study, we assess the relationship of a functional polymorphism in the SDF-1 
gene, with the development of atherosclerosis. Due to the interaction with platelets, tissue 
factor and with endothelial progenitor cells, SDF-1 might have a significant influence in 
atherosclerosis development. We found a lower number of individuals carrying the SDF1-
3’A allele in the group with carotid atherosclerosis (41.6%) than those without arterial 
lesions (57.1%; P =0.04). Further, analysis of the distribution of the SDF1-3’A mutated allele 
indicated that, among those participants with an abnormal IMT (> 0.8 mm), the SDF-1 
mutated allele was less likely to be encountered than the wild type (38.4% versus 61.6%; 
P =0.03). When carotid plaques were measured, we found that those individuals who bore 
the mutated allele for SDF-1 presented a significantly lower carotid plaque area 20.36 
±5.57 mm2, than those carrying the wild type 37.33 ±4.90 mm2 (P = 0.02).
Age and the presence of dyslipidaemia were significantly (P<0.05) associated with carotid 
atherosclerosis in the multivariate analysis. Further, the results showed a protective effect 
of the SDF1-3’A allele on the development of carotid atherosclerosis [odds ratio (OR), 0.45; 
95% confidence interval (CI), 0.19–1.02; P <0.05)]. 
We further explored, in a subset of these participants, which could be the underlying 
mechanism. We selected patients with the same antiretroviral therapy scheme and follow 
their lipid profile. We did not find significant differences between groups when total 
cholesterol, HDL-C and triglycerides were analyzed. However, when LDL-C was considered, 
those patients without carotid atherosclerotic lesions and who carried the SDF-1 
mutated allele (n =19) showed a significantly (P <0.04) lower LDL-C of 2.06 ± 0.34 mmol/l, 
throughout the follow-up period.
The main results of this study are that SDF1-3’A mutated allele revealed as a protector factor 
in the development of carotid atherosclerosis in HIV-infected patients, probably related 
with the lower LDL cholesterol concentration. Mechanisms by which the lower expression 
of SDF-1 is associated to these phenotype variations are poorly understood, but as occurred 
with CCR-2 and MCP-1, a complex interaction among cytokines and metabolic variables 
should be further explored. 
“The stromal derived factor-
1 mutated allele (SDF1-3’A) 
is associated with a lower 
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The stromal derived factor-1 mutated allele
(SDF1-30A) is associated with a lower incidence
of atherosclerosis in HIV-infected patients
Blai Colla, Carlos Alonso-Villaverdeb, Sandra Parrab, Manuel Monteroc,
Monica Tousd, Jorge Jovend and Lluis Masanab
Background: HIV-infected patients have higher rates of subclinical atherosclerosis. The
chemokine stromal derived factor 1 (SDF-1) is the natural ligand for the CXCR4 HIV
co-receptor, is highly expressed in atherosclerotic plaques, and the plasma concen-
tration is lower in individuals homozygous for the mutant allele (SDF1-30A). We tested
the influence of SDF1-30A on atherosclerosis in HIV-infected patients.
Methods: We performed carotid ultrasonography and determined the SDF1-30A DNA
polymorphism in 183 HIV-infected patients. Classical cardiovascular risk factors and
antiretroviral therapy were also recorded. From these patients, we selected a group of
134 patients taking protease inhibitor-based antiretroviral therapy and in whom the
lipid profile over an 18-month follow-up was collated.
Results: We found atherosclerosis in 113 (61.7%) and a lower number of patients with
the SDF-1 mutated allele in the group with carotid atherosclerosis compared to those
without (41.6% versus 57.1%; P ¼ 0.04). Using a logistic regression analysis, age and
dyslipidaemiawere significantly associated with atherosclerosis but the SDF1-30A allele
exerted a protective effect on the development of atherosclerosis (odds ratio, 0.45; 95%
confidence interval, 0.14–1.02; P ¼ 0.05). Further, we observed that, in the selected
group of patients there were lower plasma low-density lipoprotein cholesterol con-
centrations [mean � SEM, 2.06 � 0.34 mmol/l] throughout follow up in those patients
without carotid lesions and who also carried the mutated SDF1-30A allele (P ¼ 0.04).
Conclusion: The SDF1-30A allele is associated with a lower presence of subclinical
carotid atherosclerosis in an HIV-infected population.
� 2005 Lippincott Williams & Wilkins
AIDS 2005, 19:1877–1883
Introduction
HIV-infected patients present with higher rates of
atherosclerosis [1,2] and the incidence of myocardial
infarction has been rising in this group of patients [3],
especially in those under a protease inhibitor (PI)-based
regimen. This may be explained by the metabolic
abnormalities related to the highly active antiretroviral
therapies (HAART) coexisting with the classic cardio-
vascular risk factors in these patients [4,5]. However,
several polymorphisms of genes related to inflammation
have also been implicated in the development of
atherosclerosis [6,7]. Of these stromal derived factor-1
(SDF-1) is an additional candidate because: it is a powerful
chemoattractant cytokine for lymphocytes and mono-
cytes [8]; it has been associated with aggregation-
activation of platelets [9,10]; and it is highly expressed
in atherosclerotic plaques [9,11].
SDF-1 also plays a significant role in HIV infection
because it is the natural ligand for a well-known CD4 co-
receptor, CXCR4, which is used by HIV T-tropic strains
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to enter into the cells in advanced stages of the disease
[12]. A polymorphism in the un-translated region of the
SDF-1 b gene, SDF1-30UTR-801 G!A (abbreviated
to SDF1-30A) influences the course of HIV infection
[13–18], and individuals who bear the mutated allele
present with a minor SDF-1 expression and lower
circulating levels of SDF-1a [16]. Although a clear
association between SDF-1 and atherosclerosis has been
established in in vitro studies [9–11], these findings have
not been confirmed clinically. The circulating levels of
SDF-1a have been found to be lower in an acute
coronary heart disease study [19] and no relationship has
yet been found between the allelic frequency of the
SDF1-30A and the presence of coronary artery disease
[20].
Hence, the aims of our study were to test the association
between SDF1-30A and the presence of atherosclerosis in
a group of HIV-infected patients and to analyse, in a
group of these patients on a PI-based regimen, the known
metabolic risk factors of cardiovascular disease, such as
circulating lipid concentrations.
Methods
Study design: participants and eligibility
The study was case-controlled based on the presence or
absence of carotid atherosclerosis in 183 HIV-infected
subjects.We evaluated clinical, laboratory and genotyping
data in the cases and controls as a measure of the
atherosclerosis risk factors in this specific clinical setting.
Among the exclusion criteria were age < 18 years and
an AIDS-related opportunistic disease at the commence-
ment of the study. The Ethics Committee of the Hospital
Universitari de Sant Joan de Reus approved the study.
Clinical and laboratory measurements
A detailed clinical record was taken and a thorough
physical examination performed at interview. The
cardiovascular risk factors assessed were smoking habit,
presence or absence of hypertension, and body mass
index. Blood pressure was measured following stan-
dardized recommendations of the Spanish Society of
Cardiology [21]. The measurements of glucose, total
cholesterol, high-density lipoprotein cholesterol
(HDL-C) and triglycerides were performed using standard
laboratory methods. Low-density lipoprotein cholesterol
(LDL-C) was calculated using the Friedewald formula.
Dyslipidaemia was considered when total cholesterol
was > 6.2 mmol/l or LDL-C > 4.1 mmol/l or HDL-C
< 0.9 mmol/l. The concentration of C-reactive protein
(CRP) was measured by a particle-enhanced turbidi-
metric immunoassay (Quantex hs-CRP kit, Biokit, SA,
Barcelona, Spain) which has a sensitivity of 0.10 mg/l.
CD4, CD8 and lymphocyte cell counts were determined
by standard FAC scan flow cytometry (Becton-
Dickinson, Madrid, Spain).
Lipid course analysis
We evaluated the course of lipid profile changes in those
patients who had commenced treatment with a PI-based
HAART regimen (134 of the 183 patients) since these
formed the largest treatment group in the study. This is a
retrospective substudy in which the eligibility criteria
were that patients had been naive for PI therapies and had
been identified from our computerized database. Based
on the effects that had been demonstrated by different PI
on lipid profiles [22], we analysed the course of lipid-
profile changes segregated into two patient groups: those
patients on a PI-boosted regimen with ritonavir or
ritonavir as a single PI, and the rest of the patients who
had been treated with indinavir, saquinavir or nelfinavir.
Analyses included total cholesterol, HDL-C, LDL-C, and
triglyceride concentrations measured over the first 18
months of PI treatment. Patients with other treatment
regimens represent a small proportion of our patient
population and were not considered for this part of the
study.
Ultrasonography
Ultrasonography was used to measure intima-media
thickness (IMT) in the common carotid artery 1 cm
proximal to the carotid bifurcation, as previously
described [7,23] using a GE Logiq 700MR system
(Milwaukee, USA). The presence of atherosclerosis was
defined as IMT > 0.8 mm and/or the presence of a
plaque [23]. We used this selection criterion to define the
patient as a case or as a control.
Genotyping
Venous blood samples were collected into tubes contain-
ing EDTA, and the DNA was obtained using the Pure
Gene Kit (Gentra, Gentra Systems Inc., Minneapolis,
USA). The SDF1-30A mutation was identified according
to previously published methods [13]. For genotype
comparisons we used a general population-based control
group of unrelated subjects (n ¼ 348) the details of which
have been described elsewhere [24]. Briefly, they were
healthy people (167 female, 181 male) with an overall
mean age 42 years (range, 19–75 years). All the
participants were of Caucasian–Mediterranean ethnic
origin. Exclusion criteria were the use of medication and
vitamin supplements, having dementia or pregnancy.
Statistical analyses
Data are presented as means with SEM in parentheses.
The Shapiro–Wilk test was used to check for normality
of distributions. ANOVAwas used to compare differences
in quantitative variables and the x2 test for categorical
variables. The Hardy–Weinberg equilibrium together
with the differences in genotype distributions and allele
frequencies between groups were tested using the x2 test.
The SDF-1 genotype results indicated 96 patients
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homozygous for the wild type, 78 patients heterozygous
and nine patients homozygous for the mutated allele
(SDF1-30A). Because of this allelic distribution and
previously published precedent [25] the latter two groups
were considered as a single group for statistical purposes.
To test for significance in the changes in the lipid profile,
we combined the results of the carotid assessment and the
SDF1-30A genotype. As such, there were four possible
combinations taken into account: patients with no
atherosclerotic lesions and with the common SDF-1
allele; patients with no atherosclerotic lesions and
SDF1-30A allele; patients with carotid lesions and the
common SDF-1 allele; patients with atherosclerotic
lesions and the SDF1-30A mutated allele. A general
linear regression model was used to test the differences in
the lipid profile segregated on the basis of these four
groups. The data were adjusted for ritonavir-boosted PI
regimens or ritonavir-based therapy as a single PI and
with Bonferroni adjustment for multiple comparisons.
All P values < 0.05 were considered statistically
significant. All analyses were performed with the SPSS
statistical package (version 11.0; SPSS Inc, Chicago,
Illinois, USA).
Risk factor analysis
Multivariate logistic regression analyses were performed
to evaluate the risk factors in the development of carotid
atherosclerosis. Variables included in the multivariate
analyses were those factors that represent known
cardiovascular risk, e.g., age, body mass index, smoking
habit, CRP, dyslipidaemia, diabetes, hypertension, PI
regimens, as well as those that showed significant
associations in the univariate analyses. The data on
carotid atherosclerosis were the dependent variable and
the independent variables included age, hypertension,
smoking habit, dyslipidaemia, diabetes, CRP, PI regimens
and the SDF-1 polymorphism.
Results
From among the HIV-infected patients attending our
clinic (n ¼ 305), 183 accepted the invitation to partici-
pate in the present study, and provided fully informed
consent. Selected characteristics of the participants,
segregated according to the presence or absence of
carotid atherosclerosis, are presented in Table 1. There
was no case of any vascular event either in the coronary or
in the cerebral areas. Only seven of the patients had been
receiving a statin therapy (but over a period of less than
1 year) and fibrates had been prescribed in 10 patients over
the previous 6 months. Segregation with respect to sex
and/or age did not affect the distribution of the genotype
and, hence, all patients were analysed as a single group.
The allelic distribution of SDF1-30A genotype followed
Hardy–Weinberg equilibrium (x2; P ¼ 0.39) in HIV-
infected patients as well as in the general population-based
control group. The genotype distribution and the allelic
frequency in the HIV-infected group did not differ
significantly from that of the population-based control
group. We did not find significant differences when
comparing patients with atherosclerosis and those with-
out, when considering different types of PI-based
therapies (Table 2). Further, there were no significant
differences in PI treatment schemes when comparing
those patients with the SDF-1 mutated allele with those
with the wild-type allele (data not shown).
Atherosclerosis in HIV-infected patients Coll et al. 1879






(n ¼ 70) P
Age (years) [mean (� SEM)] 39.13 (0.54) 41.54 (0.67) 35.24 (0.68) < 0.001
Male (%) 67.8 72.6 60.0 0.07
Current smoker (%) 84.1 80.4 90.0 0.07
Hypertension (%) 12.3 16.0 6.3 0.05
BPS (mmHg)
a [mean (� SEM)] 119.12 (1.37) 122.27 (1.86) 113.89 (1.82) 0.03
BPD (mmHg)
a [mean (� SEM)] 76.98 (0.92) 78.60 (1.22) 74.26 (1.38) 0.02
Body mass index (kg/m2) [mean (� SEM)] 19.47 (0.19) 19.18 (0.26) 19.68 (0.31) 0.23
Abnormal fasting glucosea (%) 10.9 15.0 4.3 0.01
Dyslipidaemiaa (%) 35.2 50.4 28.6 0.003
C-reactive protein (mg/l) [mean (� SEM)] 4.09 (0.38) 4.08 (0.48) 4.61 (0.88) 0.56
Months since HIV diagnosis [mean (� SEM)] 86.66 (3.80) 90.60 (4.79) 80.31 (6.21) 0.18
CD4 cell count; cells/ mm3 (%)
< 350 42.1 41.6 42.9 0.98
350–500 23.0 23.0 22.9
> 500 35.0 35.4 34.3
AIDS defining conditionb (%) 32.2 31.9 32.9 0.88
Nadir CD4 cell count; cells/mm3 [mean (� SEM)] 344 (21) 322 (24) 380 (41) 0.19
SDF1-30A (%) 47.5 41.6 57.1 0.04
aHypertension was considered as systolic blood pressure (BPS) > 140 mmHg or diastolic blood pressure (BPD) > 90 mmHg; abnormal fasting
glucose was defined as fasting plasma glucose > 6.1 mmol/l; dyslipidaemia was considered as total cholesterol > 6.2 or low-density lipoprotein
cholesterol > 3.36 mmol/l or high-density lipoprotein cholesterol < 0.9 mmol/l.
bAIDS-defining condition was considered according to Clinical Report of the Guidelines for National Human Immunodeficiency Virus Case
Surveillance [30].








































UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
68 69  
Analyses of subclinical carotid atherosclerosis
We found that 113 participants (61.7%) presented with
subclinical carotid atherosclerosis despite being relatively
young (mean age, 39.13 � 0.54 years). Most of the
participants were heavy smokers. In the atherosclerosis
group, we found higher rates of hypertension, abnormal
fasting glucose and dyslipidaemia. Conversely, we did not
find differences in body mass index, or HIV-related
variables such as time since diagnosis (indicating time
of seroprevalence), duration of antiretroviral therapy,
CD4 cell count, and the prevalence of AIDS-defining
conditions. When the distribution of the genotype results
were analysed, we found a lower number of individuals
carrying the SDF1-30A allele in the group with carotid
atherosclerosis (41.6%) than those without arterial lesions
(57.1%; P ¼ 0.04). Further, analysis of the distribution of
the SDF1-30A mutated allele according to the results of
IMT indicated that, among those participants with an
abnormal IMT (> 0.8 mm), the SDF-1 mutated allele
was less likely to be encountered than the wild type
(38.4% versus 61.6%; P ¼ 0.03). When carotid plaques
were measured, we found that those individuals who bore
the mutated allele for SDF-1 presented a significantly
lower carotid plaque area 20.36 � 5.57 mm2, than those
carrying the wild type 37.33 � 4.90 mm2 (P ¼ 0.02).
To ascertain whether the SDF1-30A allele was exerting
any protective effect on the development of carotid
atherosclerosis, we used a multivariate regression analyses
to assess the influence of several known cardiovascular risk
factors on the findings of SDF-1 genotype. Age and the
presence of dyslipidaemia were significantly (P < 0.05)
associated with carotid atherosclerosis in the multivariate
analysis (Table 3). Further, the results showed a protective
effect of the SDF1-30A allele on the development of
carotid atherosclerosis [odds ratio (OR), 0.45; 95%
confidence interval (CI), 0.19–1.02; P ¼ 0.05)]. We did
not find any significant effect of the different antiretroviral
regimens used on carotid atherosclerosis.
We analysed the lipid profile changes in these individuals
(n ¼ 134) during a period of 18 months from the start of
a PI-based therapy. The relevant characteristics of these
patients are given in Table 4. Of note was that higher rates
of systolic and diastolic blood pressure were found in the
1880 AIDS 2005, Vol 19 No 16




[mean (� SEM)] n (%)
Time (months)
[mean (� SEM)] n (%)
Not ritonavir boosteda 22.85(1.97) 77 (61.6) 22.12 (2.68) 48 (38.4) 0.95
Ritonavir boosted 6.46 (1.19) 38 (65.5) 5.40 (1.50) 20 (34.5) 0.47
Efavirenz 8.09 (1.29) 61 (62.2) 7.79 (0.96) 37 (37.8) 0.88
aNo ritonavir boosted agents include indinavir, nelfinavir and saquinavir.
Table 3. Odds ratios (OR) for carotid atherosclerosis in the
multivariate analysis.
OR 95% CI P
Age (years) 1.21 1.11–1.31 < 0.001
Male 1.49 0.61–3.59 0.37
Body mass index (kg/m2) 0.91 0.80–1.03 0.15
Current smoking 1.22 0.34–4.31 0.75
Hypertension 2.67 0.57–12.54 0.21
Dyslipidaemia 2.88 1.21–6.87 0.01
Diabetes mellitus 3.28 0.53–20.15 0.19
C-reactive protein (mg/l) 0.97 0.91–1.03 0.39
Non-boosted PI regimens 1.00 0.98–1.01 0.99
Boosted PI regimens 1.00 0.97–1.03 0.95
Efavirenz-based regimen 1.03 0.99–1.07 0.12
SDF1-30A 0.45 0.19–1.02 0.05
CI, Confidence interval.






(n ¼ 50) P
Age (years) [mean (� SEM)] 38.99 (7.29) 41.23 (0.75) 35.22 (0.88) < 0.001
Male (%) 67.2 70.2 62.0 0.32
Current smoker (%) 85.7 82.1 92.0 0.10
BPS (mmHg) [mean (� SEM)] 120.34 (1.64) 123.62 (2.18) 114.71 (2.19) < 0.05
BPD (mmHg) [mean (� SEM)] 77.40 (1.11) 79.20 (1.46) 74.32 (1.61) < 0.05
Body mass index (kg/m2) 19.52 (0.23) 19.41 (0.31) 19.70 (0.36) 0.57
Abnormal fasting glucose (%) 11.9 16.7 4.0 < 0.05
Dyslipidaemia (%) 41.8 48.8 30.0 < 0.05
C-reactive protein (mg/l) [mean (� SEM)] 4.79 (0.57) 4.69 (0.60) 4.95 (1.17) 0.82
Time since HIV diagnoses (months) [mean (� SEM)] 94.71 (4.07) 96.41 (5.37) 91.86 (6.19) 0.59
Prior NRTI therapy 63.5 % 67.4% 59.6% 0.36
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atherosclerosis group, and that the patients with athero-
sclerosis were significantly older. We did not find
significant differences between the groups when total
cholesterol, HDL-C and triglycerides were analysed
(data not shown). However, when LDL-C was con-
sidered, those patients without carotid atherosclerotic
lesions and who carried the SDF-1 mutated allele
(n ¼ 19) showed a significantly (P ¼ 0.04) lower LDL-C
of 2.06 � 0.34 mmol/l, throughout the follow-up period
(Fig. 1). Multiple comparisons (with Bonferroni adjust-
ments) resulted in significant (P < 0.05) differences when
those patients without atherosclerosis and SDF1-30A
allele were compared with those patients with wild type
SDF-1.
Discussion
The identification of host genetic factors that can exert
influence in the development of cardiovascular diseases in
HIV-infected patients becomes relevant due to the
incidence of atherosclerosis observed in these patients.
Knowledge of these host variables should lead to an
individualized, and better fitted, antiretroviral approach
which should minimize the advent of cardiovascular
events in the long-term. Our main finding is that an
allelic variant of the SDF-1 gene, SDF1-30A, was
significantly less prevalent in HIV-infected patients with
carotid atherosclerosis and, further, these patients pre-
sented with a better LDL-C profile in the 18 months of
follow-up.
Classic cardiovascular risk factors such as advanced age,
hypertension, abnormal fasting glucose and dyslipidaemia
were far more prevalent in the group of patients with
carotid atherosclerosis. However, one of the most
commonly attributed cardiovascular risk factors in these
patients has been the treatment with PI [3] but, according
to our data, multivariate analyses did not reveal any
significant effect of these drugs on the development of
subclinical atherosclerosis. Conversely, a lower number of
patients bearing the mutated allele for SDF-1 were found
in this group, and the results in the multivariate analysis
confirmed the protective effect of the SDF1-30Amutated
allele in the development of carotid atherosclerosis.
Several chemokines have been identified as being
involved in the development of the atherosclerotic lesion,
and polymorphisms in these genes could exert a critical
influence on the process. SDF-1 has been shown to be
involved in different atherosclerosis developmental
processes such as platelet activation and aggregation as
well as in the activation of arterial smooth muscle cells
[9–11]. It is feasible, then, that the influence of SDF-1 on
atherosclerosis might be exerted in a dose-dependent
manner, and it is likely to be modulated by genotype.
Although this hypothesis was not confirmed when
explored in a group of patients with unstable angina [19],
the variations in the plasma concentrations of SDF-1 are
subject to various interpretations. SDF-1 is a chemokine
of stromal origin [8] so it could be that low circulating
levels of SDF-1 do not correspond to the levels in tissues.
Further, it has been demonstrated in HIV-infected
patients that circulating SDF-1 is converted into an
inactive form which appears to be smaller in size that the
original [26]. These possibilities make the interpretation
of plasma concentration of SDF-1 difficult. However, in
a non-HIV-infected population, SDF-1 expression was
decreased in those bearing the SDF1-30A allele [16]
and, therefore, it would seem reasonable to postulate
a protective effect against atherosclerosis. We did not
measure SDF-1 plasma concentration because, in HIV-
infected patients, several factors can influence its
Atherosclerosis in HIV-infected patients Coll et al. 1881
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• No atherosclerosis, SDF-1 wt
°Atherosclerosis, SDF-1 wt
Atherosclerosis, SDF1-3́ A
No atherosclerosis, SDF1-3́ A∆
Fig. 1. LDL-C values (means W SEM) in HIV-infected patients on PI-based therapy (n U 134) segregated with respect to SDF-1
genotype and the results of the carotid ultrasonography. A general linear regression model adjusted for ritonavir-boosted or
ritonavir as a single PI-based antiretroviral therapy was applied. �P ¼ 0.04.








































UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
70 71  
measurement [26,27] and, as such, a single determination
is unlikely to be of much statistical value. We have not
typed the viruses for CXCR4, and this may represent a
limitation in our study. Most of the patients studied were
asymptomatic and it may be assumed that R5 HIV strains
are predominant [28]. However, we did not aim to study
the influence of SDF1-30A mutated allele on HIV
progression but, more importantly, the influence of these
polymorphisms on the development of atherosclerosis in
a cohort of HIV-infected patients. As such, knowledge of
the virus type, whether R5 or X4, would not add much
additional insight into the development of atherosclerosis
in response to the inflammatory state induced by the HIV
infection.
We found a striking association between the lipid profile
and the SDF-1 genotype. LDL-C values were greatly
decreased in those individuals carrying the mutated allele.
This could explain, in part, the protective influence of
the mutated allele on the development of atheros-
clerosis. Although it might represent merely an epigenetic
phenomenon, it is of note that patients without
atherosclerotic lesions and who bear the mutated allele
had LDL-C values < 2.5 mmol/l throughout the course
of the follow-up period. This would need to be
confirmed in large prospective studies since it is of
considerable interest to evaluate the influence of SDF-1
on the development of carotid atherosclerosis and on
the course of lipid changes and, as such, to assess whether
the host genetic background has any influence in the
progression/regression of carotid IMT. One further
limitation of our study is that we did not evaluate
patients with antiretroviral therapies other than the
PI–HAART scheme. As such, for example, we have not
analysed patients receiving non-nucleoside reverse
transcriptase inhibitor-based regimens as the numbers
in this subsample are small. However, it has been
documented that this antiretroviral therapy can exert a
beneficial effect on the lipoprotein profile by inducing
increases in HDL-C concentrations and, as such, would
have represented a confounding variable [29] in the
present study.
In summary, the allelic variant SDF1-30Aof SDF-1 appears
to be protective against the development of carotid
atherosclerosis in a group of HIV infected patients and is
associated with a less-atherogenic lipid profile, including
lower concentrations of LDL-C. The identification of this
host polymorphism could be of major interest in
individualizing antiretroviral therapy and in minimizing
the risk of cardiovascular disease in these patients.
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Original Manuscript #4 to be published in Stroke (in 
press).
 
“The role of immunity and 
inflammation in the progression 
of atherosclerosis in HIV-
infected patients.”
The fourth study is the result of the analyses of atherosclerosis progression/regression 
of participants in the study. We applied the same protocol (carotid and femoral IMT, 
clinical assessment and biologic samples) after a median of 2.5 years of follow-up. The 
main result is that IMT values, in both carotid and femoral arteries, progressed at a rate 
of 0.045 mm/year, indicating a significant atherosclerosis progression in HIV-infected 
patients (normal rate of progression is set at 0.01 mm/year). Classical cardiovascular risk 
factors, such as age or total cholesterol, were influencing significantly the rate of IMT 
increase, but interestingly, the number of CD4 cell count and certain chemokine-related 
polymorphisms were also determinant in the course of atherosclerosis. The lower the 
nadir CD4 cell count the higher was the rate of IMT increase, which might indicate that the 
immune reconstitution experienced by HIV-infected patients severely immunodepressed 
before starting any HAART, may be deleterious in terms of atherosclerosis. Further, those 
patients who bear the SDF1-3’A or CX3CR-1 249I presented a significantly reduced rate of 
IMT increase. These data suggest a relevant influence of inflammatory and immunologic-
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The role of immunity and inflammation in the 
progression of atherosclerosis in HIV-infected 
patients
Blai Coll, MD; Sandra Parra, MD; Carlos Alonso-Villaverde, MD; Gerard Aragonés, Manuel 
Montero, MD; Jordi Camps, PhD; Jorge Joven, MD; Lluis Masana, MD. 
Background and Purpose- The initial steps of atherosclerosis and the entry of HIV into the cell share similar
biological mechanisms. Therefore, our hypothesis is that the progression of atherosclerosis in HIV-infected
patients can be influenced by variations in genes implicated in both processes. 
Methods and Results- The progression of atherosclerosis over a 2-year follow-up period was measured as the
combined carotid and femoral intima-media thickness (IMT) in 141 HIV-infected patients. The �IMT
(IMTfollow-up- IMTbaseline) values were used to segregate patients as minimal progressors or regressors (lowest
�IMT tertile), slow progressors (mid �IMT tertile) and rapid progressors (highest �IMT tertile). Mutations
CCR-5�32, CCR-2 64I, MCP-1–2518G, SDF1-3’A and CX3CR-1 (T280M and V249I) in the host DNA were
determined. Mean age of the patients was 38.96 (SEM: 0.61) and 68.8% were male. The mean �IMT was 0.045 
mm (0.01) per year which represented a significant progression (p<0.001) with respect to baseline values.
Patients with minimal progression or regression had a significantly (p=0.01) higher CD4 cell count than slow
progressors and rapid progressors. Multivariate analyses indicated that age and total cholesterol were positively
associated with IMT progression. In contrast, the CD4 cell count, the SDF1-3’A and the CX3CR-1 249 I
mutated alleles were associated with a lesser IMT progression.
Conclusion- The course of atherosclerosis in HIV-infected patients is influenced by polymorphisms in the
SDF1 and CX3CR1 genes, by metabolic variables and by the CD4 cell count. These data would be of help in
assessing therapeutic needs of these patients. (Stroke 2007; in press). 
Key words: atherosclerosis � intima-media thickness � HIV � chemokine polymorphisms � non-conventional
cardiovascular disease risk factors
HIV-infected patients have higher rates of atherosclerosis 1, 2 
and the progression is faster than in non-infected individuals 
3. Chemokines play a significant role in atherosclerosis and
HIV infection 4, 5 and chemokine-related genetic variants are 
implicated in the development of atherosclerosis as well as
in the natural course of HIV-infection 5-8.
Circulating monocytes are attracted to the sub-endothelial
space, mainly mediated by monocyte chemoattractant
protein-1 (MCP-1), where they become foam cells 7, 9. A
polymorphism in the promoter region of the MCP-1 gene
(MCP-1–2518G) is associated with a higher MCP-1
expression 10. The bearers of this mutation are more prone to 
the development of AIDS-associated dementia 11, or sub-
clinical atherosclerosis 12. Its natural receptor, CCR-2, a 
minor co-receptor for the entry of HIV into the cell 13, has
been implicated in the development of atherosclerosis 14 as
well as in disease progression in HIV-infected individuals 15.
Similarly, the stromal derived factor-1 (SDF-1) 16, activates
platelets within the atheromatous plaque 17 and promotes the 
migration of smooth muscle cells to the sub-endothelial 
space 18. A polymorphism in the untranslated region, SDF1-
3’A, which is associated with a lower SDF-1 expression 19,
influences the disease progression as well as the presence of 
sub-clinical atherosclerosis in HIV-infected patients 20, 21.
Another chemokine, fractalkine, is up-regulated in inflamed
tissues and it functions as a chemo-attractant as well as an 
adhesion molecule. DNA polymorphisms in the gene for its 
specific receptor CX3CR1 (V249I and T280M) lead to a
reduced number of fractalkine binding sites, to a reduced risk 
of coronary artery disease, and to a more rapid progression 
to AIDS 22-23.
As a consequence, patients with HIV infection are prone to
continuous inflammatory stimuli which may trigger a
cytokine imbalance that can influence the development of 
atherosclerosis 24. However, these patients also present with 
well-known, pre-existing cardiovascular risk factors 25 and 
our aim was to evaluate these variables and to evaluate their 
relative contribution to the progression of atherosclerosis. 
Design and Methods
Participants and design 
We performed a prospective study aimed at evaluating 
atherosclerosis and its related factors in a cohort of HIV-infected
patients (n=305) who were receiving regular attention in our out-
patient HIV clinic. The results of the initial assessments have been 
published previously 12, 21 and the current manuscript summarizes the 
follow-up data. In the first clinical consultation, a complete physical
examination was performed including the assessment of body
weight, height and blood pressure according to standard guidelines 26
and a venous blood sample was drawn for blood chemistry and DNA 
analyses. At the same visit the first ultrasound baseline scans of the
carotid and femoral arteries were performed. The identical protocol
was applied by the same investigators after two years of follow-up.
During this period, data on smoking habit, alcohol consumption,
time since HIV diagnoses, nadir of the CD4 cell count (CD4 cell
count before starting antiretroviral therapy), time on highly active 
antiretroviral therapy (HAART) and opportunistic infections were 
collated. Lipodystrophy and metabolic syndrome were diagnosed
using accepted criteria 27, 28. The laboratory measurements included 
plasma total cholesterol, HDL cholesterol, triglycerides, and 
glucose as well as serum HIV-1 RNA and blood lymphocyte T
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CD4+ cell count. LDL cholesterol was calculated from the 
Friedewald formula. The study was approved by the Ethics
Committee of Hospital Universitari Sant Joan. 
Genotyping
DNA was obtained using the Pure Gene Kit (Gentra Systems, Inc.). 
We determined MCP-1–2518G, CCR-2 V64I, SDF1-3’A, CCR-5
�32 and CX3CR-1 (V249I and T280M) variants using previously-
published methods 11, 16, 20, 24.  For genotype comparisons we used a
general population-based control group of unrelated subjects 
(n=348) the details of which have been described previously 29.
Briefly, they were healthy people (167 female, 181 male), mean age
42 years (range 19-75) and who were considered representative of
the general population in our area.
Ultrasound standardized protocol
dicina Interna (SP, CAV, LM) and Servei de Radiologia (MM) 
Characteristic Baseline Follow-up P value
Gender; male 97 (68.8) NA NA
Age; years 38.9 (0.6) 40.7 (0.6) NA
Body mass index; kg/m2 23.31 (0.27) 23.52 (0.29) 0.02
Systolic blood pressure; mmHg 118.04 (1.44) 120.46 (1.54) 0.07
Diastolic blood pressure; mmHg 76.96 (1.04) 78.35 (0.97) 0.16
Smoking; yes 94 (66.6) 88 (62.4) 0.09
Lipodystrophy; yes 42 (29.8) 46 (32.6) 0.09
CD4 cell count; cells/mm3 462.97 (27.02) 523.63(27.81) <0.001
Undetectable HIV-1 viral load* 89 (63.1) 98 (69.5) 0.08
Total cholesterol; mmol/L 5.06 (0.11) 4.90 (0.12) 0.004
HDL cholesterol; mmol/L 1.18 (0.04) 1.19 (0.03) 0.56
LDL cholesterol; mmol/L 2.82 (0.09) 2.68 (0.09) 0.01
Triglycerides; mmol/L 2.50 (0.19) 2.53 (0.21) 0.38
Glucose; mmol/L 5.42 (0.08) 5.40 (0.09) 0.48
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The carotid and femoral ultrasound measurements were performed
under the identical protocol by the same investigators (MM, BC)
who were blinded with respect to the results of the other measured
variables. We used a GE Logiq 700 with an ultrasound probe of 7-10
MHz. We identified and digitally recorded the far wall of  the 
common carotid artery (1cm proximal to the bifurcation), the carotid
bulb (in the bifurcation), the internal carotid artery (1cm distal to the 
bifurcation) and the common femoral artery. All the IMT 
measurements were performed at the pre-defined points using the
image processing software AnaliSYS TM (Soft Imaging System,
Münster, Germany). IMT measurements on each arterial segment
were averaged and used in the statistical analyses as combined IMT, 
as previously described 13. The intraclass correlation coefficient
between the 2 examiners in evaluating the images from 20 IMT
measurements was 0.89 (p<0.001), and the absolute IMT difference
was 0.01 mm (0.025). To assess reproducibility of measurements,
the images of 20 randomly-selected patients were re-measured
applying the same protocol. The intraclass correlation coefficient
between the 2 sets of measurements was 0.91, and the absolute
difference in IMT was 0.007 mm (0.018). To assess the 
reproducibility of re-scanning and re-measurement, 10 patients
underwent a re-scan within 1 month. The intraclass correlation
coefficient for the measurement was 0.94.
Statistical analyses
Results are expressed as the mean with standard error of the mean
(SEM) in parentheses, or in percentages. Kolmogorov-Smirnov test 
was applied to test the distribution of variables. Paired Student t-test 
was applied to evaluate differences in measurements of continuous 
variables at baseline and at follow-up and the Wilcoxon test when
the data were not normally distributed. The �2 test was used to 
compare categorical variables. The difference in the combined IMT 
value between the 2 examinations was calculated as �IMT = IMT 
follow-up – IMT baseline. Univariate analyses were used to identify
the variables having an impact on �IMT. We defined as “rapid
progressors” those individuals with a �IMT value in the highest 
tertile (�IMT �0.18 mm), “slow progressors” as being those patients 
with �IMT between 0.02 and 0.179 mm, and “minor progressors” or
“regressors” as those in the lowest tertile (�IMT �0.019 mm).
Differences among these groups were tested with ANOVA and a 
post-hoc analysis (Bonferroni test) was applied.
Stepwise regression analyses were performed to determine
prognostic factors for baseline sub-clinical atherosclerosis (defined
as the presence of an atherosclerotic plaque or as a combined IMT 
�0.8mm) and for the change in the combined IMT at 2 years of
follow-up. The stepwise analysis method added variables one-by-
one into the model, with the variable with the smallest probability
value significant at the 0.05 level.
For the identification of variables related to baseline sub-clinical 
atherosclerosis we applied a logistic regression analyses and, for the
�IMT, a linear regression analyses in which the following were the
independent variables: age, gender, BMI, systolic and diastolic 
blood pressure, fasting plasma lipid concentrations, lipodystrophy,
metabolic syndrome and CD4 cell count. Also included were the
duration of the patient’s antiretroviral treatment and the results of 
the genotype analyses. The multivariate linear regression analysis 
was adjusted for the baseline IMT values.
Results
General characteristics of HIV-infected participants 
From the 183 participants who accepted to participate, 8 died
from HIV-associated diseases, 27 were lost to follow-up or
declined to participate in the second evaluation, and in 7 
patients the recorded images were not of sufficient quality to
perform the analyses.
The clinically-relevant characteristics of the 141 patients
included are summarized in Table 1. The mean time-lapse to
HIV sero-prevalence (time from diagnoses) was 7.24 (0.36) 
years and 79 (56%) patients were co-infected with the 
hepatitis C virus. Most patients (56%) were current or past 
intravenous drug abusers and sexual intercourse-related 
factors were identified as the cause of the infection in the
remaining patients. In the baseline examination, most
patients were heavy smokers, relatively young, without 
significant obesity and with normal blood pressure values. 
Mean plasma lipid and glucose concentrations were within 
the laboratory reference ranges. Mean CD4 cell count was 
significantly higher in the second evaluation and there was a
trend towards more patients having undetectable HIV viral 
load (Table 1). Most patients (92.2%) were receiving
HAART treatment schemes and, during the follow-up, there 
were no major changes in the prescriptions (Table 1).
We found higher total plasma and LDL cholesterol
concentrations in the baseline examination but higher mean
systolic blood pressure was observed in the second 
evaluation (Table 1). Similarly, we found more patients who 
fulfilled the criteria of lipodystrophy and metabolic
syndromes in the second examination, although this 
difference did not reach statistical significance. During the 
follow-up, 3 patients had cardiovascular disease events (2
patients with stroke and 1 patient with an acute coronary
syndrome) and statins were prescribed to 10 patients. 
Table 1. Characteristics of participants (N=141) at
baseline and at follow-up.
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As shown in Table 2, there were no significant differences
either in allele frequencies or genotype distributions between 
the group of HIV-infected patients (N=141) and the general 
population (N=348).
For statistical purposes, those patients with at least one 
mutated allele for MCP-1, SDF-1, CCR-5 or CCR-2, were
analyzed as a single group. From among the 9 possible
CX3CR-1 haplotypes, we did not find any study participant 
with the VV/TM, VV/MM and VI/MM genotypes. This 
indicated that the CX3CR-1 polymorphisms were in
complete linkage disequilibrium. Since the 249I allele has 
been shown to be associated with less-extensive
development of atherosclerosis (24), we compared the
V249V genotype against the other genotypes as a combined 
group (V249I or I249I).
There were no significant differences in the CD4 cell count 
and HIV viral load between those patients carrying the
mutated alleles compared to those carrying the wild type
and, as such, the HIV-related variables did not segregate 
with genotypes.
Table 2. Genotype distribution of the polymorphisms in the 
HIV-infected patients and the general population 
Factors influencing baseline and follow-up values of 
combined IMT 
There was a significant (p<0.001) mean annual increase 
(0.045 mm) in the combined IMT between the baseline
measurements [0.75 (0.01) mm] and the follow-up values 
[0.84 (0.01)] (Figure 1), and this tendency did not vary when
carotid and femoral arteries were analyzed separately (data
not shown). Males showed higher baseline IMT values than 
females, although patients of both genders had similar rates 
of increase (Figure 1). Baseline values were not significantly
influenced by the lipid profile, the presence of metabolic
syndrome or the treatment with protease inhibitors (PI).
Figure 1. Combined IMT in baseline and follow-up examination
in females (open bars), males (hatched bars) and overall study
participants (closed bars). * p<0.05 comparing baseline IMT
values between females and males (ANOVA) ** P<0.05 follow-up









































































We used the �IMT values to segregate the patients into 
regressors (N=45), slow progressors (N=48) and rapid
progressors (N=48) so as to identify variables that may
influence the course of atherosclerosis (Table 3). None of the
classical cardiovascular disease risk factors were
significantly associated with the course of IMT. The 
proportion of patients with metabolic syndrome was lower 
among the regressors but the difference did not reach
statistical significance (p=0.09). There were significant
differences in the CD4 cell counts among groups. Regressors
had a higher nadir and baseline CD4 cell counts than slow 
progressors and rapid progressors (Table 3 and Figure 2), 
indicating that the better the immune status the lower the 
likelihood of atherosclerosis progression.
Figure 2. Rate of IMT progression segregated with respect to
selected genotypes. Open bars represent patients bearing the wild 
type allele and closed bars those with the mutated allele. * P=0.05
and ‡ P=0.04 comparing the different rates of IMT progression
segregated with respect to SDF-1 and CX3CR-1, respectively
(ANOVA).
Genetic variables were distributed in a similar manner 
among groups, although the variant CX3CR-1 249I was
more frequent among the regressors (p=0.08). Moreover, the 
simultaneous presence of the putatively atherosclerosis-
protective alleles (i.e. SDF1-3’A + CX3CR-1 249I + MCP-
1–A2518), was significantly (p=0.008) higher in the group of
regressors.
The differences in the rates of progression were not 
statistically significant with respect to the genetic variants in 
CCR-5, CCR-2 and MCP-1. However, those patients with
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either the SDF1-3’A or the CX3CR-1 249I alleles showed a 
significantly lower IMT increase than those with the 
corresponding wild-type alleles (Figure 3).
Figure 3. Progression of CD4 cell counts in relation to the course 
of atherosclerosis. Nadir (at the moment of initiating antiretroviral 
therapy), Baseline (first clinical evaluation) and Follow-up (second
clinical evaluation). CD4 cell counts are presented as the mean
(SEM). There were no significant differences between the groups
with respect to time-lapse to HIV sero-prevalence; * P=0.01
comparing the 3 groups of atherosclerosis progression rates 
(ANOVA).
Variables related with atherosclerosis progression
We applied multivariate regression analyses to identify those 
variables that could influence baseline IMT values and 
atherosclerosis progression. The results of the analyses
revealed that age, diastolic blood pressure and the MCP-
1�2518G mutated allele were positively, and significantly,
associated with a higher likelihood of atherosclerosis in the
baseline measurements (Table 4). The combined IMT in the 
baseline measurement was the strongest predictor of the 
course of IMT i.e. the higher the baseline values the slower
the rate of IMT increase. Age and total cholesterol were 
positively associated with a higher IMT increase (Table 4).
The CD4 cell count was also an important determinant i.e.
higher CD4 cell counts predicting slower IMT increase.
Finally, the mutated SDF1-3’A allele and the presence of the
I allele in position 249 of the CX3CR1 gene were also
identified as protective factors in the increase of IMT (Table
4).
Table 4. Multivariate stepwise analyses of atherosclerosis. R2 of
the linear regression analyses for the �IMT = 0.56.
The formula resulting from the application of the 
multivariate model predicts 60% of the variance of �IMT,
and the predicted values correlated closely (Pearson
coefficient=0.74, p<0.001) with those observed (Figure 4).
Figure 4. Correlation between observed and predicted �IMT
The predicted �IMT was obtained using the following formula:
�IMT= 0.43 + [�0.72� baseline IMT(mm)] + [0.006� age(years)]
+ [0.025� Total cholesterol (mmol/L)] + [�0.00008� CD4 cell 
count(cells/mm3)] + [�0.05� CX3CR-1( 0 wild type, 1 mutation)]
+ [�0.04� SDF-1 (0 wild type, 1 mutation)] Data presented as
mean and 95 % confidence interval. 
Discussion
Our data indicate that the IMT in HIV-infected patients
increases at a faster rate (0.045 mm/year) than that
considered as the threshold value (0.03 mm/year) beyond
which the risk of suffering from cardiovascular disease 
events is significantly higher 30. Among the causes of such 
progression, only age and total cholesterol are among the
classical cardiovascular risk factors that we observed to be
significantly associated with a higher rate of IMT increase.
Our data are similar to that of a previous study by Hsue et al
3 which had shown an IMT increase of 0.07 mm/year. The
mean age of participants and different genetic background
may explain the differences in the rates of atherosclerosis
progression between studies. Further, one relevant source of 
variability among studies, is that we used different protocols
to acquire and read the IMT images. However, their data 
reached similar conclusions and, as such, are highly
informative.
Another variable that influences the rate of IMT increase is
the baseline IMT. The use of a structural measure to assess
atherosclerosis reflects the retrospective lifetime exposure to 
risk factors. Indeed, it may indicate that those patients with
higher baseline IMT had been also exposed to a larger
number of classical risk factors, and which have been 
prospectively controlled. This may explain the negative
association between baseline IMT and progression.
However, a specifically designed controlled clinical trial
would need to be performed to answer to this question. 
We observed, as well, that the CD4 cell count may play a
relevant role in atherosclerosis progression; the higher the 
CD4 cell count the lower the rate of atherosclerosis 
progression. It is plausible that patients with a better CD4 
recovery were not under the deleterious influence of CD4
activation 31-33. Atherosclerotic plaques are constantly being 
Baseline atherosclerosis Odds ratio 95%CI P value
Age ; years 1.23 1.11- 1.36 <0.001
Diastolic blood pressure, mmHg 1.06 1.01- 1.10 0.006
MCP-1�2518G 7.78 2.31- 26.16 0.001
4b. Follow-up examination
� IMT; mm � 95%CI P value
Baseline combined IMT ; mm �0.69 �0.84- �0.59 <0.001
Age ; years 0.21 0.002- 0.009 0.001
Total cholesterol ; mmol/L 0.17 0.008- 0.04 0.003
CD4 cell count ; cells/mm3 �0.13 �0.03- �0.01 0.02
CX3CR1-249I �0.14 �0.09- �0.01 0.01
SDF1-3’A �0.12 �0.09- �0.002 0.04
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remodeled, and this determines the rate of
progression/regression of the disease. CD4� cells can
influence this dynamic process, as has been described for 
monocytes in animal models of atherosclerosis regression 34.
The detrimental influence of low CD4 cell counts in the IMT
increase may be explained by a higher rate of antiretroviral
prescriptions. However, in the multivariate analyses none of 
the treatments analyzed were positively associated with 
ho bear the 249I allele have
ical atherosclerosis but seems, however, to have a 
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otid and femoral arteries). Also,
ral vascular
.
clerosis and not just the
osclerosis in HIV-infected patients
y metabolic, inflammatory and immunological 
d protocols to measure IMT and the
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pment award from the Carlos III
atherosclerosis progression.
The progression of atherosclerosis in HIV-infected patients
can be controlled through a reduction in cardiovascular risk 
factors, a reduction in the prescription of PIs and an increase
in concomitant treatments with lipid-lowering agents 35.
These results warrant confirmatory large-scale multi-
centered trials ought to incorporate an assessment of the IMT 
within a standardized protocol. This is being recognized in 
clinical trials assessing the efficacy of lipid-lowering drugs
36.
Chemokines and their natural receptors have received
increasing attention in atherosclerosis research 5. This is 
especially relevant in HIV-infected patients because the
chemokines have been implicated in both processes: the
entry of HIV-into the cell, and the ability of the monocyte to 
enter the sub-endothelial space. MCP-1 is the more active
molecule implicated in chemotaxis 7, a phenomenon in 
which other molecules such as fractalkine and its receptor 
CX3CR-1 participate. The fractalkine/CX3CR-1 axis is of 
particular interest because it can function as a chemo-
attractant and as a direct adhesion molecule 23. The presence
of the 249I mutated allele has been associated with a lower 
CX3CR-1 expression 24 and, as such, the interaction between 
fractalkine and CX3CR-1 is less likely. Our results indicate
that HIV-infected patients w
significant protection against atherosclerosis progression. 
Since heterozygous patients may have only a partial
deficiency in CX3CR-1 function, and since alternative
monocyte recruitment pathways can exist, our study
addressing the role of MCP-1 and SDF-1 adds a different
perspective to the atherosclerosis process. The SDF1-3’A
mutation is associated with a lower SDF-1 expression. It 
appears not to have relevance in determining baseline sub-
clin
beneficial influence on the progression of the disease. 
Moreover, the putative “atherosclerosis-protective”
combination, such as CX3CR-1 249I+ SDF1-3’A+MCP-1–
2518A, is associated with a lower rate of IMT increase. 
Limitations of the study 
Previous reports in non-HIV-infected patients, assessed the 
influence of genetics in the values of IMT, It was estimated
that 35–45% of the variability in multivariable-
adjusted carotid IMT is explained by genetic factors 37. One
of the aims of our study was to investigate the relationship
between selected genetic polymorphisms and the IMT
course. Although the associations observed in univariate 
were not very robust, we included these variables in the
multivariate model in order to determine, specifically, the
influence of certain genetic variations in this clinical setting. 
However, to confirm such genetic associations, a larger 
patient population sample would be necessary. Further, to 
preclude the effect of confounding variables associated with
HAART therapies, the study would need to be performed in 
treatment-naïve patients. There are lines of evidence
suggesting a deleterious effect of PIs on the atherosclerosis
process 38-40 but, to-date, no studies have been specifically
designed to prove such hypotheses and, as such, they have
yet to be definitively demonstrated.
We expressed our data from carotid and femoral IMT as 
combined IMT mainly because the course of IMT in both
territories was observed to be similar (significant progres
was found in both car
atherosclerosis is a systemic disease in which disturbances in 
carotid and femoral arteries have been associated with a
higher incidence of cardiovascular and periphe
disease, respectively 41.
Implications
Our multivariate analyses resulted in the configuration of a 
formula that predicts 60% of the variance in �IMT. The only
significant modifiable factors were total cholesterol and the
CD4 cell counts. For example, in a 40 year-old patient with a 
baseline IMT of 0.8 mm and wild type for the 2 critical 
genotypes (SDF1-3’A and CX3CR-1 249I), the reduction of
1 mmol/l of total cholesterol and the increase of 100 CD4
cells/mm3 would result in a 20% reduction in the predicted 
�IMT. Our data also indicate that the putative deleterious
effect of antiretroviral therapy is unlikely to occur if the
patient’s plasma cholesterol concentration is properly
managed
In measuring IMT, we support the exploration and
measurement of the degree of atheros
assessment of risk-factor status in the development of the
disease. We propose that lipid-lowering agents should be 
used not only for the patient with high values of total plasma 
cholesterol and LDL cholesterol but also for those patients
with pathological baseline IMT as well as those with a
higher rate of IMT increase.
Summary
The progression of ather
is influenced b
variables. Our results indicate that, in the assessment of a 
patient population with HIV infection, the classical
cardiovascular disease risk factors should be complemented 
with the study of the inflammatory response (especially
those genetic factors that have an influence in HIV and in
atherosclerosis. These include MCP-1, SDF-1 and CX3CR-
1, and immune status (CD4 cell count at the moment of HIV 
diagnoses). This conclusion has been reached by another 
study in non-HIV-infected patients in which a combination 
of genetic polymorphisms and a pro-inflammatory score was 
strongly related with carotid and femoral IMT 42.
Standardize
identification of the genetic susceptibility should be 
implemented for a better, and more individualized,
cardiovascular disease risk assessment of the patient. 
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Notes to Table 3: For definition of “regressors”, “standard progressors” and “rapid progressors” see text for details; * P <0.05 of the 
differences between rapid progressors and regressors (post hoc analysis, Bonferroni test); ‡Indicate overall p value <0.01 (ANOVA). 
Definition of the Metabolic syndrome (see text). All values are expressed as mean (Standard Deviation) 
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This thesis analyses the influence of genetics on different fields regarding 
HIV infection, such as atherosclerosis and the course of immune and 
virologic variables. The study was designed prospectively in 2002 to assess 
the incidence, causes and mechanisms of atherosclerosis in a population 
under the influence of a chronic infection, and to further explore those 
genetic variables that may impact in both processes, atherosclerosis and 
HIV-infection (ATEROVIR study, which was partially financed by the Fondo 
de Investigación Sanitaria, Instituto de Salud Carlos III, 2004-2007).  This 
approximation lead us to collate clinical data, not only related to infectious 
diseases but also, metabolic and cardiovascular risk factors. We have 
performed a collection of images of carotid and femoral arteries of each 
participant for the measurement of IMT. The design of the study includes 
also the storage of biological samples, such as DNA, plasma, serum and 
lymphocytes.
I present in this thesis the first four original manuscripts although the study 
is under a constant actualization and revision. As such, it is still open and 
active for further studies and modifications.  
Genetics, atherosclerosis 
and HIV
The identification of markers for the early detection of atherosclerosis is 
highly relevant. This is especially interesting in young populations, because 
primary preventive strategies are available, and therefore, the incidence 
and consequences of cardiovascular diseases should be positively 
diminished. In that sense, the use of IMT has revealed a very effective tool 
in assessing the risk of suffering from cardiovascular diseases, and as such, 
it is a very effective tool to study atherosclerosis in different populations 
243. We have studied HIV-infected patients for many reasons. First, they are 
under the influence of a chronic infection, that might provoke a chronically 
inflamed status in most of these patients 244. It is known that a chronic 
inflammatory state has been strongly associated to a higher incidence of 
atherosclerosis related events 245, and in fact, several studies addressing the 
influence of chronic infections such as, Chlamydia or Helicobacter, on the 
development of atherosclerosis have already been published 246. Second, 
the generalization of HAART schemes are closely linked with a longer life 
expectancy, and then the appearance of age-related conditions, such as 
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by which HIV entry into the cell and monocytes reach the subendothelial 
space, are similar, i.e.: a complex interactions of chemokines and their 
natural receptors. Interestingly, HIV itself is able to influence the expression 
of these chemokines, the inflammatory response (for instance, Tat and MCP-
1) and also the metabolism of the infected cells (blocking the properties of 
macrophage ABCA1) 247. 
For all these reasons, and taken into account that the identification of these 
patients more vulnerable to the development of atherosclerosis might 
be critical, we have developed a prevention strategy, summarized in the 
Figure 25, which is based in:
 1.- to detect atherosclerosis non-invasively: using in a standardized 
fashion the measurement of the IMT.
 2.- to collate classical cardiovascular risk factors.
 3.- to analyze genetic polymorphisms influencing both HIV and 
atherosclerosis.
Figure 25. General approach to the study of atherosclerosis in HIV-
infected patients.
The first study revealed the impact of MCP-1 in the development of 
atherosclerosis in HIV-infected patients; either the mutated MCP-1–2518G 
allele or the plasma concentration of MCP-1 are closely related with a higher 
likelihood of having atherosclerosis. We also studied 248 which variables 
were related to MCP-1 concentration in HIV-infected and un-infected 
population (Annex #1). Plasma MCP-1 concentration was significantly 
higher in HIV-infected patients than in healthy participants, in whom, 
MCP-1 were significantly correlated with age, smoking status, triglyceride 
concentrations and with the presence of MCP-1-2518G mutated allele.  In 
HIV-infected patients, MCP-1 was significantly and positively correlated 
with HIV viral load and inversely correlated with the number of CD4+T 
cells, indicating that a close interaction between HIV and MCP-1 may exist. 
However, in a multiple regression model, only age, the MCP-1 genotype 
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An interesting conclusion of these studies is the loss of association between 
C-reactive protein and circulating MCP-1 157, 248. This feature is of particular 
interest because they are usually studied together, in order to better assess 
the inflammatory status 249. According to our results, MCP-1 and CRP might 
represent different ways of inflammation and thereby studies based on 
both molecules should not be taken together.
One of the conclusions of our first study is that the higher the MCP-1 
concentration, the higher the IMT values, and it is specially relevant in those 
HIV-infected patients who bear the mutated allele. This is also applicable 
to HIV-infected patients who have developed lipodystrophy, in whom a 
different expression of cytokines and adypokines have been observed 250. We 
have studied in a sub-set of HIV-infected patients the relationship between 
carotid IMT and MCP-1251 (Annex #2), and we found that lipodystophic 
HIV-infected patients presented higher plasma concentration of MCP-1, 
that in turn were closely related with a higher carotid IMT (Figure 26). This 
observation lead us to hypothesize that a possible mechanism explaining 
the higher IMT values in these patients was mediated by MCP-1. 
Further, we have studied which would be an effective way to control the 
expression of MCP-1. In non-infected population, the use of statins 252 or 
insulin sensitizers 253 have been associated to a decrease in the plasma or 
serum concentrations of MCP-1. In a collaboration study with the group 
of the Erasmus Medical Center in Rotterdam, we studied the impact of 
several cytokines and anti-oxidant variables in lipodystrophic HIV-infected 
patients who had received metformin or rosiglitazone 254 (Annex #3). 
Both treatments decreased plasma concentrations of MCP-1 significantly 
after 26 weeks of therapy.  Whether this action has a direct impact in 
the development of atherosclerosis remains to be shown, and further 
Figure 26. Relationship between carotid IMT and plasma MCP-1 in HIV-
infected patients with lipodystrophy (A) and without lipodystrophy ( B).
“lipodystophic HIV-
infected patients 
presented higher plasma 
concentration of MCP-1 
closely related with a 
higher carotid IMT
“ loss of association 
between C-reactive protein 
and circulating MCP-1
“MCP-1 and CRP might 
represent different ways of 
inflammation and thereby 
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and  larger clinical trials should be initiated. van Wijk et al. 255 reported in 
a clinical trial of lipodystrophic HIV-infected patients that rosiglitazone 
increased subcutaneous and visceral abdominal fat. They also assessed 
cardiovascular status using endothelial function parameters, such as flow-
mediated vasodilation, that was significantly increased with metformin. 
They also performed carotid IMT studies of these patients and those values 
were compared with diabetic patients and with healthy participants 256. 
Carotid IMT was similarly increased in the group of HIV-infected patients 
with metabolic syndrome (comparable to those diabetic patients), and 
significantly higher than healthy participants.
In a subset of HIV-infected patients with hypercholesterolemia we have 
used lipid lowering agents to ascertain its impact on an early atherosclerosis 
marker, the assessment of endothelial function 257 (Annex #4). Although 
we have not data concerning the course of cytokines in these treated 
patients, either fluvastatin or ezetimibe effectively reduced LDL cholesterol 
concentration. They improve endothelial function after the treatment 
period, although differences did not reach statistical significance; however, 
these differences may warrant the utilization of these agents not only as 
lipid lowering drugs, but also to their pleiotropic effects in HIV-infected 
patients.
Footnote: white bars represent the results of the exams performed before 
treatment and filled bars after treatment.
Figure 27. Overview of the main 
results of treating HIV-infected 
patients either with fluvastatin 
or ezetimibe.
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A part from these results, chemokine-derived research has revealed that 
chemokines are key mediators in directing the deleterious influence of 
classical cardiovascular risk factors in the artery wall, and as such, focusing 
therapies beyond lowering cholesterol concentration is, theoretically, 
highly desirable. In Phase I-II clinical trials, several compounds have 
directed its action to block the interaction between MCP-1 and CCR-2 258. 
Blocking some chemokine receptors may lead to a down or up regulation 
of other receptors. A proof of this is the ability of  Tak-779 to block CCR-
5 and CxCR-3 making this agent a good candidate for the HIV treatment, 
but also, it has been demonstrated in a pro-atherogenic animal model, 
to be highly effective in reducing the development of atherosclerosis 171. 
This study deserved an editorial in Arteriosclerosis Thrombosis and Vascular 
Biology entitled “Killing two birds with one stone”, indicating that chemokine 
research focused at both conditions, HIV-infection and atherosclerosis, 
deserve further consideration 259. 
Summarizing the first two studies of this thesis, we identified a functional 
polymorphism in the promoter region of MCP-1 that, in HIV-infected 
patients, although it is associated with a better course of the HIV-infection 
(in terms of CD4 cell course and undetectable HIV-viral load) yields patients 
with the mutated allele to a higher likelihood of developing atherosclerosis 
(a five-fold increased risk). Taking both results into account, it would be 
highly desirable to design therapeutic strategies directed to MCP-1/CCR-
2 axis, in order to treat HIV-infection and atherosclerosis, as it has been 
similarly proposed in other conditions such as multiple sclerosis260, cancer261 
or graft versus host disease 262.
In the search of susceptible genes for the development of atherosclerosis, 
we studied the role of SDF-1. SDF-1 is the natural ligand of CXCR-4, a known 
HIV co-receptor, specially involved in the late stages of the HIV infection. 
The lower gene expression related to the presence of the mutated SDF1-3’A 
allele, confers protection for the development of carotid atherosclerosis in 
HIV-infected patients. The relationship between SDF-1 and cardiovascular 
events is scarce, and the case-control studies published in the literature 165 
showed no association between coronary artery disease and the presence 
of the SDF1-3’A allele. However, we found an striking association between 
the mutated allele and the lower concentrations of LDL cholesterol, that 
might be indicating an indirect effect in the appearance of carotid lesions. 
This analyses was performed taking into account the results of previous 
studies, in which the MCP-1 mutated allele was obtained. Again, a functional 
polymorphism in a cytokine-related gene has revealed as protector in the 
development of atherosclerosis in a chronically inflamed population. These 
results were further confirmed in the study of atherosclerosis progression. 
Those patients who bear the mutated alleles either SDF1-3’A or CX3CR-1 
249 I were resistant to a higher rate of IMT increase. 
Any of the polymorphisms presented in this study, met the set criteria to 
be considered as clinically relevant 263:
1. The change in the gene causes a relevant alteration in the 
function or level of the gene product.
“ it would be highly 
desirable to design 
therapeutic strategies 
directed to MCP-1/CCR-2 
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2. The number of cases associating an allele with a particular 
phenotype must be large enough to be convincing.
3. The beneficial and harmful phenotypes being studied must 
have clear-cut clinical differences.
4. The plausibility of the hypothesis must be convincing.
According to our results, the study and application of future therapeutic 
molecules targeting chemokine and chemokine receptors studied in our 
work, should be specially warranted.
We observed, as well, that CD4 cell count may play a relevant role in 
atherosclerosis progression; the higher the CD4 cell count the lower the 
atherosclerosis progression. It is plausible that patients with a better CD4 
recovery, were not under the deleterious influence of CD4 activation264,265 , 
and this may explain a lesser IMT increase. These results are in accordance 
with those presented by Hsue P. et al 46, and it should have clinical 
implications. HIV-infected patients did not receive antiretroviral therapy 
since their CD4 cell counts get down below 350 cells/mm3 266. If the 
deleterious impact of the antiretroviral therapies were minimized, we 
probably should reconsider these recommendations, and start therapy 
earlier in life with higher CD4 cell counts. However, some authors agreed 
that the progression of atherosclerosis in HIV-infected patients can be 
controlled through a reduction in cardiovascular risk factors, a reduction 
in the prescription of PIs and an increase in concomitant treatments with 
lipid-lowering agents 267. These results warrant confirmatory large-scale 
multi-centered trials, as those employed in the validity of lipid-lowering 




We have not performed a case-control study (infected and non-infected) 
by several reasons. Firstly, our aim was not to compare the incidence of 
atherosclerosis in HIV-infected patients (other research groups have 
been involved in that issue), but the influence and genetic associations 
determining the appearance of these lesions. Secondly, it is very difficult 
to obtain suitable controls to HIV-infected patients, because, they usually 
represent a highly specific population (cultural and socio-economic 
background, addicted to a great number of substances) that make the 
comparison very difficult to be standardized.  
“These results warrant 
confirmatory large-scale 
multi-centered trials, as 
those employed in the 
validity of lipid-lowering 
therapies, which should 
incorporate an assessment 
of the IMT within a 
standardized protocol
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Atherosclerosis has been considered as a  paradigm of a complex disease, 
and as such, a very intriguing interaction between environmental and 
genetic variables take place in its origin and development. This is particularly 
important when considering patients with a chronic infection caused by 
HIV, that in turn interacts with molecular pathways of the inflammatory 
lesions of the artery wall. We have approached atherosclerosis focusing 
in selected chemokines, genetic polymorphisms, clinical data and the 
information coming from the image (carotid and femoral IMT), but the next 
step should be to direct our efforts in assessing atherosclerosis with the 
information from the gene expression. We are conducting such an study 
considering not only the above mentioned genes, but also a wide range 
of metabolic and inflammatory related genes. The rationale for doing so 
is that we should be able to know the influences on the expression of key 
genes, in patients who bear a mutated allele. This strategy should lead us 
to a better comprehension of the molecular processes implicated, and 
to a better design of therapeutic targets. These results are planned to be 
analyzed in the present year.
Atherosclerosis is a highly devastating disease 269, in which hundreds of 
risk factors have been identified 270. Preventive strategies are based on 
the calculation of risk according to several scores, Framingham, Score or 
Regicor, that basically collect clinical and laboratory information. These 
preventive strategies have revealed useful in identifying patients at very 
high risk, but their role as an effective and sensitive preventive strategy is 
far to be accomplished 271. All these preventive strategies are focused on 
the individual assessment of cardiovascular risk, based on factors that are 
highly prevalent in the general population. Therefore, they provide limited 
prognostic value in an individual setting 272. Probably, this might be the 
reason why 6 over 10 patients with a myocardial infarction are considered 
to have a low/intermediate risk 273, in whom the current guidelines do not 
indicate the use of drug therapies to control risk factors 274. In this context, 
the use of the image (the measurement of carotid IMT, for example) and 
the genetic information should strengthen the assessment of individuals, 
in order to better identify those vulnerable patients, and not only those at 
risk.
The study developed by our group is the result of this approach in HIV-
infected patients. It has several limitations, and the results have to be 
validated in larger population studies, but the main conclusion is that 
in the study of atherosclerosis, the assessment of risk factors are clearly 
insufficient to accomplish with the goal of reducing atherosclerosis-
related events. A wider assessment, which should include genetic and 
image information, should guide future cardiovascular medicine, at least 
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Annex #1:
The influence of HIV infection on 
the correlation between plasma 
concentrations of monocyte 
chemoattractant protein-1 and 
carotid atherosclerosis.
Joven J, Coll B, Tous M, Ferre N, Alonso-Villaverde C, Parra S, 
Camps J.
Clin Chim Acta. 2006;368:114-9.
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The influence of HIV infection on the correlation between plasma
concentrations of monocyte chemoattractant protein-1
and carotid atherosclerosis
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Abstract
Background: Monocyte chemoattractant protein-1 (MCP-1) plays a crucial role in atherosclerosis and it has been recently proposed as a
surrogate biomarker of long-term clinical outcomes in patients with acute myocardial infarction. Little is known of the factors that may
influence plasma MCP-1 concentrations.
Methods: We studied 384 healthy volunteers and 226 HIV-infected patients as a model of chronic inflammatory condition that predisposes to
sub-clinical atherosclerosis.
Results: In healthy participants there were significant associations between plasma MCP-1 concentration and age, smoking status, and serum
triglyceride concentrations that were not observed in the HIV-infected patients. The plasma concentration of MCP-1 was significantly
associated with the polymorphism at position –2518 of the MCP-1 gene and, in patients, with the carotid artery intima–media thickness.
There were also significant correlations indicating a close association between MCP-1 and HIV disease activity. However, in a multiple
regression model, only age, the MCP-1 genotype and smoking status showed significant, and independent, associations with plasma MCP-1
concentrations.
Conclusion: Plasma MCP-1 concentration is genetically determined and associated with age and smoking habit and it also correlates with
subclinical atherosclerosis in HIV-infected patients.
D 2005 Elsevier B.V. All rights reserved.
Keywords: Cardiovascular risk factors; Human immunodeficiency virus; Infection; Inflammation
1. Introduction
Inflammation plays an important role in the development
of atherosclerosis, and may be a predictive factor for the
further progression of acute coronary syndromes [1,2].
Monocyte chemoattractant protein-1 (MCP-1) is a chemo-
kine responsible for the recruitment of monocytes to sites of
inflammation where they promote atherosclerotic lesions
and plaque vulnerability [3–5]. The data obtained from
clinical and experimental studies provide support for a role
of MCP-1 on the initiation, and progression, of atheroscle-
rosis [6,7]. It is of note that plasma MCP-1 concentration
seems to be genetically determined [8], and appears to be
influenced by certain therapeutic agents and conditions such
as myocardial infarction, hypertension, hypercholesterol-
emia and stroke [9–14].
To further explore the relationship between plasma MCP-
1 concentration and atherosclerosis, we sought associations
with cardiovascular disease risk factors in a population-based
0009-8981/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.cca.2005.12.014
Abbreviations: BMI, body mass index; CRP, C-reactive protein; PI,
protease inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors.
* Corresponding author: Tel.: +34 977 310300; fax: +34 977 312569.
E-mail address: jcamps@grupsagessa.com (J. Camps).
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www.elsevier.com/locate/clinchim
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sample of ostensibly healthy participants. We studied, as
well, a group of HIV-infected patients since they are
constantly challenged by various inflammatory stimuli which
result in an imbalance in circulating cytokines [15]. In these
patients, premature sub-clinical atherosclerosis is frequent
and influenced by a mutant MCP-1 allele [16,17]. As such,
we hypothesize that there would be significant alterations in
circulating markers of vascular inflammation such as C-
reactive protein (CRP) and, as we currently propose, MCP-1.
We also sought associations between these markers and the
carotid intima–media thickness (CIMT), a well-validated
surrogate marker for atherosclerotic vascular disease [18].
2. Materials and methods
2.1. Study population
A population-based sample of 384 subjects (187 women,
197 men; mean age 42.1 years; range 19 to 75 years) was
randomly selected from the local town hall’s population
register. The detailed characteristics have been presented
elsewhere [19]. All the participants were of Mediterranean
(Caucasian) ethnic origin, and were ostensibly healthy with
no evidence of renal insufficiency, hepatic damage, cancer,
or psychiatric disease that may alter their lifestyle habits.
Also, there was no family history of premature cardiovas-
cular disease and none had noted chest pain or claudication
on usual or recreational physical efforts. All the selected
subjects were invited to attend a clinical examination at
which their socio-demographic details were solicited and a
venous blood sample taken for analyses. Current medication
use was an exclusion criterion. From among the patients
attending our Outpatient Clinic, 226 HIV-infected subjects
(68 women, 158 men; mean age 39.7 years, range 22 to
66 years) agreed to participate in the present study. The
variables recorded at interview were age, gender, smoking
habit, time since HIV diagnosis, main risk factor for HIV-
infection, CD4 cell count at diagnosis, antiretroviral therapy
history, height, weight, and body mass index (kg/m2). No
patient had evidence of atherosclerosis-related events. The
study was approved by the Ethics Committee of the Hospital
Universitari de Sant Joan de Reus and all patients provided
full informed consent to participation.
2.2. Laboratory measurements
Blood samples were obtained during the clinical exam-
ination and collected into potassium EDTA-containing tubes
for MCP-1 and lipoprotein(a) [Lp(a)] determinations, or into
tubes with no anticoagulants added for the other biochem-
ical analyses. Assays for plasma MCP-1 were performed by
ELISA (Peprotech, London, UK) according to the instruc-
tions of the manufacturer. Recombinant human MCP-1
antigen was used as the calibrator for assay standardization.
We used plasma EDTA because we had previously observed
an inconsistent increase of between 40% and 80% in
concentrations in serum, relative to those in plasma. The
measurable range was between 10 and 1000 ng/L. Coef-
ficients of variation at 60 and 120 ng/L were <2% and 4.1%,
respectively (intra-assay); and <4% and 8.2%, respectively
(inter-assay). Plasma Lp(a) was measured as previously
described [20]. The serum concentration of C-reactive
protein was measured using a high sensitivity method with
a lower limit of detection of 0.10 mg/L [21]. HDL-
cholesterol concentration was analyzed using a homoge-
neous method [22]. Serum cholesterol and triglycerides
were determined by enzymatic techniques (ITC Diagnostics,
Barcelona, Spain). Serum viral load was measured with the
Amplicor HIV-1 monitor assay (Roche, Basel, Switzerland)
and CD4+ T-cell counts by standard FACscan flow
cytometry (Becton-Dickinson, Madrid, Spain).
2.3. Genotyping
Reactions were carried out in a 10 AL total volume
containing 10 ng of genomic DNA, 0.25 U of Taq DNA
polymerase and its buffer (1�), MgCl2 1.5 mM, DNTP mix
0.2 mM, and 0.2 AM each of sense and antisense primers.
The primers used were: 5V-TCT CTC ACG CCA GCA CTG
ACC-3V and 5V-GAG TGT TCA CATAGG CTT CTG-3V for
MCP-1 A�2518G and 5V-TTG TGG GCA ACATGATGG-
3V and 5V-GAG CCC ACA ATG GGA GAG TA-3V for CCR-
2 V64I. To type the MCP-1 allele, the amplicon (234 bp)
was digested with 1 U of PvuII. This results in fragments of
159 and 75 bp when a G is present at nucleotide position-
2518. For the CCR-2 allele, the amplicon (128 bp) was
digested with BsaBI which produces fragments of 110 and
18 bp when A is present at nucleotide position 160.
2.4. Ultrasonography
Ultrasonography was performed with a GE Logiq
700MR system (Milwaukee, USA) equipped with a 7–
9 MHz linear array transducer, in high-resolution B-mode.
The specialist physician performing this procedure was
blinded with respect to specific clinical information of the
patients. The evaluation included bilateral measurements of
the common carotid artery, the carotid bifurcation and the
proximal portion of the internal carotid artery as described
previously [17].
2.5. Statistical analyses
The Kolmogorov–Smirnov test was used to check for
normality of distributions. Because the distribution of
plasma MCP-1 concentration is highly skewed, the analyses
were conducted on the concentration quartiles. The log
transformation of these values did not completely normalize
the distribution and we preferred to use non-parametric
tests. The probability values (P values) for trends were
obtained by linear regression. To test the association of
J. Joven et al. / Clinica Chimica Acta xx (2005) xxx–xxx2
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MCP-1 with other variables we used the Spearman
correlation test. To evaluate differences between MCP-1
quartiles with respect to the variables studied, ANOVA was
used, or the Kruskal–Wallis method followed by the
Mann–Whitney U-test corrected for multiple comparisons,
when appropriate. To preclude undue outlier value influence
in the regression analyses, we excluded values of MCP-1
>200 ng/L. Multiple linear regression models were used to
verify associations between MCP-1 and the other variables.
The stepwise backward procedure includes only the most
influential of the variables. All statistical procedures were
performed with the SPSS 11.0 statistical package.
3. Results
3.1. Distribution of plasma MCP-1 concentrations
There were no statistically significant differences in
plasma MCP-1 concentrations between males and females,
nor in the healthy volunteers [median (inter-quartile range)
49.0 (25.7) ng/L and 48.3 (24.6) ng/L, respectively;
P=0.55] neither in the HIV-infected patients [median
(inter-quartile range) 61.2 (38.5) ng/L and 56.4 (30.2) ng/L,
respectively; P=0.10]. Consequently, in all subsequent
analyses data are presented without considering sex. The
median MCP-1 concentration was 49.3 ng/L (inter-quartile
range 28.3 ng/L) for healthy participants and 59.7 (inter-
quartile range, 37.4) ng/L for HIV-infected patients. The
values for the 2.5th, 25th, 50th, 75th and 97.5th percentiles
were 31.0, 39.6, 49.3, 67.7 and 136 ng/L, respectively, for
healthy participants and 32.1, 44.7, 59.7, 82.1 and 195.7 ng/
L, respectively, for the patients. The distributions are shown
in Fig. 1. Plasma MCP-1 concentration was significantly
higher in HIV-infected patients than in healthy participants
(P <0.001)). The same trend was observed in the values of
serum hs-CRP (4.1T5.6 vs. 2.6T4.2 mg/L; P <0.001)
indicating the presence of chronic inflammatory stimuli.
However, the correlation between MCP-1 and hs-CRP
values was not statistically significant (n =610; q =�0.02;
P=0.85).
3.2. Relationship between CIMT and risk factors for
atherosclerosis
In HIV-infected patients, univariate analysis showed that
the average CIMT values correlated with age (r =0.360;
P <0.001) and plasma MCP-1 concentration (q =0.214;
P=0.002), but not with other parameters. Interestingly, there
was no significant correlation with hs-CRP values
(r =0.012, P=0.89), indicating that the association with
MCP-1 was specific and not a consequence of a global
inflammatory response.
3.3. Associations between plasma MCP-1 concentrations
and other variables
The associations are summarized in Tables 1 and 2. In
healthy participants, plasma MCP-1 concentration was
positively associated with age, smoking status and plasma
triglycerides, and negatively associated with serum HDL-
cholesterol. The non-smokers (n=257) showed significantly
lower plasma MCP-1 concentrations than those measured in
smokers [median (inter-quartile range) 46.2 (25.7) ng/L and
56.4 (39.7) ng/L, respectively; P=0.006]. In contrast, there
were no significant associations with gender, BMI and the
concentrations of serum cholesterol, serum CRP and plasma
Lp(a). In HIV-infected patients, no significant associations
between these variables were observed. The data were




































Fig. 1. Distribution of plasma MCP-1 concentrations in healthy volunteers (white bars) and HIV-infected patients (black bars).
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activity i.e. the number of CD4+ lymphocytes and serum
HIV-RNA. These variables were related to plasma MCP-1
concentrations; the lower the MCP-1 levels the lower the
HIV RNA, and the higher the CD4+ cells (Table 2). Also, in
HIV-infected patients, there was a positive and significant
correlation between plasma MCP-1 concentration and the
serum HIV RNA (q =0.380; P <0.001).
3.4. The influence of CCR-2 and MCP-1 polymorphisms
The genotype frequencies were similar to those reported
for other Caucasian populations, and there were no signif-
icant differences between the control and patient groups in
our study (Table 3). The inheritance of the G allele
predisposes to higher MCP-1 concentrations in both groups,
but this was only significant in the healthy participants. In
patients with serum HIV RNA <200 copies/mL, the
absence of the G allele was significantly more frequent
than its presence (61.3% vs. 38.7%, respectively; P <0.05).
We found no differences in the other variables measured
with respect to carriers and non-carriers of the G allele.
The presence of the CCR-2 mutation (64I) did not appear
to affect the concentrations of plasma MCP-1. None of
these genetic variants influenced significantly the CIMT
values.
3.5. Stepwise backward multivariate linear regression
analyses
Variables shown to be significant in the univariate
analyses were retained in the multivariate analysis both in
the healthy participants and in HIV-infected patients. An
additional model which included the whole population study
(n =610) indicated that the significant predictors were age,
Table 2
Baseline characteristics of HIV-infected patients segregated by quartile distributions of MCP-1
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Trend; P
Range, ng/L 28.1–44.4 44.8–59.7 59.8–81.9 82.4–344 –
Age, years 38.8 (8.8) 37.7 (6.7) 39.1 (6.1) 39.2 (5.6) 0.517
Males, % 70 60 72 79 0.175
Body mass index, kg/m2 19.6 (2.7) 18.9 (2.5) 19.7 (3.1) 19.7 (2.8) 0.448
Current smoker, % 85.7 80.7 82.5 87.5 0.774
Biochemical and other clinical variables
Cholesterol, mmol/L 4.91 (1.23) 4.89 (1.30) 5.29 (1.49) 4.57 (1.33) 0.488
Triglycerides, mmol/L 2.07 (1.75) 2.44 (2.74) 3.64 (4.86) 2.09 (1.98) 0.477
HDL-cholesterol, mmol/L 1.24 (0.46) 1.18 (0.41) 1.09 (0.41) 1.14 (0.43) 0.148
C-reactive protein, mg/L 3.21 (4.51) 5.96 (8.23) 3.12 (3.23) 3.94 (4.85) 0.840
Log HIV RNA 2.5 (0.9) 3.1 (1.2) 2.7 (1.1) 3.1 (1.3) <0.05
CD4+ lymphocytes, cells/mL 533 (338) 393 (240) 477 (339) 369 (272) <0.05
PI treated, % 26.8 33.3 47.4 32.1 0.123
NNRTI treated, % 48.2 35.1 26.3 25.0 <0.05
Untreated, % 25.0 31.6 26.3 42.9 0.598
Values are presented as means (SD).
Table 1
Baseline characteristics of healthy participants segregated on quartile distributions of MCP-1
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Trend; P
Range, ng/L 26.9–39.6 39.7–49.3 49.3–67.7 68.1–425.7 –
Age, years 38.4 (14.8) 43.3 (15.6) 43.6 (15.0) 44.1 (14.9) 0.043
Males, % 55 52 49 53 0.553
Body mass index, kg/m2 26.3 (4.9) 27.0 (5.2) 26.9 (5.0) 27.1 (4.9) 0.314
Alcohol intake, g/day 9.5 (16.2) 9.3 (15.6) 9.2 (16.3) 12.3 (22.6) 0.310
Smoking status
Current smoker, % 27.1 25.0 37.5 42.7 0.009
Cigarettes per day 4.5 (9.7) 3.6 (7.8) 5.4 (8.3) 8.7 (12.5) 0.002
Duration, years 8.1 (10.1) 8.7 (13.2) 11.3 (13.4) 10.2 (11.5) 0.104
Biochemical variables
Cholesterol, mmol/L 5.13 (0.86) 5.39 (1.01) 5.21 (1.09) 5.35 (1.11) 0.319
Triglycerides, mmol/L 1.11 (0.63) 1.26 (0.74) 1.32 (0.79) 1.64 (1.48) <0.0001
HDL-cholesterol, mmol/L 1.57 (0.34) 1.56 (0.36) 1.52 (0.39) 1.45 (0.40) 0.018
Lipoprotein(a), mg/L 238 (253) 240 (305) 201 (268) 247 (299) 0.939
C-reactive protein, mg/L 2.23 (3.12) 3.07 (4.95) 2.96 (5.56) 2.37(2.51) 0.875
Values are presented as means (SD).
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smoking habit, and the presence of the �2518 G mutation.
Interestingly, the association with serum triglycerides did
not reach statistical significance.
4. Discussion
We have studied the association of plasma MCP-1 values
with other relevant variables in a healthy population, and
compared to a group of HIV-infected patients. PlasmaMCP-1
concentration is regulated by genetic factors [8] and different
inflammatory and/or oxidative conditions [10–14,23]. Par-
ticularly, the presence of the G allele in the functional A-
2518G MCP-1 promoter polymorphism influences the
expression of MCP-1 and it has been shown to be associated
with inflammatory diseases [24–26] andwith coronary artery
disease [27]. We observed that plasma MCP-1 concentration
is higher in HIV-infected subjects and the increase in
circulating levels of MCP-1 in healthy participants is related
to aging, smoking and serum lipid alterations, which are
major cardiovascular disease risk factors. This may represent
further evidence that the plasma MCP-1 concentration could
be considered a candidate marker for atherosclerosis [23,28].
The associations found, however, are lost in the group of
HIV-infected subjects indicating the influence of inflamma-
tion and/or a cytokine imbalance.
Unexpectedly [29–31], however, we did not find any
relationship between circulating levels of C-reactive protein
and MCP-1 concentrations in the group of HIV-infected
patients or in the group of non-infected participants. This
lack of correlation should be considered within the overall
assessment of cardiovascular risk, and warrants further
investigation. More important is the finding that in our
patients CIMT values are correlated with plasma MCP-1
concentrations but not with CRP levels confirming data
obtained in healthy Japanese population [23] and in non-
diabetic patients under chronic haemodialysis [32].
We also found that the MCP-1 A-2518 G polymorphism
is a genotypic, heritable, predictor of plasma MCP-1
concentration that may help explain inter-individual and
inter-population differences in MCP-1 dependent immune
responses. It is also of note that the presence of the CCR-2
mutation (64I) has no effect on circulating plasma MCP-1
concentrations and of other biochemical variables in our
study population. The presence of the MCP-1 mutation is
frequent in our population (>40%), indicating that a higher
MCP-1 expression represents a possible evolutionary
advantage likely to be related to the inflammatory response
[33]. However, there is growing evidence that the overpro-
duction of pro-inflammatory cytokines, and MCP-1 in
particular, could be an adverse factor in the clinical
evolution of some diseases [10–14,24–27] as well as a
predisposition to AIDS-related complications [34,35]. This
is further reinforced by our finding in HIV-infected patients
of a direct relationship between the plasma MCP-1
concentration and the serum viral load, and the
corresponding inverse association with CD4+ T-cells.
Therefore, we conclude that increased plasma MCP-1
concentration may exert detrimental effects in the clinical
progression of the disease and its complications. The
relationship of MCP-1 with clinical atherosclerosis [36]
and the correlation we found between cardiovascular risk
factors and plasma MCP-1 concentrations suggest that this
variable may represent a useful marker in the evaluation of
inflammatory diseases.
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Abstract
Individuals with HIV-1 infection are at increased risk for cardiovascular events, and lipodystrophy is generally associated with pro-
atherogenic metabolic disturbances. We conducted a case–control study to assess the presence of sub-clinical atherosclerosis in HIV-1-
infected patients with or without lipodystrophy (LD) and to evaluate the influence of monocyte chemoattractant protein-1 (MCP-1) on
the development of both carotid atherosclerosis and LD. The study population consisted of 43 patients with LD and 86 patients without
LD. We determined carotid intima-media thickness (IMT), MCP-1 concentrations in plasma, and MCP-1 genotype (presence or absence
of the �2518G allele). HIV-1-infected patients with LD showed increased risk (OR = 3.71, 95% CI = 1.10–12.47, p = 0.03) for sub-clin-
ical atherosclerosis, and MCP-1 plasma concentration was significantly correlated with IMT in these patients (Pearson = 0.31, p = 0.03).
Furthermore, presence of LD was a determinant for MCP-1 plasma concentration (b = 0.18, p = 0.05). In summary, HIV-1-infected
patients with clinically manifest LD are at higher risk for atherosclerosis and our observations support the relationship between inflam-
mation and atherosclerotic disease.
� 2006 Elsevier Ltd. All rights reserved.
Keywords: MCP-1; Sub-clinical atherosclerosis; Lipodystrophy; HIV; Inflammation
1. Introduction
Highly active antiretroviral therapy of HIV rapidly
decreases morbidity and mortality in HIV-1-infected
patients [1]. However, due to the long-term survival, other
deleterious effects due to treatment and the chronic inflam-
matory state emerge. In particular, the effects of lipodystro-
phy and the increased cardiovascular disease risk are of
great clinical impact [2]. In an earlier report we considered
the risk of atherosclerosis in HIV-1-infected patients from
the perspective of inflammatory disease, by examining the
role of the pro-inflammatory b chemokine monocyte che-
moattractant protein 1 (MCP-1) [3] in sub-clinical athero-
sclerosis, assessed by carotid intima-media thickness
(IMT), a validated surrogate marker of atherosclerosis
[4]. MCP-1 is mainly produced by monocytes, endothelial
cells, and adipose tissue, and has been shown to activate
and recruit monocytes/macrophages in the arterial wall
[5]. Changes in adipose tissue have been correlated with
changes in MCP-1 gene expression [6], and MCP-1 release
is higher in visceral than subcutaneous human adipose
tissue [7].
We hypothesized that the changes in distribution of
fat tissue observed in patients with LD may influence plas-
ma MCP-1 concentrations, which in turn may exert a
1043-4666/$ - see front matter � 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.cyto.2006.03.013
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detrimental effect in the development of atherosclerosis.
We also investigated whether HIV-1-infected patients with
LD present higher rates of sub-clinical atherosclerosis than
do those without LD.
2. Materials and methods
We designed a case–control study to examine sub-clini-
cal atherosclerosis in HIV-1-infected individuals with or
without LD. This study is a part of a longitudinal follow-
up design in which the investigators collate clinical and lab-
oratory data besides the analyses of surrogate markers of
atherosclerosis in HIV-infected patients. LD was defined
as the presence of body-fat changes that could be clearly
recognised by the patient and confirmed by the doctor.
Body-fat changes included subcutaneous lipoatrophy (hol-
low cheeks, prominent superficial veins in the limbs or flat-
tening of the buttocks) and central obesity (increased
abdominal girth, breast enlargement or dorsocervical fat
pad) [8].
The study population [3] consisted of 305 HIV-1-infect-
ed patients aged 18 years or older who regularly attend our
Hospital. They were eligible to participate if they had no
AIDS-related opportunistic diseases at study entry. We
identified a total of 43 patients with LD who met the case
criteria, and we then selected 2 controls for each case
among the HIV-1-infected patients without LD who were
matched for age (±5 years), sex and length of clinic fol-
low-up from the initial visit. All participants gave informed
consent and the Ethics Committee of Hospital Universitari
de Sant Joan approved the study.
The clinical data collected were time from seropreva-
lence, history of antiretroviral therapy, CD4 cell counts,
and HIV-1 viral load. High blood pressure was defined as
systolic blood pressure >140 or diastolic >90 mmHg.
A diagnosis of dyslipaemia was made when one of the fol-
lowing conditions was met: (i) total cholesterol >5.3 mmol/
L; (ii) HDL cholesterol <0.9 mmol/L; or (iii) LDL choles-
terol >3.3 mmol/L. Hyperglycaemia was defined as fasting
glucose >6.1 mmol/L. Metabolic syndrome was defined
according to the ATPIII report [9]. Patients were geno-
typed for MCP-1-2518G polymorphism, and plasma
MCP-1 concentrations were determined as previously
described [3]. All study participants underwent an ultraso-
nography examination of the carotid arteries. The IMT
was measured in the common carotid artery 1 centimetre
proximally to the carotid bulb. IMT values over 0.8 mm
were considered to represent an early sign of atherosclero-
sis [10].
Results are expressed as mean ±SEM. Differences
between categorical variables were analysed with the v2 test
and continuous variables with the t-test. Bivariate correla-
tions were tested using Pearson coefficient and interaction
tests using the univariate general linear model were per-
formed. When appropriate we analysed data using non-
parametric tests. For analyses of the MCP-1 genotype,
patients homozygous for the �2518G allele were grouped
with patients heterozygous for the �2518G allele. A logis-
tic regression analysis was performed to determine which
variables were associated with IMT values. Multiple linear
regression analysis was performed to evaluate the influence
of several variables on the plasma concentration of MCP-1.
The significance level was set at a p-value < 0.05.
3. Results
Selected characteristics of the 129 study participants are
depicted in Table 1. LD patients, representing 14.1% of the
infected patients, had a higher prevalence of dyslipaemia,
abnormal fasting glucose and metabolic syndrome than
Table 1
Characteristics of participants according to the presence or absence of lipodystrophy (LD)a
LD–HIV (N = 43) Non-LD–HIV (N = 86) p value
Age, years 42.48 (1.09) 40.59 (0.75) 0.15
Sex, male 26 (60.5) 54 (62.8) 0.79
Current smoker 31 (72.1) 71 (82.6) 0.17
Body mass index, kg/m2 23.43 (0.46) 22.65 (0.33) 0.17
High blood pressure 7 (17.5) 9 (11.1) 0.33
Waist-to-hip ratio 0.94 (0.01) 0.89 (0.01) 0.05
Dyslipaemia 37 (86.0) 56 (65.1) 0.009
Abnormal fasting glucose 10 (23.3) 9 (10.5) 0.06
Metabolic syndrome 7 (16.3) 5 (5.8) 0.06
Time on Estavudine, months 25.56 (2.31) 11.57 (1.83) <0.001
Time on PIs, months 34.76 (3.98) 25.83 (2.81) 0.07
Time since diagnoses, years 7.56 (0.59) 7.22 (0.48) 0.67
CRP, mg/L 4.19 (0.65) 4.63 (0.82) 0.72
MCP-1, pg/mL 75.47 (7.21) 62.10 (3.03) 0.04
MCP-1-2518G 14 (32.6) 32 (37.2) 0.26
Carotid IMT, mm 0.88 (0.04) 0.76 (0.02) 0.007
Atherosclerotic lesion 36 (83.7) 48 (55.8) 0.01
a Results are expressed as mean (SEM) or in percentages. PIs indicate protease inhibitors. CRP refers to C-reactive protein and MCP-1 to monocyte
chemoattractant protein-1. IMT is intima-media thickness and atherosclerotic lesion refers to a carotid IMT >0.8 mm or the presence of an atherosclerotic
plaque [10].
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control patients (Table 1). Patients with LD had been treat-
ed for a significantly (p < 0.001) longer period of time with
stavudine than had patients without LD (25.56 ± 2.31
months vs. 11.57 ± 1.83 months, respectively). The two
groups showed no significant differences in treatment histo-
ry with respect to any other antiretroviral agents used.
Although the differences between the two groups in
mean CRP values did not reach statistical significance,
plasma MCP-1 concentrations were significantly higher in
HIV-1-infected patients with LD compared to those with-
out LD (75.47 ± 7.21 pg/mL vs. 62.10 ± 3.03 pg/mL,
respectively; p = 0.04). Moreover, carotid IMT was signif-
icantly higher in patients with LD than in those without
LD (0.88 ± 0.04 mm vs. 0.76 ± 0.02 mm, respectively;
p = 0.007) and those LD + HIV-infected patients present-
ed higher rates of carotid atherosclerotic lesions (Table
1). When patients were segregated according to the diagno-
sis of lipodystrophy and carotid atherosclerotic lesion, we
observed four groups of patients in which the distribution
of plasma MCP-1 concentration was significantly different
(Kruskal–Wallis test, p = 0.04). LD + patients with carotid
atherosclerotic lesions had the highest MCP-1 plasma con-
centration (Fig. 1).The carotid IMT was positively and sig-
nificantly (p = 0.04) correlated with MCP-1 concentration
in plasma in those patients with LD (Fig. 2A), and the
results of the interaction test revealed that the presence of
lipodystrophy and the plasma concentration of MCP-1
may exert a significant influence in the variability of the
carotid IMT (F coefficient = 4.53, p = 0.03). We did not
find the same trend in patients without LD (Fig. 2B). Since
MCP-1 and carotid IMT were correlated in HIV-1-infected
patients with LD, we next applied a multivariate model to
assess the role of variables known to influence MCP-1
expression, such as age, weight, MCP-1 genotype, duration
of treatment with PIs, HIV-1 viral load plus the presence or
absence of LD (Table 2a). The presence of LD was the only
variable significantly associated with MCP-1 concentration
in plasma, with a b coefficient of 0.18 (p = 0.05).
Using a multivariate model, we next analysed those vari-
ables related to the development of carotid atherosclerosis,
including age, sex, body mass index, and metabolic syn-
drome, as well as presence or absence of LD, time on pro-
tease inhibitors (PIs), MCP-1 genotype and MCP-1
concentration in plasma (Table 2b). In confirmation of pre-
vious results in a general population of HIV-1-infected
patients [3], MCP-1-2518 genotype [OR = 5.29; 95% CI
(1.67–16.76), p = 0.005] was associated with carotid athero-
sclerosis. Notably, presence of LD was also significantly
associated with the development of carotid atherosclerosis
[OR = 3.71, 95% CI (1.10–12.47), p = 0.03].
4. Discussion
The higher rates of sub-clinical atherosclerosis seen in
HIV-1-infected individuals, although controversial, are
usually attributed to classic cardiovascular risk factors
and to side effects of antiretroviral therapies [11–13]. How-
ever, the chronic infection status suffered by these individ-
uals might also lead to a higher risk for atherosclerosis by
triggering the inflammatory response. As a disease that
causes an aberration in several metabolic pathways, such
as lipid and glucose metabolism, LD might also increase
cardiovascular risk in individuals with HIV-1 infection.
Taken together, these factors suggest that HIV-1-infected
patients with LD might be at an even higher risk of
atherosclerosis.
Our results indicate that the presence of LD increases by
3-fold the risk of sub-clinical carotid atherosclerosis in
patients with HIV-1 infection. Mercie et al. [14] showed a
significant association between carotid IMT and LD in a
univariate analysis of 161 HIV-1-infected patients with
LD, but the effect disappeared in the multivariate model.
A likely explanation for the discordance between our
results and those obtained by Mercie et al. is that the latter
group evaluated a healthier population since the mean
carotid IMT was 0.54 mm (range 0.50–0.60 mm), while in
our patients the mean carotid IMT was 0.80 mm (range
0.40–1.80 mm).
MCP-1 has been shown to influence the development of
atherosclerosis both in individuals with HIV infection [3]
and in those without [15]. Several inflammatory states,
as well as MCP-1 genotype, may increase MCP-1 gene
expression [16], which in turn leads to higher MCP-1-de-
NO LIPODYSTROPHY LIPODYSTROPHY
*
Fig. 1. Distribution of plasma concentration of MCP-1 (mean ± SEM)
according to the presence or absence of LD ± carotid atherosclerotic
lesion. *Overall p value using the Kruskal–Wallis test = 0.04.
N Mean SEM
LD�, No lesion 38 61.61 3.97
LD�, Lesion 48 62.49 4.47
LD+, Lesion 36 80.90 8.29
LD+, No lesion 7 47.53 3.80
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rived inflammatory responses. Notably, adipose tissue is
one source of MCP-1 production. Obese subjects have
higher plasma MCP-1 levels before weight reduction [6],
and MCP-1 release is higher, in vitro, in visceral human
adipose tissue than in subcutaneous human adipose tissue
[7]. These observations suggest that a similar scenario
might occur in the LD syndrome. In our study, multivari-
ate analysis showed that, although statistically weak, LD
may be a determinant of MCP-1 in plasma, and IMT val-
ues were positively correlated with MCP-1 in LD patients.
Due to the fat redistribution syndrome, adipose tissue in
HIV-1-infected patients with LD might be overproducing
MCP-1, and higher levels of MCP-1 may in turn have a
detrimental effect on the development of atherosclerosis
in these patients. This association should be further
explored in larger studies in order to ascertain the detri-
mental effects of lipodystrophy on MCP-1 concentration
and in turn in the development of atherosclerosis. This is
especially warranted because we found a minimum number
of patients who fulfilled the criteria of LD without athero-
sclerotic lesions (N = 7), and this fact may be a bias in
interpreting the conclusions.
One of the limitations of the study is that we diagnosed
LD using clinical criteria without objective measurements
of fat redistribution, but such measurements are not stan-
dardized. However, those patients assigned to the LD
group based on the clinical criteria are severely affected
Fig. 2. Correlation plots between carotid IMT and MCP-1 plasma concentration in LD–HIV-1-infected patients (A, solid circles) and non-LD–HIV-
1-infected patients (B, open circles). Mean and 95% CI values are depicted. *MCP-1 plasma concentration and carotid IMT values have been
log-transformed for statistical purposes Pearson coefficient 0.31, p = 0.03.
Table 2a
Multivariate analyses of the determinants of MCP-1 (2a) and the presence
of carotid atherosclerosis (2b). Determinants of MCP-1 plasma concen-
tration using a linear regression analyses
B Coefficient p value
Age, years 0.03 0.72
Body mass index, kg/m2 0.14 0.12
Saquinavir, months 0.01 0.91
Indinavir, months 0.05 0.60
Nelfinavir, months �0.05 0.54
Ritonavir, months �0.03 0.69
Efavirenz, months �0.03 0.73
HIV-1-viral load 0.08 0.39
Lipodystrophy, yes 0.18 0.05
MCP-1-2518G, yes �0.08 0.38
Dependent variable: plasma concentration of MCP-1, pg/mL. The criteria
defining lipodystrophy are further detailed in the text.
Table 2b
Multivariate analyses of the determinants of MCP-1 (2a) and the presence
of carotid atherosclerosis (2b). Determinants of sub-clinical carotid
atherosclerosis using logistic regression analyses
Odds ratio Confidence interval p value
Age, years 1.21 1.06–1.37 0.03
Sex, male 2.11 0.80–5.56 0.12
Body mass index, kg/m2 0.88 0.76–1.03 0.13
High blood pressure, yes 7.07 0.73–68.14 0.09
Dyslipaemia, yes 1.62 0.41–6.30 0.48
Fasting glucose, mmol/L 1.06 0.52–2.15 0.85
Time on PI, months 0.99 0.97–1.01 0.32
Lipodystrophy, yes 3.71 1.10–12.47 0.03
MCP-1, pg/mL 1.01 0.99–1.03 0.06
MCP-1-2518G, yes 5.29 1.67–16.76 0.005
We used carotid atherosclerosis as a dependent variable, that is a com-
posite variable of the presence of an atherosclerotic plaque or a carotid
IMT >0.8 mm [10]. High blood pressure was defined as systolic pressure
>140 mmHg or diastolic pressure >85 mmHg. Dyslipaemia was defined as
total cholesterol >5.3 mmol/L, HDL cholesterol <0.9 mmol/L, or LDL
cholesterol >3.3 mmol/L (further details in text).
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by the fat redistribution syndrome, and therefore easily
identifiable, and further LD + HIV-infected patients pre-
sented with higher rates of dyslipaemia and a significantly
higher waist-to-hip ratio than non-lipodystrophic patients,
indicating that they probably are influenced by the meta-
bolic abnormalities usually diagnosed in these patients [17].
Another limitation is that the over expression of MCP-1
might be associated with down-regulation of its receptor
CCR-2. We did not analyze CCR-2 expression in circulat-
ing monocytes, however, CCR-2 is a known HIV-co-recep-
tor [18], and its expression might also be altered according
to HIV status (R5 vs. X4). Moreover, an alternative recep-
tor for MCP-1 has been identified in smooth muscle cells
[19], indicating a non-unique receptor for MCP-1, and
another pathway to exert its pro-inflammatory influence.
In order to reduce the inflammatory stimulus, we should
investigate the effects of switching antiretroviral therapies
or offering statins to HIV-infected patients with LD and
sub-clinical atherosclerosis.Statins are known to have ben-
eficial effects on the arterial wall [20] and in the expression
of the MCP-1/CCR-2 axis [21].
In summary, the study of the inflammatory status and
the arterial wall thickness in LD–HIV-infected patients
supports the relationship between inflammation and ath-
erosclerosis development.
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Abstract
Highly active antiretroviral therapy in Human Immunodef iciency Virus (HIV) has been associated with lipodystrophy, insulin resistance and
atherosclerosis. We investigated the effects of rosiglitazone or metformin on fasting and postprandial inflammatory and antioxidant variables in
HIV-infected males with lipodystrophy.
Thirty-one patients were randomly assigned to receive either rosiglitazone (4 mg twice daily) or metformin (1 g twice daily) for 26 weeks. At
baseline and after treatment, standardized 10-h oral fat loading tests were performed. Before treatment, inf lammatory variables remained unchanged
but there was a postprandial decrease in high density lipoprotein (HDL)-cholesterol and paraoxonase (PON1) activity. Rosiglitazone and metformin
reduced homeostasis model assessment index (HOMA) similarly (−34% and −37%, respectively, P<0.05 for each). Both treatments increased
fasting and postprandial PON1 activity and decreased postprandial monocyte chemoattractant protein 1 (MCP-1) concentrations. However, plasma
C-reactive protein (CRP) and Interleukin-6 (IL-6) concentration did not change throughout the study.
To decrease insulin resistance results in a higher anti-oxidant and consequent lower pro-inf lammatory action of HDL. This may confer
protection against accelerated atherosclerosis in these patients.
© 2006 Elsevier B.V. All rights reserved.
Index words: HIV; Paraoxonase; Monocyte chemoattractant protein-1; Postprandial; Metformin; Rosiglitazone
1. Introduction
The use of highly active antiretroviral therapy (HAART) in
Human Immunodeficiency Virus (HIV) has greatly reduced mor-
bidity andmortality due to acquired immunodeficiency syndrome
(AIDS) (Palella et al., 1998), but it is strongly associated with
changes in fat distribution (lipodystrophy), dyslipidemia and
insulin resistance, which increase the risk of atherosclerosis (Carr
et al., 1998; Balasubramanyam et al., 2004; Hadigan et al., 2001;
Friis-Moller et al., 2003). Atherosclerosis is generally accepted to
be a low-grade inflammatory disease, initiated by the oxidation of
lipoproteins in the subendothelial space, which induces chemo-
taxis and adhesion and transmigration of circulating monocytes
into the arterial wall (Ross, 1999). Inflammation is mediated by
cytokines. Particularly, the recruitment of monocytes to the sub-
endothelial space is stimulated by monocyte chemoattractant
protein 1 (MCP-1) (Gu et al., 1997). Other biomarkers of inflam-
mation, C-reactive protein (CRP), has shown to be a direct toxic
of endothelial cells (Libby and Ridker, 2004), and Interleukin-6
(IL-6) has been demonstrated to be higher in HIV-infected
European Journal of Pharmacology xx (2006) xxx–xxx
+ MODEL
EJP-63631; No of Pages 7
www.elsevier.com/locate/ejphar
⁎ Corresponding author. Centre de Recerca Biomèdica, Hospital Universitari
Sant Joan, 43200 Reus, Tarragona, Spain. Tel.: +34 977310300; fax: +34
977312569.
E-mail address: jjoven@grupsagessa.com (J. Joven).
1 Both authors contributed equally.






s in atherosclerosis and HIV-infection
UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
patients (Dolan et al., 2005), that represent predictors of cardio-
vascular events.
The enzyme paraoxonase 1 (PON1), located on High Density
Lipoprotein (HDL), has potent antioxidant properties by hydro-
lyzing oxidized lipids formed on LowDensity Lipoprotein (LDL)
andHDL (Mackness et al., 1993).As such, it inhibits the oxidation
of lipoproteins in the subendothelial space that, otherwise, could
lead to the formation of foam cells. Supporting this concept, serum
PON1 activity is low in patients with insulin resistance and ath-
erosclerosis (Durrington et al., 2001; Mackness et al., 2000) and
mice lacking serum PON1 activity are more susceptible to athero-
sclerosis (Shih et al., 1998). Furthermore, it has been demonstrated
in vitro that PON1 attenuates the endothelial production ofMCP-1
mediated by oxidized-LDL (Mackness et al., 2004). Therefore,
PON1 has anti-inflammatory and anti-atherogenic properties and
it is related to the action of MCP-1.
Since humans are non-fasting most part of the day, this period
may be of particular importance in the pathogenesis of athero-
sclerosis. It is known that HIV-infected patients have delayed
clearance of postprandial triglyceride-rich lipoproteins compared
with healthy controls (Stein et al., 2005) and increased
postprandial lipemia has been linked to accelerated atherosclero-
sis (Groot et al., 1991; Weintraub et al., 1996). The underlying
mechanisms may involve increased generation of oxidative stress
leading to endothelial dysfunction (van Oostrom et al., 2003;
Ceriello et al., 2004). Metformin and rosiglitazone are used in
clinical medicine to improve insulin resistance and glycemic
control in patients with type 2 diabetes (Yki-Jarvinen, 2004;
Hundal and Inzucchi, 2003). However, these agents may also
have a role in treating patients with nondiabetic insulin-resistant
conditions, such as HIV-lipodystrophy (Hadigan et al., 2000,
2002, 2004; Saint-Marc and Touraine, 1999; Carr et al., 2004;
Sutinen et al., 2003). Presumptively, the treatment of the
metabolic and inflammatory derangements may exert a protec-
tive effect from atherosclerosis in HIV-infected patients. We have
studied the effects of a high-fat meal on inflammatory (MCP-1,
CRP and IL-6) and antioxidant (PON1 activity and HDL-
cholesterol) variables in HAART-treated HIV-infected patients
with lipodystrophy, and investigated the effects of the insulin-
sensitizing agents rosiglitazone and metformin on these variables.
2. Materials and methods
2.1. Study population
We included thirty-one males aged between 30 and 65 with a
documented HIV infection and HIV-RNA values<10,000
copies/ml, who were on HAART for at least 18 months with
no changes in the treatment regimen during the 6 months prior
to inclusion. We did not consider those with HIV-related symp-
toms (opportunistic infectious disease, malignancies or unex-
plained weight loss), renal, thyroid and/or liver diseases, diabetes
mellitus and an alcohol intake >3 U a day. The presence of HIV-
lipodystrophy was defined as signs and symptoms of loss of
subcutaneous fat (face, arms, legs and buttocks) with or without
increased abdominal girth or development of a buffalo hump. The
research project was primarily designed to study the effects of
treatment on lipodystrophy course as well as endothelial function
studies, the results of which have been already published (van
Wijk et al., 2005).
2.2. Study design
At inclusion, a fasting blood sample was obtained and height,
weight, blood pressure and waist and hip circumference were
measured. A complete medical recordwas obtained and a thorough
physical examination was performed. Participants underwent a
standardized 10-h oral fat loading test, andwere randomly assigned
to receive either rosiglitazone (4 mg twice daily) or metformin
(1000 mg twice daily) for 26 weeks. Patients visited the hospital
after 2 and 4 months of treatment for safety evaluation. At the end
of the period the second oral fat loading test was performed. The
study protocol was approved by the local research ethics commit-
tees of the University Medical Center (Utrecht, the Netherlands)
and the Hospital Universitari de Sant Joan (Reus, Spain).
2.3. Oral fat loading test
The subjects fasted overnight for at least 12 h and did not drink
alcohol on the day before the test. After placing a cannula for
venous blood sampling, subjects rested for 30 min before the fat
load was administered. Fresh cream was used as the fat source. It
was a 40% (weight/volume) fat emulsion with a poly-unsaturated/
saturated fat ratio of 0.10, containing 0.001% (w/v) cholesterol and
3% (w/v) carbohydrates. The total energy content was 3700 kcal/l.
Cream was ingested within 5 min at a dose of 50 g fat and 3.75 g
glucose per m2 body surface. The participants remained supine
during each test and were only allowed to drink mineral water.
Blood samples were collected into sodium EDTA-containing
tubes forMCP-1, IL-6 and lipoproteinmeasurements, andmost of
the other biochemical analyses. Samples were collected into tubes
with no anticoagulants added to measure PON1 activity. Samples
were obtained before the fat load meal and at 2-h intervals up to
10-h postprandially.
Table 1







Age, years 48.3 (1.9) 48.4 (1.8) 0.95
HIV diagnoses, years 8.4 (0.8) 12.2 (1.1) 0.01
Time under HAART⁎, years 7.6 (0.8) 9.06 (0.9) 0.23
ART prescribed, %
Nucleoside analogues 100 100
Protease inhibitors 61 68 0.59
Non nucleoside analogues 39 32 0.16
Cardiovascular risk factors
(see also Table 2)
Current smoker, % 22 26 0.71
Body Mass Index, kg/m2 24.9 (0.4) 22.5 (0.6) 0.002
Systolic blood pressure, mm Hg 132 (3.45) 133 (3.73) 0.88
Diastolic blood pressure, mm Hg 81 (1.83) 82.2 (2.71) 0.77
HIV viral load, log10/ml 1.96 (0.14) 2.20 (0.22) 0.37
CD4 cell count, cells/mm3 573 (58) 868 (87) 0.008
Unless otherwise indicated, values are mean (S.E.M.).
⁎HAART=highly-active antiretroviral therapy.
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Plasma glucose, total cholesterol and triglycerides were mea-
sured by standard methods. LDL was isolated by ultracentrifuga-
tion. HDL-cholesterol was analyzed using a homogeneousmethod
(ITC Diagnostics, Barcelona, Spain). Insulin, plasma MCP-1 and
IL-6 were measured by enzyme-linked immunosorbent assay
(ELISA) (Mercodia, Uppsala, Sweden and Peprotech, London,
UK). The Homeostasis model assessment index (HOMA) was
calculated as [fasting insulin (mU/l)×fasting glucose (mmol/l)] /
22.5. The serum concentration of CRP was measured using a high
sensitivity method (hs-CRP) (Quantex hs-CRP kit, Biokit, S.A.,
Barcelona, Spain) with a lower limit of detection of 0.10 mg/l.
PON1 activity towards paraoxon was measured after the reaction
of paraoxon hydrolysis into p-nitrophenol and diethylposphate, as
described previously, Ferré et al. (2003).
2.5. Statistical analysis
Results are expressed as means (S.E.M.). Continuous variables
were compared using analyses of variance (ANOVA) and the
categorical variables using the Chi square test. During serial
measurements, time effects were tested by repeated measures
ANOVA. The effects of treatment were analyzed with paired t-
tests, and in non-normal distributed variables log transformation
was applied. To compare the differences between the effects of
treatment an ANOVA of the mean change was applied. To evaluate
the effect of treatment and during serialmeasurements, we took into
account these variables that presented significant differences
between groups in the baseline situation. Calculations were per-
formed using SPSS 12.0 (SPSS Inc. Chicago, IL, USA). Statistical
significance was taken at the 5% level. The size of the sample was
calculated with β=0.10 and α=0.05 and based on a reduction of
20% in inflammatory variables. A multistep regression analyses
was performed to study the variables that might have an influence
on the response of MCP-1, PON1 activity, CRP and HDL cho-
lesterol. We considered dependent variables ΔAUC MCP-1,
ΔAUC PON1, ΔAUC CRP, ΔAUC IL-6 and ΔAUC HDL
cholesterol, and independent variables those which had been
correlated in a significant manner in a univariate analyses.
3. Results
3.1. General characteristics
Thirty-one HIV-infected patients were included in the study.
The baseline characteristics of the study group are depicted in
Table 1. Patients assigned to rosiglitazone were diagnosed of
HIV infection significantly earlier and their CD4 cell count was
higher than those patients in the group of metformin (Table 1).
Table 2
Effects of rosiglitazone and metformin on fasting clinical and laboratory variables
Overall (N=31) Metformin (N=16) Rosiglitazone (N=15)
Pre treatment Post treatment P value Pre treatment Post treatment P value Pre treatment Post treatment P value
Body Mass Index, kg/m2 23.8 (0.4) 24.0 (0.3) 0.43 24.9 (0.4) 24.5 (0.4) 0.05 22.5 (0.6) 23.2 (0.5) 0.02
Waist to Hip Ratio, m 0.98 (0.01) 0.98 (0.01) 0.31 0.99 (0.01) 0.97 (0.01) 0.02 0.98 (0.01) 0.98 (0.01) 0.43
Glucose, mmol/l 5.51 (0.13) 5.15 (0.18) 0.003 5.64 (0.24) 5.30 (0.35) 0.10 5.37 (0.09) 5.0 (0.11) 0.004
Insulin, mU/l 7.90 (1.18) 5.64 (0.74) 0.005 8.06 (1.13) 5.51 (0.67) 0.03 7.72 (2.17) 5.78 (1.38) 0.08
HOMA index⁎ 2.03 (0.34) 1.31 (0.19) 0.002 2.16 (0.43) 1.36 (0.26) 0.01 1.88 (0.54) 1.26 (0.28) 0.06
Total cholesterol, mmol/l 5.70 (0.16) 5.70 (0.23) 0.98 5.68 (0.24) 5.33 (0.28) 0.08 5.72 (0.24) 6.11 (0.35) 0.12
HDL cholesterol, mmol/l 1.12 (0.05) 1.10 (0.04) 0.67 1.03 (0.04) 1.10 (0.06) 0.17 1.22 (0.09) 1.11 (0.08) 0.06
LDL cholesterol, mmol/l 3.42 (0.15) 3.27 (0.18) 0.34 3.55 (0.22) 3.15 (0.25) 0.05 3.26 (0.20) 3.41 (0.28) 0.53
Triglycerides, mmol/l⁎⁎ 3.02 (0.53) 3.81 (0.47) 0.09 3.61 (0.94) 4.05 (0.77) 0.59 2.39 (0.43) 3.56 (0.56) 0.01
MCP-1, pg/ml 85.99 (5.33) 76.96 (3.20) 0.10 83.50 (6.71) 70.14 (2.71) 0.05 88.64 (8.56) 84.25 (5.45) 0.61
CRP, mg/l⁎⁎ 4.63 (0.93) 3.41 (0.71) 0.15 4.75 (1.58) 2.78 (1.20) 0.15 3.99 (1.20) 3.78 (0.99) 0.52
IL-6, pg/ml⁎⁎ 284.32 (56) 246.20 (51) 0.36 147.90 (23) 165.88 (66) 0.91 390.42 (105) 321.01 (84) 0.28
PON1, U/l 340.01 (30) 392.64 (33) 0.002 364.70 (48) 426.45 (52) 0.04 313.66 (35) 356.58 (42) 0.003
Values are expressed as mean (S.E.M.). ⁎HOMA = Homeostasis Model Assessment. ⁎⁎These were log transformed for statistical purposes.
Fig. 1. Mean (S.E.M.) plasma triglyceride concentrations in HIV-infected
patients before (●) and after treatment (○) in metformin (A) and rosiglitazone
(B)-treated groups. There were no significant differences before and after
treatment in the triglyceride response to fat overload. ⁎ Indicates P<0.01
comparing with t=0 when a paired t-test was applied.
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Further, patients in the group of metformin presented with a
significant higher body mass index. All participants were on a
nucleoside analogue agent plus a protease inhibitor and/or a
non-nucleoside reverse transcriptase inhibitor. We did not find
significant differences either in the baseline lipid profile or in
the inflammatory (MCP-1, CRP) and anti-oxidant (PON1 ac-
tivity and mass) variables, among patients assigned to receive
rosiglitazone or metformin.
Both, rosiglitazone and metformin significantly decreased
fasting insulin and HOMA index compared with baseline. Pa-
tients assigned to rosiglitazone, experienced a significant increase
in the fasting triglyceride concentration (Table 2). Patients
Fig. 2. Mean (S.E.M.) serum PON1 activity and HDL cholesterol in HIV-infected patients before (●) and after treatment (○) in metformin (panels A and B) and
rosiglitazone-treated patients (Panels C and D). Although a significant (P<0.05) increase in fasting PON1 activity was observed in both groups (†), postprandial
decreases were found significant (⁎P<0.03) when compared to t=0.
Fig. 3. Mean (S.E.M.) plasma MCP-1 and CRP concentrations in HIV-infected patients before (●) and after treatment (○) in metformin (panels A and B) and
rosiglitazone-treated patients (panels C and D). We did not find significant differences among groups but there was a significant decrease in postprandial MCP-1 in the
oral fat loading test performed after treatment with metformin and rosiglitazone ⁎P<0.01, when compared to t=0.
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assigned tometformin experienced a significant increase in fasting
HDL cholesterol (0.06 mmol/l) when compared to those assigned
to rosiglitazone (−0.10 mmol/l, P=0.02). Furthermore, in the
patients onmetformin, fasting total cholesterol showed a decrease
(−0.35mmol/l) that was significantly different when compared to
those with rosiglitazone (+0.38 mmol/l, P=0.02 for treatment
effect). We did not find significant differences between groups,
before the randomization, in MCP-1, CRP, PON1 and IL-6.
3.2. Postprandial study
Plasma triglycerides increased significantly after fat inges-
tion, reaching maximum concentrations 4-h postprandially, and
returning to baseline at the end of the test. Both, rosiglitazone
and metformin did not change the AUC for triglycerides com-
pared with the pre-treatment situation (Fig. 1). PON1 activity
experienced a significant postprandial decrease throughout the
postprandial test (Fig. 2). Both, metformin and rosiglitazone
increased fasting PON1 activity (Table 2), but the postprandial
course of PON1 showed a progressive and significant decrease
in the postprandial period after both treatments. The course of
HDL-cholesterol after the oral fat load was similar to that
observed for PON1 activity, reaching a nadir 6 h postprandially
(Fig. 2). Treatment with metformin or rosiglitazone did not
significantly affect the response of HDL cholesterol to the oral
fat load.
Before treatment, plasmaMCP-1 decreased significantly in the
group treated with metformin reaching a nadir at 4 h; however
MCP-1 did not change after the oral fat load in rosiglitazone-
treated participants (Fig. 3). After 26 weeks of treatment, how-
ever, fasting MCP-1 decreased with metformin, but not with
rosiglitazone (Table 2). There was a progressive and significant
decrease in plasma MCP-1 concentration in the postprandial
period thatwas observedwith both treatments.Metformin, but not
rosiglitazone, tended to reduce fasting CRP levels, but there were
no postprandial changes as a effect of treatment. Although pa-
tients assigned to receive rosiglitazone presented with higher
concentration of plasma IL-6 before treatment, the difference was
not statistically significant (P=0.10). Similarly, the postprandial
response of IL-6 did not present significant variations when
compared the effect of treatment and throughout the postprandial
period (Fig. 4).
In a univariate analyses, we found a significant and positive
correlation between theΔAUC ofMCP-1 and the increase in the
total cholesterol and LDL cholesterol concentrations (P=0.01),
but changes in insulin concentration or body mass index through-
out the study did not correlate with changes in inflammatory
variables, such as MCP-1 and CRP concentrations. Further, the
ΔAUC of PON1 activity was correlated with HDL cholesterol
(P=0.02). However, when a multistep, multivariate analyses was
applied we did not find any significant association with any of the
dependent variables in any of the treatment groups.
4. Discussion
As the survival of subjects with HIV increases, metabolic and
vascular complications will become an increasingly important
aspect in the management of these patients, specially those
derived from accelerated atherosclerosis (Carr et al., 1998;
Balasubramanyam et al., 2004; Hadigan et al., 2001; Friis-Moller
et al., 2003). Since humans in Western societies are in a
postprandial state most of the day, it is important to explore the
postprandial period, which is thought to play an important role in
the pathogenesis of atherosclerosis (Groot et al., 1991; Weintraub
et al., 1996; van Oostrom et al., 2003; Ceriello et al., 2004). This
effect will be presumably more intense in HIV-infected patients
with lipodystrophy who show insulin resistance and increased
postprandial lipaemia (Stein et al., 2005). These metabolic
disturbances and the infection itself, represent a considerable
degree of inflammation and oxidative stress to these patients. We
determined the effects of two different insulin-sensitizing agents
on fasting and postprandial inflammatory and antioxidant
variables. We found that rosiglitazone and metformin both
increased fasting PON1 activity, suggesting increased protection
from oxidation. In addition, both treatments decreased the
postprandial response of MCP-1, suggesting a reduction of the
postprandial inflammatory response. These potentially beneficial
effects may be the result of improved insulin sensitivity.
Both treatments significantly increased fasting PON1 activity,
despite their different modes of action. Metformin mainly acts by
decreasing hepatic glucose output, while the molecular mechan-
isms underlying the improved insulin sensitivity remain
controversial (Hundal and Inzucchi, 2003). Rosiglitazone
improves peripheral insulin sensitivity through transcriptional
mechanisms (Yki-Jarvinen, 2004). It is likely that increased insulin
sensitivity, which occurred similarly in both groups, may partially
explain the observed effects on PON1 activity (Yamada et al., 2001;
Mackness et al., 1998; Senti et al., 2003), however, these variables
Fig. 4. Mean (S.E.M.) plasma IL-6 concentrations in HIV-infected patients
before (●) and after treatment (○) in metformin (A) and rosiglitazone (B)-
treated groups. There were no significant differences before and after treatment
in the IL-6 response to fat overload.
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were not significantly correlated in a linear regression model.
Moreover, insulin supplementation in apolipoprotein E-deficient
mice reduced the atherosclerotic lesion size by 22–37%, and
showed a concomitant 30% increase in PON1 activity and an 18%
reduction in lipid peroxide levels (Shamir et al., 2003). The
postprandial response of PON1 was consistent with this concept
and PON1 activity was higher at all time points which is probably
due to a significant increase in fasting serum PON1 activity.
Whether the increment in PON1 activity produced by rosiglita-
zone or metformin in our patients translates into clinical benefit
with a reduced cardiovascular risk remains to be shown. We also
expected changes in inflammatory variables. Serum CRP is a
reliable and easily accessible marker of inflammation and is a
strong predictor of cardiovascular events (Libby and Ridker,
2004). We found that the postprandial serum CRP concentrations
did not change. Previous studies in type 2 diabetic patients treated
with rosiglitazone have shown marked reductions in serum CRP
concentrations (Haffner et al., 2002;Mohanty et al., 2004) and the
postprandial concentration of IL-6 experimented a significant
increase in type 2 diabetic patients (Ceriello et al., 2005).
However, we should take into account that our HIV-infected
patients are under an inflammatory stimulus which is probably
unaffected by insulin-sensitizing agents. Also, the population
studied was receiving HAART, which may have direct effects on
inflammation. Metformin tended to reduce serum CRP concen-
tration but did not reach statistical significance. However, we
should take into account that larger trials assessing these variables
should be of great value, since we are aware of the limitation of
our study due to, at least in part, to sample size. The lack of a
placebo control group is a limitation of our study; it should be of
great value to perform the same design in non-HIV-infected
participants with the concomitant presence of classic cardiovas-
cular risk factors, such as patients with high blood pressure,
diabetes or overweight. This comparison could give us interesting
data in recognizing HIV infection as a pro-atherogenic status.
MCP-1 plays a crucial role in initiating atherosclerosis by
recruiting inflammatory cells to the subendothelial space (Gu et al.,
1997). Although the response ofMCP-1 to a high-fat challenge has
not been studied before, in vitro studies have suggested that
chylomicrons induce a higher expression ofMCP-1 (Domoto et al.,
2003). At baseline, MCP-1 levels did not change postprandially.
However, both metformin and rosiglitazone modified the post-
prandial response of MCP-1 by reducing the postprandial plasma
concentrations of MCP-1. This may be a beneficial effect, because
MCP-1 has been identified as a crucial mediator of atherosclerosis,
and its plasma concentration has been positively correlated with
subclinical atherosclerosis (Deo et al., 2004). We have also shown
that HIV-infected patients with the MCP-1−2518G allele, which
increases the expression of the MCP-1 gene, have a 5-fold in-
creased risk of atherosclerosis (Alonso-Villaverde et al., 2004).
Such a postprandial decrease in MCP-1 observed after treatment
might be the direct result of improved insulin sensitivity, but the
changes in body weight may be an additional factor to be con-
sidered (Christiansen et al., 2005).
In summary, a high-fat meal has only minor effects on inflam-
matory and antioxidant variables in HIV-infected patients with
lipodystrophy, but treatment with metformin or rosiglitazone
increased fasting and postprandial protection from oxidation and
reduced the postprandial pro-inflammatory response by reducing
plasma MCP-1 concentrations.
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Ezetimibe effectively decreases LDL-cholesterol in
HIV-infected patients
Blai Colla,b, Gerard Aragonésa, Sandra Parrab, Carlos
Alonso-Villaverdeb and Lluis Masanab
We tested the security and efficacy of ezetimibe
in the treatment of HIV-associated dyslipemia.
Twenty HIV-infected patients were randomly
assigned to receive ezetimibe 10 mg/day or fluvas-
tatin 80 mg/day. Patients receiving ezetimibe
experienced a statistically significant (P ¼ 0.003)
20% reduction in the concentration of LDL-cho-
lesterol, similar to that observed with fluvastatin
(24%, P between groups 0.70). We concluded that
ezetimibe monotherapy effectively decreases LDL-
cholesterol in HIV-infected patients.
The control of cardiovascular risk factors in HIV-infected
patients is relevant because the incidence of myocardial
infarction [1] and other atherosclerosis-related events [2]
are increasing. Lipid abnormalities are commonly present
in this clinical setting [3], but the majority of 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors, with
the exception of pravastatin and fluvastatin, are
metabolized by the cytochrome P450 3A4, which in
turn is also the metabolic pathway of many of the
antiretroviral agents, especially the protease inhibitors (PI)
[4]. Recent evidence supports the use of ezetimibe in
combination with statins to add a powerful lipid-lowering
effect [5]. However, the metabolism of ezetimibe, which
is P450 independent, and the low incidence of drug
interactions and side-effects, make this drug suitable to be
tested in monotherapy in HIV-infected patients.
Patients were enrolled during the 3 months of the
inclusion period if they fulfilled the eligibility criteria:
more than 6 months on stable HAART, more than
18 years of age, and a fasting LDL-cholesterol concen-
tration of 3.30 mmol/l or greater. Classic cardiovascular
risk factors were recorded, and fasting total cholesterol,
HDL-cholesterol, triglycerides, and glucose were deter-
mined. LDL-cholesterol values were obtained using the
Friedewald formula. CD4 and CD8 lymphocyte counts
and HIV-1 viral load were determined using standard
techniques.
Endothelial function was analysed using peripheral
arterial tonometry [6]. Briefly, this system (Itamar
Medical Ltd., Caesarea, Israel) utilizes a finger probe to
assess digital volume changes accompanying pulse waves.
The peripheral arterial tonometry data were analysed by a
computer in an operator-independent manner. A ratio of
less than 1.6 was considered to be a marker for endothelial
dysfunction [6].
Patients were then randomly assigned (according to the
HAART regime: boosted PI or non-nucleoside
analogues) to receive ezetimibe 10 mg/day or fluvastatin
extended release 80 mg/day in a 1 : 1 ratio. Patients were
evaluated 2–3 weeks after the initiation of lipid-lowering
agents to assess tolerability and adherence, and at 6 weeks,
the baseline protocol was re-applied.
Results are expressed as mean (SEM) or in percentages.
Univariate analyses, using non-parametric tests, were
used to compare differences between groups (Mann–
Whitney) and between pre and posttreatment (Wilcoxon
and McNemar tests). The independent Ethics Commit-
tee of the Hospital Universitari Sant Joan approved
the study.
There were no significant differences in lipid values, age,
and baseline endothelial function between patients taking
non-nucleoside analogues (N ¼ 10) and those with
boosted PI (N ¼ 10). Patients randomly assigned to
receive ezetimibe exhibited higher systolic [137 (5.6)
versus 117 (2.7) mmHg, P ¼ 0.01] and diastolic blood
pressure [90 (3.3) versus 76 (4.5) mmHg, P ¼ 0.02] than
those on fluvastatin. There were no significant differences
either in the other cardiovascular risk factors or in the
HIV-related variables between groups, although most of
the patients assigned to be given ezetimibe were receiving
lopinavir/ritonavir. None of the participants experienced
related side-effects and none of them interrupted the
lipid-lowering therapies.
In both groups, total cholesterol and LDL-cholesterol
were significantly decreased after therapy (Fig. 1). Those
patients receiving ezetimibe 10 mg presented a statisti-
cally significant (P ¼ 0.03) 10% reduction in total
cholesterol and a 20% reduction in LDL-cholesterol
concentrations (P ¼ 0.02, Fig. 1). The results in the
fluvastatin group were similar, showing a 17% reduction
in total cholesterol (P ¼ 0.06) and a 24% decrease in the
concentrations of LDL-cholesterol (P ¼ 0.02). We did
not find significant differences in either triglycerides or
HDL-cholesterol (Fig. 1). There were no significant
differences in the reduction of lipid concentrations
between groups, showing a similar effect of both lipid-
lowering agents (Wilcoxon test, P ¼ 0.2 for total
cholesterol and P ¼ 0.4 for LDL-cholesterol).
Furthermore, those patients receiving ezetimibe did not
exhibit significant changes in endothelial function after
QAD 200519
ISSN 0269-9370 Q 2006 Lippincott Williams & Wilkins 1
UNIVERSITAT ROVIRA I VIRGILI 
INFLUENCE OF CHEMOKINE RELATED POLYMORPHISMS IN ATHEROSCLEROSIS AND HIV-INFECTIONS 
Blai Coll Crespo 
Dipòsit Legal: T.1044-2012 
  
 
QAD/200519; Total nos of Pages: 3;
6 weeks of therapy (Fig. 1). However, those in the
fluvastatin group experienced a non-significant (P ¼ 0.5)
increase in the rate of endothelial function (11% better
result in the second evaluation, Fig. 1).
The treatment of HIV-associated dyslipidemia should
avoid drug–drug interactions and potentially detrimental
concentrations of statins [7–10]; therefore, the use of
lipid-lowering agents without significant interactions
with HAART is highly desirable.
Pravastatin is not preferentially metabolized by cyto-
chromes [10], and fluvastatin is metabolized through the
CYP2C9 enzyme. Both reduce the concentrations of
total cholesterol without significant toxicities [10,11], but
other lipid-lowering drugs should be evaluated in this
particular group of patients in order to control potential
toxicities. Ezetimibe is the first available selective
cholesterol absorption inhibitor, blocking cholesterol
absorption at the intestinal brush border to reduce LDL-
cholesterol [12]. The dual inhibition of cholesterol
synthesis and absorption, through the co-administration
of a statin and ezetimibe, has been shown to provide
significantly greater reductions in LDL-cholesterol than
statin monotherapy alone [5]. However, if confirmed, we
also support the use of ezetimibe in monotherapy in HIV-
infected patients, because it yields similar results to those
obtained with fluvastatin, and none of the participants
experienced any ezetimibe-related side-effects.
The small sample size and the different distribution of
the boosted PI between groups are severe limitations to
be considered. Even then, the results favour the use of
ezetimibe to control lipid-related cardiovascular risk
factors.
An important issue addressed in our study was the
influence of these agents on endothelial function; HIV-
infected patients exhibit higher rates of endothelial
dysfunction than the non-infected population [13], and
those on PI have even worse values [14]. Agents that
ameliorate endothelial function contribute to a reduction
in cardiovascular risk, because endothelial dysfunction is
the initial disturbance in the development of atheroscle-
rosis [15]. Those patients on ezetimibe, although
reducing significantly the values of LDL-cholesterol,
did not experience any change in endothelial function.
Conversely, patients receiving fluvastatin ameliorated,
although not significantly, their endothelial function.
In summary, ezetimibe monotherapy effectively decreases
LDL-cholesterol in HIV-infected patients. Because of the
small sample size, these results should be further addressed
in larger trials, but the use of ezetimibe in these patients
can be advised.
aCentre de Recerca Biomédica; and bServei de
Medicina Interna, Hospital Universitari Sant Joan,
Reus, Spain.
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Fig. 1. Results of lipid parameters and endothelial function in HIV-infected patients before (white bars) and after (filled bars)
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De tu se n’aprèn, se n’aprèn molt, no paris. 
Masana, gràcies per haver estat el referent de tot aquest treball, 
referent per la teva empenta i dedicació científica. T’he d’agrair 
especialment l’haver fet d’un Servei de Medicina Interna un ambient 
propici per que aquest tipus d’idees vegin la llum. Aquesta tesi ha 
d’ésser el fruit inicial de grans projectes, de grans idees posades a la 
disposició del joc científic, i espero fer-ho junts.  
Al reduït, però immens equip dedicat al VIH; Honorio, ets el “rookie” 
de l’equip; et dono les gràcies per la teva col·laboració i t’animo a 
continuar amb nosaltres.
Asun, no crec ser capaç de trobar l’agraïment que et correspon 
després de tots aquests anys de treball junts, sense tu tot hagués 
estat diferent, molt diferent. 
Gerard, gràcies per ser-hi, per posar el CRB ben a prop de l’Hospital 
de Dia i per transmetre una mica de laboratori a aquestes ments 
mèdiques poc sistemàtiques.
Sandra, gràcies per formar part d’aquest equip, per aportar-hi 
l’alegria i les inquietuds necessàries per que es mantingui viu. Espero 
assistir ben aviat a la teva defensa de tesi, ànims.
Carlos, podria escriure fulls sencers per descriure el que han significat 
per mi aquests  anys. No ha estat tant sols un període de formació 
tècnica, has sabut donar allò que saps fer millor, ser proper. Vam 
començar plegats explorant els camins de la recerca clínica en 
clau de gladiador “...holding the line...”, ”... as one...”  i recordo amb 
molt de carinyo “..... you will be in the Eliseum...” coincidint amb la 
publicació del primer paper. Des d’aleshores hem compartit alegries, 
desil·lusions, i molts projectes, tots ells des d’una perspectiva de 
col·laboració i entesa perfecta. Per tot això que has creat, t’he de 
donar les gràcies i espero que d’altres puguin tenir la mateixa sort 
que he tingut jo. Gràcies Director.
Pare i Mare, gràcies per haver-me ensenyat a treballar, per haver-me 
transmès l’esperit de superació, la necessitat de col·laboració amb 
la resta i especialment  per haver-me ensenyat a donar-li sentit al 
compromís. Aquesta tesi, és en gran manera un resum de tot això i 
per tant  ha estat possible gràcies a la vostra incansable lluita per 
ensenyar-ho, tot, als vostres fills; prova de tot això aquí la teniu. 
Enhorabona.
Carmina, estic convençut que coneixes molt bé el contingut de la tesi. 
No és el contingut científic el que ara preocupa, és el que es respira, 
es palpa i se sent al veure-la, i per tant el que ha implicat; i això tu ho 
saps millor que ningú, per que sempre hi has estat, sempre, per tot, 
íntegra, disposada i  traient-me d’ensopecs, d’altra part  necessaris 
perquè m’adonés que tinc al costat una persona fantàstica i que 
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